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Antibody Targeting of Non Ionic Surfactant Vesicles to Vascular Inflammation 
Elizabeth D. Hood 
ABSTRACT 
 
Cardiovascular disease (CVD) and particularly atherosclerosis is a leading 
cause of morbidity in the developed world.  Atherosclerosis and the rupture of 
vulnerable atherosclerotic plaque cause 70% of deaths from CVD.  The 
progression of atherosclerosis has been identified as a pathological inflammatory 
process.  Targeting atherosclerotic drug therapies to inflammatory markers has 
emerged as an important and growing research area.  The adhesion molecule 
CD44 has been implicated in the onset and build-up of atherosclerotic lesions 
throughout the course of development.  The research in this dissertation is aimed 
at targeting anti-inflammatory therapy to activated vascular endothelium with 
directed with an anti-CD44 antibody, IM7, conjugated to a non ionic surfactant 
vesicle (niosome) drug carrier.  The IM7 conjugated immunoniosome has been 
shown to bind to endothelial and synovial lining cells in vitro.   
The preliminary research is involved with the development of the drug 
delivery vesicle, and the antibody linkage chemistry, along with an analysis of 
vesicle characteristics and stability.  A novel linking chemistry using 
polyoxyethylene sorbitan monostearate and cyanuric chloride allows antibodies 
to be conjugated to vesicle surface polymer groups without prior derivatization. 
  xvi
Subsequent research tested the resulting ‘immunoniosome’s’ ability to bind to 
target antigens with selectivity and specificity.  Bovine aortic endothelial cells 
activated with cytokines provide a model of inflammation.  Analysis of binding 
was done through fluorescent and scanning electron microscopy.  In vivo uptake 
of vesicles at sites of inflammation is size dependent.   In order to overcome this 
barrier to uptake, niosome suspensions were thermally extruded to create 
uniform 200 nm vesicles.   Further analysis of the efficacy of the system looked 
at live cell uptake of the immunoniosomes measured by confocal and 
transmission electron microscopy.  Preparation for in vivo murine studies 
required that the antibody component was modified to counteract the immune 
response.  Finally, the conjugation of antibody fragments to niosomes and the 
binding and uptake of the vesicles in a live endothelial cell model is evaluated.  A 
viable drug delivery particle showing binding and cellular uptake capabilities in 
inflammatory cells was produced by this research using a novel surfactant-
antibody linker.
  1
 
1. Prelude 
Immunotherapy, the use of antibodies to treat disease, is of great interest 
in the fields of chronic infectious disease, cancer, cardiovascular, and arthritis 
research, among others.  In 1796, Edward Jenner used a cowpox virus to 
develop a vaccine against small pox.  He discovered that deliberate infection with 
the virus brought on a mild state of the disease and a subsequent immunity to it1.  
It was Paul Erlich at the beginning of the 20th century who originally discovered 
antibodies and described the role they play in humoral immunity.  He proposed 
the ‘magic bullet’ concept of using antibodies to send therapeutic agents to target 
cells2. He also imaged that “a carrier by which to bring therapeutically active 
groups to the organ in question” would be advantageous3.  Not until the 
development of monoclonal antibody (mAb) production could his ‘magic bullet’ 
concept be realized.  In the 1970s the B cell melanoma was identified as 
producing a single type of antibody.  Georges Jean Franz Köhler and César 
Milstein invented the process to produce monclonal antibodies in 1975 for which 
they won a Nobel Prize in Physiology or Medicine in 19844.  Gregory Winter 
developed techniques to humanize monoclonal antibodies for therapeutic uses5.  
In 1965 Dr. Alec Bangham published ‘Diffusion Of Univalent Ions Across 
Lamellae Of Swollen Phospholipids’ which is the seminal work of liposome6, and 
therefore, vesicular drug delivery.  More than forty years later strategic drug 
delivery using phospholipid or other bilayer model structures continues to be 
pursued for myriad applications such as vaccinations7, gene delivery8, 
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thrombolysis9, topical applications10, tumor targeting 11, vascular targeting12, 
transdermal13, and ophthalmic treatments10,14 among many others.   
The combination of immunotherapy and vesicular drug delivery originated 
with Paul Erlich at the beginning of the 20th century.  Almost eighty years later in 
1981, Torchilin and Klibanov reviewed methods for immobilizing proteins on the 
surfaces of liposomes15.  Immunotargeting of drugs using an antibody vector 
bound to a drug carrier has continued to be developed in the fields of cancer and 
tumor therapy16-27, and cardiovascular research28-34.  The use of immunotargeted 
drug delivery to effect treatment and block progression of damaging inflammatory 
processes has not been as widely pursued as cancer and tumor targeting, most 
likely due to the more highly toxic effects that anticancer drugs have on healthy 
tissues.  However, the prevalence of cardiovascular disease and especially 
atherosclerosis35, the challenges of restenosis of arteries after angioplasty, the 
build up of plaques on stent implants, and other effects of inflammatory 
processes in cardiovascular disease, as well as the questionable systemic side 
effects produced by cardiovascular drugs36,37 provide motivation and 
opportunities for a more succinct therapeutic approach. 
Current research into innovative anti-atherosclerotic treatment includes 
identifying and manipulating the inflammatory mechanisms consistent with the 
progression of the disease from initial fatty streaks to fibrous plaques to 
vulnerable complex lesions, uptake mechanisms of macrophage derived foam  
cells38, and the identification of the regulatory factors controlling inflammatory 
response in endothelial cells and uptake of lipoproteins39,40.   
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The hypothesis of this research is that an antibody conjugated non ionic 
surfactant vesicle could be developed and targeted to inflammation with the 
potential to provide therapeutic benefit by targeting specific inflamed tissues.  In 
order to test this hypothesis the following aims were pursued: 
 
Aim 1.  Develop and characterize a targeted drug delivery system using non ionic 
surfactant vesicles conjugated to monoclonal antibodies specific to an 
inflammatory target antigen. 
 Aim 2.  Quantify and optimize the immunoniosome-antigen binding in fixed 
culture aortic endothelial cells with respect to concentrations of both vesicle 
concentration and antibody density using fluorescence microscopy and computer 
image analysis. 
Aim 3.  Observe, describe, and quantify cellular uptake of immunoniosomes in 
live cells using confocal and electron microscopy. 
Aim 4.  Once the drug delivery system is sufficiently described, develop a 
protocol for the in vivo evaluation of the adherence and effect of the 
immuniosomes encapsulating atorvastatin on plaque development in the ApoE 
knockout mouse model. 
 
The successful completion of these aims would produce a well described drug 
delivery system ready for in vivo testing in an atherosclerotic model. 
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2. Literature Examination 
2.1. Overview 
Developing a drug delivery system provokes inquiry into several different 
disciplines of research. The original idea was to develop a targeting system that 
would treat atherosclerosis, specifically the vulnerable plaque of atherosclerosis.  
Investigations into the recent developments and conclusions about 
atherosclerosis revealed that the disease, like numerous other chronic 
pathologies such as arthritis, lupus, and chronic obstructive pulmonary disease, 
is an inflammatory disorder.  Systemic implications and common mechanisms in 
the build up of inflammatory disease are demonstrated by the high incidence of 
atherosclerosis in rheumatoid arthritis patients without traditional risk factors for 
the disease41.  The onset and characteristic phases of atherosclerosis are 
described, as well as the mechanisms of inflammation and the disease 
progression.  Literature reviews of atherosclerosis lead to investigation of other 
inflammatory pathologies as a means to identify potential treatment strategies.  
Furthermore, the mechanisms of disease onset and progression provide 
targeting strategies; cellular adhesion molecules are mediators of progression of 
atherosclerosis, among other inflammatory diseases, and are reviewed generally, 
and the candidate adhesion molecule, CD44 specifically.   
  Identifying the appropriate drug delivery vehicle provoked research into the 
large body of work representing drug targeting generally, vesicular drug 
targeting, and liposomal and niosomal drug delivery specifically.  Drug targeting 
may be directed passively or actively; active targeting is usually mediated with a 
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vector molecule, and some of the methods and applications of actively targeted 
drug delivery are reviewed.  Finally, a review of targeted imaging and therapy in 
cardiovascular medicine is reviewed.  
2.2. Cardiovascular Disease and Atherosclerosis 
2.2.1. Implications of Cardiovascular Disease 
 
The American Heart Association (AHA) lists prevalence among Americans 
of having one or more types of cardiovascular disease (CVD) at 37.1% for 2004.  
Over 36% of all deaths of Americans in 2004 were attributed to CVD35.  Of the 
different types of CVD, coronary heart disease and its underlying cause, 
atherosclerosis, is the largest single cause of death42.    Atherosclerosis is a type 
of arteriosclerosis, which describes the thickening and hardening of the arteries 
generally.  Atherosclerosis is the build up of lipids, cholesterol, calcium, cellular 
waste, and fibrin and the proliferation of smooth muscle and inflammatory cells 
within the sub endothelial space of medium to large arteries43, specifically 
including the aorta, carotid, coronary, and peripheral arteries44.  This evolving 
accumulation of plaque causes narrowing of the arteries reducing the lumen and 
the area available for blood flow, and decreases flexibility of vessels to absorb 
the pressures created by blood flow.  Stenosis is defined as “the constriction or 
narrowing of a passage or orifice”45.   
Atherosclerotic plaques are prone to erosion and/or  rupture which 
produces a release of core lipid and inflammatory contents into the blood stream.  
As the coagulation factors in the blood contact the inflammatory tissue factor (TF) 
expressed by the macrophages and the smooth muscle cells, along with other 
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expressed materials, a blood clot or thrombus forms in the lumen of the blood 
vessel42.  A thrombus is the product of the coagulation cascade of the blood; the 
platelets activated by thrombin form a plug immediately and are further enforced 
as fibrin fibers are formed by the cascade of coagulation factors46.  This process 
is necessary for hemostasis, to reduce blood loss in a damaged blood vessel, for 
example, however the formation of occlusive thrombi as a result of plaque 
rupture is the major instigating factor of coronary events47.  Additionally it has 
been shown that the plaque’s composition is a greater predictor to susceptibility 
to rupture than size, or degree of stenosis42.   In fact, many plaques prone to 
rupture do not appear to be severely stenotic in a coronary angiogram48-51. 
2.2.2. Atherosclerosis Development 
 
Traditionally, atherosclerosis was considered to be a passive lipid 
processing disorder with plaques gradually evolving over time to eventual 
occlusion of the blood vessel.  In this view the blood vessel itself is considered to 
be an ‘inert tube’, not a dynamic structure interacting with blood and extracellular 
matrix elements and cells, and proteins,  which are seen in the normal artery but 
also actively contribute to the progression of the disease.    
Plaques may form as either stable, or unstable, vulnerable.  Stable 
plaques are characterized by a thick fibrous cap, a small core of lipid materials 
and an unchanged lumen area, whereas vulnerable plaques are characterized by 
a thin fibrous cap covering a large lipid core containing inflammatory cells.   
Atherosclerosis is classified in stages assigning levels of severity to 
plaques as they develop  as seen in Figure 2.144.  The initial stage, Phase 1, is 
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the development of the fatty streak and proliferation of monocytes; the 
endothelium may be unaffected at this stage and no symptoms are evident52 as 
the vasculature compensates by ‘remodeling’ and maintaining the size of the 
lumen53.   
 
 
Figure 2.1 The Stages of Atherosclerotic Plaque Development. From 47.   
 
Figure 2.2 shows an outline of the stages describing the disease 
progression as defined by atherosclerotic lesion development and architecture47.   
At the first stage the small lesions are of three types of increasing complexity; 
type I consists of lipid-filled foam cells derived from macrophages.  Type II 
lesions contain smooth muscle cells and lipids from the extracellular matrix along 
with fatty foam cells, and in type III lesions the smooth muscle cells are 
immersed in connective tissue, fibrils and lipids54.  Phase 2 is described as 
advanced, with pre-stenotic lesions with potential to rupture, and progresses into 
either Phase 3 or 4.  Plaques at Phase 2 are either type IV, or type Va; the 
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former characterized by a large lipid volume and smaller fibrous cap, and the 
latter having a more extensive cap47.  Phase 3 lesions are type VI developed 
from type IV or Va lesions that have ruptured or eroded and form non occlusive 
thrombi.    
Phase 4, as shown in Figure 2.2, is the alternate path from Phase 2, and 
has severe characteristic symptoms from type VI lesions.  Occlusions may be 
constant or periodic and present clinically as acute coronary syndrome.  Because 
a third of occlusive thrombi come from non stenotic plaque disruption the 
syndrome may not be obvious until there is severe sudden ischemia or a 
myocardial infarction (MI)47.  Finally, in Phase 5 lesions are type Vb or Vc and 
are either, respectively, calcified or fibrous and may both cause angina (chest 
pain due to constricted oxygen flow) or ischemia44.   
 
Figure 2.2 The Phases of Atherosclerosis. From 55  
 
To further complicate an intricate process, the progression of 
atherosclerotic plaques vulnerable to rupture and thrombus formation and their 
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triggering events are not homogenous across different areas of the vasculature.  
Plaque disruption is a critical trigger for acute events in coronary arteries, less so 
in the carotid, and in the peripheral arteries thrombogenicity (the propensity to 
form thrombi) is more crucial42.     
2.2.3. Atherosclerosis and Inflammation 
Inflammatory processes play a role in vascular disease, rheumatoid and 
osteoarthritis, chronic obstructive pulmonary disease, and inflammatory bowel 
disease, lupus, among others.  The inflammatory process is characterized by 
accumulation of inflammatory cells, leukocytes, and macrophages that 
perpetuate the process and contribute to tissue destruction.   
Once understood to be a disorder of lipid accumulation and cholesterol 
metabolism, atherosclerosis is now described as a “chronic inflammatory disease 
of the arterial system”56; inflammatory factors are implicated in every phase of 
plaque development.    Endothelial cells contacting flowing blood mediate 
interactions of underlying vessel tissue with blood cells and components.  In 
normally functioning endothelium, which forms a monolayer of cells on a 
basement membrane that cover the intimal layer, expression of inflammatory-
response cellular adhesion molecules (CAMs) and the subsequent attachment of 
circulating leukocytes, is minimal42.   
There is general agreement that atherosclerosis begins with an inciting injury 
to the endothelium provoking an inflammatory immune response57.  When normal 
homeostasis is not restored, endothelial cell dysfunction continues as the 
disease progresses58.  It is the expression of adhesion molecules and the influx 
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of leukocytes that perpetuate the disease throughout the process.   Vascular 
adhesion molecule-1 (VCAM-1) has been shown to play a major role in leukocyte 
recruitment, binding to monocytes and T lymphocytes59.   Further description on 
the role and mechanisms of adhesion molecules in the inflammatory process will 
be discussed in Section 2.3.  A monocyte crossing the endothelium and entering 
the tunica intima becomes a tissue macrophage, which then takes up lipids and 
lipoproteins, in particular oxidized low density lipoprotein (LDL) in the plaque and 
further transforms into a foam cell60.  The build up of foam cells is a characteristic 
of plaques.  The foam cells produce pro-inflammatory cytokines which further 
provoke immune response in the plaque and promote reactive oxygen species61.  
Eventually the foam cells accumulate in the center of the lesion, die, and form a 
necrotic core within the plaque.  Death of the foam cells is attributed to either 
apoptosis (programmed cell death) or the toxic effects of oxidized lipoprotein 
uptake62. 
The products of the inflammatory cells within the plaques disrupt the stability 
of the fibrous cap covering the plaque.  Macrophages and smooth muscle cells 
release proteinases, such as collagenase and elastase, which break down the 
structural proteins collagen and elastin.  The degradation of elastin also disrupts 
the ability of cells to move though the plaque61.    
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2.3. Adhesion Molecules 
Cellular adhesion molecules (CAMs) mediate blood -endothelial cell 
interactions common to all segments of the vasculature under physiological or 
pathological conditions 62.  They are glycoproteins which have cytoplasmic, 
transmembrane and extracellular domains63.  CAMs are expressed by nearly 
every cell type55, and are characterized by strong ligand binding.  They 
participate in cell to cell and cell to matrix interactions and in some cases also 
signalling, migration, motility,  gene transcription and differentiation64. 
As was mentioned  previously, a hallmark of endothelial dysfunction at the 
initiation of atherosclerosis is the persistent adherence of circulating leukocytes 
and their subsequent uptake into the tunica intima65.  The inflammatory cells are 
recruited by CAMs.   CAMs expressed by the endothelium include intercellular 
adhesion molecule-1 (ICAM-1), vascular adhesion molecule-1 (VCAM-1), and 
platelet-endothelial cell adhesion molecule-1 (PECAM-1), integrins, and 
selectins66.   
Once the adhesion molecules bind with monocytes, macrophages, 
lymphocytes or platelets, those bound elements become activated themselves, 
and release proinflammatory cytokines, membrane receptors, and a myriad of 
enzymes, including the interleukins, tissue necrosis factor alpha (TNF-α), 
interferon-α, and numerous others. Cytokines have been shown in increase the 
expression of adhesion molecules including TNF-α, and interleukin-1 β (IL-1β) 
and increase the binding of leukocytes to the endothelium67.   The expression of 
inflammatory proteins creates a positive feedback loop by further inciting uptake 
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of inflammatory cells, promoting aggregation of oxidized LDL on the endothelial 
surface and thus causing injury to the endothelium, and excreting further 
inflammatory mediators68. 
Since VCAM-1 is at the forefront of monocyte recruitment in lesion formation69 
it has been identified as a potential therapeutic target and has been widely 
studied70.    In knock out gene studies with mouse models the elimination of 
VCAM-1 but not ICAM-1 was shown to reduce plaque formation in 
atherosclerotic mice71.   In vitro studies with monocytes co-cultured with 
endothelial cells showed that adhesion was reduced when cells were treated with 
antibodies raised against VCAM-1 and E-selectin, but not P-selectin61.   Levels of 
expressed VCAM-1 are used as a measurement in the efficacy of drug therapy72.   
Adhesion molecule P-selectin is expressed on activated endothelial cells and 
platelets.  Targeting P-selectin demonstrated therapeutic efficacy in an 
atherosclerotic mouse model which are cross bred with a P-selectin null mouse 
model.  Reduction in plaque formation and proliferation of leukocytes was 
observed.  However, the presence of soluble P-selectin in the bloodstream 
complicates the strategy73.   
Depending on the therapeutic strategy, these adhesion molecules could 
provide drug targeting candidates.  There have been numerous studies using  
anti-VCAM74, anti-ICAM-175, and the anti-selectins76 antibodies as targeting 
vectors which show great potential in vitro, however, there has been very little 
translation of  these studies in vivo over the last decade.  Collaboration with 
arthritis researchers70 led to the investigation of another adhesion molecule 
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candidate, CD4477, ligand to hyaluronan (HA), a polysaccharide a major 
component in the extracellular matrix (ECM) of mammalian cells.  The 
interactions of CD44 and HA have been implicated in cancer, autoimmune 
diseases, and inflammatory processes78.    
2.3.1. Adhesion Molecule CD44 
CD44 is a family of adhesion molecules that are characterized by their 
function, and mainly described as hyaluronan receptors.  There are 10 standard 
isoforms and 10 variant isoforms of CD44, and the most populous is the CD44s 
isoform. The variation among the forms is found in ECM domain of the structure 
and accounts for the isoforms variation in function78.  CD44 isoform CD44-v6 is 
highly expressed in the smooth muscle cells of the intima and media of injured 
arteries78, CD44 isoforms including CD44-v6 are expressed on the endothelium 
suggesting regulatory function of growth factors28  CD44 v10 is expressed by 
aortic endothelial cells28. Isoforms CD44-v3 and CD44-v6 where shown to be 
expressed on plaque microvessel, whereas CD44H and CD44v6 both express on 
endothelial cells after exposure to IL-1β and TNF-α. Cd44H, CD44-v5, CD44-v6, 
CD44-v7/8 isoforms are all expressed on macrophages and are all highly 
regulated by the cytokines74.  CD44 and HA were shown to mediate leukocyte 
endothelial cell adhesion, previously thought to be the sole domain of the selectin 
family79.  These studies taken all together indicate that CD44 isoforms are 
implicated in the pathogenic inflammatory process of atherosclerosis and that 
their role is highly complex and regulated.   
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Interruption of the inflammatory process has been studied using CD44 
blocked by antibody IM7 (anti-CD44)80.  Expression of CD44 and its variants was 
augmented when exposed to pro-inflammatory cytokines within human 
atheroma, implicating CD44 expression with the pathogenesis of arterial 
diseases74.  CD44 was further implicated in the progression of atherosclerosis.  
Hyaluronan was shown, in a low molecular weight form, to stimulate vascular 
cellular adhesion molecule (VCAM-1) and proliferation of smooth muscle cells 
(SMC), whereas high molecular weight forms of HA inhibit SMC proliferation81.   
Atherosclerotic prone ApoE-deficient mice bred with CD44-null mice showed a 
50-70% reduction in aortic lesions compared to CD44 heterozygous and wild 
type mice 82.  These results suggest that CD44 promotes atherosclerosis by both 
mediating inflammatory cell recruitment to atherosclerotic lesions and by altering 
smooth muscle function 81. 
2.4. Drug Targeting  
Drug targeting is a strategy aiming at the delivery of a compound to a 
particular tissue of the body. Drugs can be delivered singly or in large amounts 
by using drug carriers.  Drug carriers are substances that facilitate time-
controlled delivery, organ-specific targeting, protection, prolonged in vivo 
function, and decrease of toxicity of drugs to unspecified tissues.  Drug targeting 
may allow for increased permeability of membrane barriers, allowing for 
molecular movement between tissues.  Ideally, drug targeting would provide a 
high local concentration of drug at the site of disease and a concentration below 
levels of toxicity in healthy tissues81.  Examples of drug carriers are myriad, 
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including but not limited to, liposomes, micelles, polymeric vesicles, and nano-
particles6. 
Normal administration of drugs or therapeutic agents does not allow for 
concentrated accumulation of drug at diseased sites due to an essentially 
uniform distribution of drug throughout the body.  In order to adequately treat 
affected sites using traditional systemic administration high doses of drug must 
be delivered.  This not only increases costs, but also can create toxic side effects 
as normal tissues and organs are needlessly exposed to pharmaceuticals 83.    
Encapsulation of drugs for passive targeting, either by liposome 81, niosome 68,  
or polymeric 81 media has shown increased retention time, decreased therapeutic 
dose, and reduced toxicity to unspecified tissues.    
Targeting schemes include direct application into the affected organ or 
tissue, passive application to tissues through leaky vasculature-tumors, infarcts, 
or inflammation.  Another scheme is physical targeting, which can be based on 
manipulating an abnormal pH or temperature at the target by using pH or 
temperature sensitive drug carriers.  Magnetic targeting of drugs to affected 
areas within the body can be achieved using paramagnetic carriers attached to 
magnetic drugs and then directed by an external magnetic field84.  Active drug 
targeting is generally described as the use of a vector molecule with a high 
specific affinity toward the affected tissues bound to a drug or drug carrier 21.  
Active drug targeting using a monoclonal antibody vector is the approach of this 
research. 
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2.4.1. Vesicular Drug Delivery  
Among drug carriers listed previously, vesicular drug carriers provide 
advantages over individual single molecule carriers.  They not only allow greater 
payload of drug to be delivered, but also provide isolation of the drug from the 
system overall and thereby provide protection immune responses.  Vesicle 
bilayers mimic biological membranes which enhance absorption of encapsulated 
drugs across cell membranes and into tissues.   Vesicular drug delivery allows 
protection of the encapsulated drugs from enzymatic degradation85, prolonged 
circulation time, and therefore a reduced rate of release of drug into the 
bloodstream86, and the shielding of an immunogenic drug from recognition by the 
reticuloendothelial system (RES)85. 
2.4.1.1. Liposomes 
Vesicles made from organically-derived amphiphilic (having both 
hydrophilic and hydrophobic moieties) phospholipids, like those that comprise 
cell membranes, are the most prevalent and widely researched drug delivery 
particle87.   These liposomes, or “fat bodies” from the Greek, were first observed 
by researchers in the 19th century using lecithin in blood clotting studies.   In 
1911, Otto Lehmann published a representation of micrograph of what he called 
‘artificial cells’ which resembled a dispersion of multi-lamellar liposomes 88.  Even 
though work with lecithin dispersions continued the properties and potential 
applications of these dispersions were not described until Dr. Alec Bangham and 
his colleagues published their seminal work 89.  They described how these 
particles, formed from the hydration of lipid thin films, retained some of the 
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hydrating solution that they formed in within their core creating a ‘permeability 
membrane’.  Researchers used the self assembly vesicles to study biological 
membranes and other applications, and these pursuits eventually led them to  
drug delivery.  Liposome applications that developed thereafter, both 
commercially and within academia, are many and varied including multiple 
scientific disciplines; medicine, immunology, diagnostics, cosmetics, ecology, 
cleansing and the food industry 90.  Promising laboratory research did not always 
translate to commercially viable scale-up within the medical realm, however, and 
repeatability and stability problems caused early liposome based  start-up 
pharmaceutical companies to fail91.   
Liposomes’ interaction with cells has been studied not just for drug 
targeting purposes but also in developing further understanding of cell-cell 
interactions.  Liposomes’ interaction with cells can be characterized in four ways 
shown in Figure 2.3.  First, the liposome may exchange material, either lipids or 
proteins, with cell membranes.  Secondly, liposomes may bind or adsorb with 
cells, and once bound may be internalized through either endocytosis or 
phagocytosis. Alternately, the bound liposome may instead fuse with the 
membrane.  Whichever of these possibilities arise is dependent on the size, 
charge, and makeup of the vesicle92.  
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Figure 2.3 Vesicular Interactions with Cells. (Adapted from Lasic 81) 
 
The problem of early and rapid elimination from the bloodstream of the 
first liposome formulations was solved by the development of the ‘Stealth’ or 
‘sterically stabilized’ liposomes93.  The addition of small amounts of a hydrophilic 
polymer, frequently polyethylene glycol (PEG), extended the half life of a ‘classic’ 
liposome from a few minutes to several hours94.  Researchers have developed 
several synthesis techniques to enhance desired characteristics.  Along with 
varying methods of synthesis, vesicular drug delivery also varies in physical 
makeup.  Multiple vesicle layers have been shown to enhance release rates 
significantly when compared to free drug and uni-lamellar vesicle delivery95. 
Development of commercially available vesicle applications, passive and 
active, have been pioneered by cancer research96.  One multiple-application 
technology that is being developed commercially is called DepoFoam™ and is 
made by the Swiss company SkyePharma.  They produce foams of spherical 
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lipid-bilayer aqueous chambers, or multivescular liposomes that are used to 
encapsulate drugs, vaccines, DNA, peptides or large particle bio-therapeutics 
which may be administered locally or systemically97. 
2.4.1.2. Niosomal Drug Delivery 
Niosomes are analogues of liposomes synthesized from synthetic 
surfactants rather than organically derived phospholipids.  They are also self 
assembly vesicles usually composed of a surfactant, cholesterol and a steric 
stabilizer, such as dicetyl phosphate98.   Niosomes behave similarly to liposomes 
in vivo by prolonging circulation time of the encapsulated drug and altering 
chemical distribution within the body 99,100.  However, niosomes have advantages 
over liposomes as drug carriers, including chemical stability, lower cost, easier 
storage and handling, and a reduced likelihood of becoming toxic through 
oxidation 8.  Like liposomes, niosomal encapsulation reduces toxicity of drugs to 
untargeted tissues in many different applications and therapies.  Niosomal drug 
delivery has been studied using  various methods of administration 7 including 
intramuscular 10, intravenous 101, peroral, 102and transdermal 103.  Niosomes can 
be used to solubilize insoluble agents86.  Nebulized surfactants entrapping all-
trans-retinoic acid were delivered as an inhaled aerosol reducing the drug toxicity 
and altering the pharmacokinetics 84. In addition, as drug delivery vesicles, 
niosomes have been shown to enhance absorption of some drugs across cell 
membranes 26, to localize in targeted organs 17 and tissues 84,104, and to elude 
the RES 105.  Cellular uptake of niosomes can be via endocytosis 106; however 
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they have been shown to bind and fuse with cell plasma membranes via cellular 
receptors when vesicle surface charge is sufficiently negative 26.   
Niosome entrapment of methotrexate administered orally and 
intravenously in a mouse model was shown to increase residence time in the 
body and decrease clearance27.  Tumor targeting of niosomal formulations of 
doxorubicin26, vincristine sulfate105, cisplatin107, camptothecin24, shown increased 
residence times and anti-tumor efficacy compared to free drug. 
Recent examples of niosomal drug delivery research are varied and 
include topical vaccination generally24 and of DNA108,106 and treatment of 
acne109, alternate insulin delivery methods2,  oral immunizations110, transdermal 
anti-inflammatories111, and ophthalmic applications112, among others. 
2.5. Background and Current Practices in Antibody Mediated Drug Targeting 
The discovery of the nature of antibodies and the development and 
refinement of monoclonal antibody production had a revolutionary effect of the 
treatment of infectious disease and has provoked the pursuit of numerous 
targeting strategies in cancer and cardiovascular medicine113. 
Anticancer therapy, and especially tumor targeting, has been the 
forerunner in the development of liposomal 28, niosomal 32, and other drug 
delivery systems32 and is the most widely pursued application of antibody 
mediated targeted drug delivery 32.   Early clinically approved and commercially 
available nanoscale (200 nm or smaller) systems for untargeted drug delivery 
were developed for cancer treatment and  include DOXIL®,  a liposomal 
encapsulation of doxorubicin (1995), and Ambisome®, liposomal amphotericin 
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(1990)32.  Innovations in vesicle-antibody linking schemes were also driven by 
cancer researchers.  In order to increase circulation time and decrease the rapid 
clearance of classic liposomes from circulation, polymer groups (usually PEG 
groups) were added to liposomes surfaces32.  These liposomes showed 
favorable passive targeting to tumors and leaky vasculature.  The addition of site 
specific targeting vectors, monoclonal antibodies and fragments most prevalent 
among them, provided active targeting capabilities to improve therapeutic 
capacity and decrease non specific tissue interactions.  When antibodies were 
coupled to the vesicle surface of a PEG coated liposome both the ability of the 
antibody to bind to the surface of the liposome was hindered, as well as its 
capacity to attach to the targeted antigen site68.  The PEG groups that inhibited 
the desired qualities of an immunoliposome provided an attractive site for 
antibody attachment and increased antibody-antigen site recognition versus 
attachment of antibodies at the vesicle surface34.   
Liposomal immunotargeting has been used extensively for cancer and 
cardiovascular applications.  Antibody-vesicle conjugation chemistries are varied 
but there are similar physical configurations of linkers that result in increased 
efficacy of antigen binding when the ligand is attached distal to the vesicle 
surface.  This increases rotational freedom of the targeting moiety and decreases 
hindrance by the bulky polyethelyne glycol (PEG) groups at the surface of a 
‘stealthy’ liposome114.  Attachment of ligand distal to the vesicle on a PEG 
terminus was found to have increased binding to target cells compared to 
attachment on the surface31.  Development of a polyethylene end group  on a 
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phospholipid molecule functionalized with cyanuric chloride allowed for 
attachment of antibodies without prior derivatization of antibodies  115.  Improved 
tumor targeting was shown using niosomes with PEG-glucose conjugates using 
a paramagnetic agent encapsulant28.  Echogenic liposomes conjugated with 
targeting antibodies show in vitro promise for simultaneous imaging capabilities 
and targeted therapeutics 116. 
Differing antibody-polymer linkage schemes were developed, usually by 
creating a functionalized PEG group coupled to a phospholipid molecule (‘linker 
lipid’92,95,117-126) and incorporated into the vesicle membrane for subsequent 
antibody or targeting vector coupling.  These schemes included differing 
formulations of thioether bonds coupling an antibody to the terminal end of a 
PEG group, either by activating a maleimide group attached to a thiolized 
antibody  7,8,91,99,100,102,127-131, or hydrazide group reacted with an aldehyde group 
on an oxidized antibody10,99,132-135, among others.  An end-group functionalized 
PEG linkage was developed that did not require activation or functionalizing of 
the antibody105.  A cyanuric chloride molecule to was added to the head group of 
a membrane component phospholipid linking a PEG molecule to that, and then 
another cyanuric chloride molecule to the terminal end of the PEG which would 
then be coupled to an antibody via nucleophilic substitution115,136-138. 
Although the group subsequently found unfavorable in vivo blood 
circulation times of their immunoliposome (IL) formulation19,28,29,139, subsequent 
studies have identified the Fc region of the whole antibodies used as the culprit in 
provoking an immune response, and promoting rapid clearance of ILs.  
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Researchers have demonstrated this with liposomes conjugated with anti-HER2 
monoclonal antibody fragments (the protein HER2 is a member of the epidermal 
growth factor family and is over-expressed in breast cancer and implicated in its 
pathogenesis) 105.  The  anti-HER2 IL-were shown to have identical blood 
residence time as compared to non-targeted sterically stabilized liposomes in 
vivo, and further showed no increased clearance with subsequent 
administrations.  Incubation with cells that over-expressed HER2 had a 700 fold 
increase in cellular uptake of drug compared to non-targeted liposome140.  Active 
targeting of niosomes was shown using glucose targeting with the inclusion of a 
glucose-palmitoyl glycol chitosan conjugate in a sorbitan monostearate 
niosome141.  Improved tumor targeting was shown using niosomes with PEG-
glucose conjugates using a paramagnetic agent encapsulant142.   To our 
knowledge there is no literature on any other group studying antibody targeting of 
niosomes.   
2.6. Cardiovascular Antibody Mediated Imaging and Therapy 
2.6.1. Imaging and Therapy 
 
Diagnostic medical imaging is a prevalent and non invasive technology 
widely used in obstetric and cardiovascular disciplines, among others.  
Innovations in technology have transformed ultrasound (US) images from grainy 
and poorly-resolved to sharp digital imaging115.   The non invasive nature of US 
tissue penetration makes it an attractive therapeutic strategy.  Active therapeutic 
targets within the cardiovascular system include atherosclerotic plaques, or other 
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areas of damage within the vascular walls and bed,  infarcts, thrombi and blood 
elements115.  US targeted imaging 88 and imaging driven therapy of thrombi has 
been widely pursued143.  Contrast agents have been studied not just for the 
ability to enhance ultrasound (US) imaging but also for thrombolytic potential 
created by the very high localized pressures created when US exposed contrast 
agents burst driving their therapeutic load into target thrombi88.   Ultrasound 
imaging of a liposomal combination of echogenic contrast agent and drug 
delivery vehicle has shown also the ability to guide therapy and disrupt thrombi 
88,144.  Additionally contrast agents, or ‘microbubbles’, have been studied as 
potential gene delivery vectors by exploiting the explosive cavitation of US 
exposure driven bursting to propel plasmid DNA into vessels88.   
Detection of expressed adhesion molecules as antibody directed contrast 
agents bind locally can be used to identify inflammation and early detection of 
cardiovascular pathologies115.  Atherosclerotic animal models demonstrate the 
facility of targeted MRI imaging of thrombus producing ruptured plaque to 
potentially guide therapy136.   Atherosclerotic plaques can also be imaged using 
targeted US contrast techniques accessing either expressed inflammatory 
adhesion molecules on the endothelial surface or activated bound leukocytes 
through contrast agent antigen receptors136. 
 The potential to direct therapy through imaging and simultaneously control 
drug delivery and release could address several challenges of inflammatory 
pathologies as greater understanding of the complex chemical and molecular 
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interactions of inflammatory processes drive plaque buildup, instability and 
vessel restenosis115. 
2.6.2. Current Research in Vesicle Mediated Drug Delivery in 
Inflammation and Cardiovascular Disease. 
Reviews of cardiovascular targeted drug delivery cover the myriad 
applications pursued in targeting pharmaceuticals to cardiovascular disease145.  
Thrombus treatments and imaging have been targeted with and without antibody 
or other protein mediation, and through magnetically driven thrombolytics.  
Atherosclerotic lesions, circulating blood cells and elements, and endothelial cells 
have all been addressed as therapeutic targets.  In treatment of lung disease, 
aerosols have been developed to accumulate drug delivery in the lungs92, as 
have antibody-mediated delivery to antigens in the lungs146, to malignant lung 
disease145, and immuno-liposomes directed to the pulmonary endothelium30,147-
149.  The mechanisms and techniques of successful targeted and untargeted 
accumulation of drug delivery vesicles in the pulmonary endothelium are relevant 
to developing other vascular inflammation strategies.   
Imaging of pathogenesis in the heart through targeting has been studied 
post myocardioal infaction and in myocarditis.  Liposomal accumulation has been 
shown in ischemic heart tissue 150.   Liposomal cardiovascular targeting has been 
reviewed in detail specifically32.  While limited to intravascular tissues only, in 
vitro and in vivo studies of liposomes and immunoliposome as a drug carriers to 
many antigens were addressed151.  Among the topics reviewed was the targeting 
of vessel wall injury.  Multiple pathologies, atherosclerosis, and coronary 
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thrombosis among them, are initiated by vessel injuries which promote platelet 
activation and binding.  Early detection of the disrupted endothelium through 
targeting of expressed antigens providing a ‘signal’ has been studied.  This 
included an in vitro examination of targeting extracellular matrix antigens where 
collagen gaps provide binding sites for liposomes conjugated with antibodies to 
type 1 collagen, and similarly proven against laminin and fibronectin also.  These 
studies showed good affinity, specificity, and selectivity.  Also the liposomal 
antibody-antigen binding mimicked nature: cell binding studies showed that 
liposomes conjugated with antibodies provided a dissociation constant (describes 
the affinity between ligand and protein) on the order of 10-9 M, which corresponds 
to physiological antigen to free antibody binding constants151.  
Human endothelial cells incubated with immunoliposomes conjugated with 
cell surface antibodies (anti-T antigen A25) were shown to bind at 4˚C and 
endocytose 30% of bound ILs at 37˚F.  Liposomes and ILs were seen to 
accumulate in an ischemic heart providing imaging and therapeutic targeting 
potentials to damaged myocardium.  Positively charged  untargeted liposomes 
were observed to accumulate in experimentally produced myocardial  tissues as 
early as the 1970s; further studies confirmed further the propensity for liposomes 
to accumulate in depolarized myocytes and in ischemic tissues in general151.  
These findings provided the groundwork for liposome passive targeting to 
ischemic tissue and infarcted heart tissue. 
Active targeting of anti-myosin conjugated ILs to myocardial tissue was 
studied in vivo and showed good accumulation in the ischemic myocardial tissue.  
  27
This effect is limited in traditional liposomes when access is restricted because of 
lack of blood supply and vesicles are eliminated by the RES before accumulation 
occurs.  As with other traditional liposomes, surface alterations by the 
incorporation of PEG groups along with antibodies provided targeting and 
prolonged circulation time showed greater penetration152.   
Another consequence of ischemia is the formation of lesions of the cell 
membrane.  Loss of membrane integrity is further exacerbated upon reperfusion 
leading to cell death as cell contents are exposed and reperfusion injury ensues.   
The capacity to target and seal lesions created in hypoxic in vitro conditions 
using cardiocytes with immunoliposomes (ILS) shown to be effective, greatly 
increasing post hypoxic cell viability after IL incubation.  Furthermore, hypoxic 
and IL treated cells were shown to grow normally in culture after the event109. 
Immuno-liposomes targeted to intercellular adhesion molecule 1 (ICAM-1) 
were shown to bind to and be internalized by epithelial cells in vitro, 
demonstrating their potential of the anti-ICAM antibody bearing vesicles to deliver 
an anti-inflammatory drugs to sites of increased ICAM expression 153. With an 
aim to combat restenosis following coronary angioplasty, liposomes conjugated 
with peptide sequences were created to target to glycoprotein IIb-IIIa receptors 
on activated platelets34.  Platelet aggregation and deposition is implicated in the 
pathogenesis of restenosis through deposition of growth factors and 
inflammatory mediators.  To increase circulation time they modified the vesicle 
surfaces with an oligodextran polymer, analogous to the use of PEG groups to 
elude the RES 152.   The effect of stress by reactive oxygen species on 
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endothelial cells is implicated in cardiovascular diseases making antioxidant 
drugs therapeutic candidates.  Antioxidant enzymes such as superoxide 
dismutase and catalase make good therapeutic candidates but are rapidly 
eliminated from the bloodstream, inhibiting their efficacy.  Muzykantov’s group30 
showed that by encapsulating the enzymes, which they coupled to PEGs, the 
elimination was greatly reduced and the efficacy and bioavailability of the 
enzymes were increased.  Binding to expressed antigens in the endothelium in 
vivo was shown by targeting angiotensin converting enzyme (ACE) and adhesion 
molecules (ICAM-1 and PECAM-1).  Vascular accumulation, endothelial uptake, 
and increased antioxidant protection were all shown with this targeting 
scheme136.   ICAM-1, but not PECAM-1 was shown to be susceptible to 
pathological stimulus, exhibiting increased expression and uptake in and by 
endothelial cells.  Anti-ICAM1 targeted immunoliposomes of 100-300 nm 
diameters showed specificity of uptake compared to non specific antibodies or 
large vesicle targeting115. 
 The aim of the literature review was to not only establish a foundation of 
knowledge in the different disciplines involved in creating a targeted drug delivery 
system but also to identify the most appropriate carrier system, antigen target, 
mode of delivery and mechanism of uptake.    
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3. Project Description 
 
The objective of this project was to develop and test a drug delivery 
system that could be targeted to vulnerable atherosclerotic plaque.  Figure 3.1 
shows the interdependent relationship of the physical elements needed to meet 
this objective. In order to design the system effectively, the affinity of the drug 
delivery vehicle must be established for both the drug of interest and the drug 
delivery vector that will be targeting the biological site.  The targeting vector is 
chosen not only for its ability to seek and deliver the drug delivery system to the 
site of interest but also to help facilitate the uptake of the drug on site.  Obviously 
the efficacy of the drug delivered must be appropriate to treat the affected site. 
 
Figure 3.1  Interdependence of Elements of the Drug Delivery System. 
 
The drug delivery vehicle that was chosen for the system is a non ionic 
surfactant vesicle, or niosome.  The vesicle’s stability, versatility, biocompatibility, 
and cost made the choice compelling.   Surfactant components available are 
numerous, allowing versatility in formulation strategies to not only manipulate 
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stability136 (the ability to retain the encapsulated component) but also to allow the 
potential to incorporate various linkers to the vesicle surface105.  The biological 
target provides the therapeutic conduit, and therefore should be specific to the 
disease pathogenesis and if possible, implicit in it.  The development of 
atherosclerosis and the morphological changes in plaque along the progression 
of the disease provide varied targeting strategies105.  The inflammatory 
processes implicated in each progressive step of plaque development and the 
shift in stability of the plaques have associated biomarkers which provide not only 
a targeting potential for in situ drug delivery, but also a mechanism to interrupt 
disease progression.  Adhesion molecules are mediators in the process of 
inflammation and make logical therapeutic targets70. 
3.1. Development and Testing of an Immunoniosome 
The use of an antibody-conjugated non ionic surfactant vesicle or 
‘immunoniosome’ to target vascular inflammation is an original concept.  
Niosome research has been largely in the realm of cancer154, immunization155, 
and topical therapies156.  The process of vesicle development included evaluating 
the formation and stability of niosomes composed of sorbitan monoester 
components that had been well described the literature and  whose surfactants 
were commercially available71.  Liposome literature describes the widespread 
use of polyethylene glycol (PEG) groups on the surface of liposomes, originally 
incorporated to elude the immune system, as a desirable site for targeting vector 
attachment.  The addition of PEG may be accomplished by adding the polymers 
after vesicle formation to linkers attached to phospholipids accessible on the 
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liposome surface or by creating phospholipid PEG compound molecules and 
incorporating those as the vesicles form157. A similar polymer group was 
incorporated in one of our sorbitan ester surfactants but the stability of the 
polyoxyethylene sorbitan monostearate (Tween 61) niosome was not favorable. 
This led to investigating blending the surfactant components to evaluate the 
potential to introduce a linking site while maintaining the desired properties of 
stability and entrapment.   Liposome literature reviews described multiple 
schemes linking proteins to vesicles141.  Cyanuric chloride has been used in the 
past to adhere proteins to surfaces and was described as a linker in 
immunoliposomes12,28,32,158.  From these ideas I developed the linking chemistry 
of the polyoxyethylene sorbitan monostearate functionalized with cyanuric 
chloride in order to provide a protein binding site on the surface of a formed 
vesicle.  This is a novel process and a non-provisional patent application has 
been filed and published 159.  The resulting immunoniosome (IN), see Figure 3.2, 
was tested in a fixed synovial lining cell model for specificity, selectivity and 
binding.  Adhesion molecule CD44 was identified as a target antigen implicated 
in the progression of atherosclerosis160, so the binding studies were done with 
anti-CD44 as the targeting vector.   
Bovine aortic endothelial cells were used to test the ability of the niosomes 
to binding to inflammatory cells specifically expressing target antigens.  The 
binding of fluorescent INs to cells was measured using a customized MatlabTM 
program (see Appendix D), which relates the binding of immunoniosomes to the 
cells relative to experimental variables.  
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Figure 3.2 Immunoniosome Membrane Structure. 
3.2. Binding and Uptake of Vesicles 
Uptake of INs by cells was investigated.  Prior to the live cell incubation 
studies, changes in the synthesis process were necessary.  Reduction of 
niosome size by extrusion created niosomes of 200 nm, a size demonstrated as 
preferential in uptake by atherosclerotic lesions148.  Additionally, in some studies 
antibodies were fragmented prior to conjugation and incubation with cells to 
evaluate the ability of the linkers to attach Fab fragments.  Studies showing 
unfavorable uptake of whole antibody immunoliposomes implicated the 
conserved Fc region of the antibody107,161, so in preparation for in vivo studies, 
uptake of  Fab conjugated immunoniosomes, as well as the uptake of whole 
antibody targeted vesicles by cells was tested using confocal and TEM 
microscopy.  
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Finally, in order to test the efficacy of the system in vivo a protocol for a 
study using an atherosclerotic mouse model and treated with atorvastatin 
containing immunoniosomes compared to free drug treatment was developed 
and approved by the USF Institutional Animal Care and Use Committee (IACUC) 
and the US Army Medical Research and Material Command Animal Care and 
use Review Office.  
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4. Vesicle Development  
4.1. Immunoniosome Synthesis Project Description                                                               
The development of the immunoniosome took place in four distinct 
phases.  In the first phase, the general formulation of the vesicle had to be 
identified, synthesized, measured, and tested for viability.  Niosome literature and 
availability of components favored using surfactants from the sorbitan ester 
family, both for stability, encapsulation capacity, and economy 30.  Vesicles of 
different compositions of those sorbitan esters, and their encapsulation and 
retention capacities were evaluated using fluorescent dye as a drug model.  
Chromatography, particle sizing, fluorescence intensity, and microscopy were 
employed to purify and measure vesicle formulations162-164.  Vesicles were 
stressed with diagnostic levels of ultrasound to evaluate membrane stability.  
Also of interest was the potential to create a ‘tuneable’ targeted drug delivery 
vesicle that would not only be site specific but would have controlled release 
upon activation with US exposure.  The next phase was a refinement of the first, 
and looked at the potential of blending surfactant components in quantities that 
retained desired stability properties while providing potential linker candidates.  
Once the blended formulation was established, the next phase involved the 
development and evaluation of the linker chemistry.  Finally, once the ability of 
the surfactant linker to bind a monoclonal antibody to the surface of a niosome 
was established the last phase tested the ability of the resulting  
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‘immunoniosome’ to bind to a target antigen on a fixed cell using an activated 
fixed synoviocyte as a cell model of inflammation.  
4.2. Material and Methods 
4.2.1. Introduction  
The ability of lipids to form bilayer vesicles instead of micelles is 
dependent on the hydrophilic-lipophilic balance (HLB) value of the surfactant, the 
chemical structure of the components and the critical packing parameter (CCP) 
which is the relationship between the structure of the surfactant including size of 
hydrophilic head group, and length of lipophilic alkyl chain (Figure 4.1).  The 
formula is 
0al
vCCP
c
=  where lc = the length of the alkyl chain, v = the volume of 
the hydrophobic chain volume, and a0= area of the hydrophilic head group115.  
The HLB value can measured experimentally for each surfactant by reversed 
phase thin layer chromatography165.  The value represents a relative proportion 
of the hydrophobic and hydrophobic groups comprising the molecule and 
provides a guide for evaluating potential vesicle formation.  Generally it has been 
reported that HLB for sorbitan esters are between 4.0-8.0115.  For of an HLB 
value of greater than ~6, cholesterol must be added to the surfactant in order for 
a vesicle to form166. The general form of a single bilayer vesicle is shown in the 
left of Figure 4.1. 
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Figure 4.1  Critical Packing Parameter and Bilayer Membrane. Left: Schematic 
for calculating the critical packing parameter of an amphiphile (Adapted from 
Uchegbu 1998115.)  Right: Bilayer Membrane Structure 
 
Niosomes are similar to liposomes in structure and methods of synthesis.  
The fundamental component of both is an amphiphile, a molecule containing 
both a hydrophobic and hydrophilic moiety, and the structure of the resulting 
vesicle is formed by a single or multiple bilayer membrane enclosing an aqueous 
core.  There is a wide array of commercially available, inexpensive, 
biocompatible surfactants that enable specified structural design of vesicles167.  
Niosomes can form from many of these surfactants, and are commonly made by 
the combination of a single alkyl chain nonionic surfactant and cholesterol, in 
addition to an ionic electrostatic stabilizer, such as dicetyl phosphate.   The 
addition of cholesterol enables more hydrophobic surfactants to form vesicles 
and suppresses the tendency of the surfactants to flocculate or form 
aggregates167.  The addition of cholesterol has been shown to lend greater 
stability to the bilayer membrane by raising the gel liquid transition temperature of 
the vesicle.  This stability decreases leakage of the vesicles and stabilizes 
against osmotic gradients168. 
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The formation of single or multiple bilayer (lamellar) vesicles upon 
hydration is a result of the amphiphilic surfactant’s (surface active agent’s) 
interaction with the aqueous solution caused by the high interfacial tension 
between the water and the hydrophobic alkyl chains.  This tension causes the 
hydrocarbon regions to associate simultaneously as the hydrophilic head groups 
orient towards the water; the actions of each opposing force culminate in the 
formation of the vesicle assembly 168.  The thermodynamics of formation dictated 
by Gibbs free energy (∆G-∆H−∆S≥0, at a given temperature) states that in order 
for the self assembly to go forward there must be sufficient enthalpy (∆H) to 
overcome the negative entropy of the system (-∆S) and the reduction in free 
energy (-∆G).   The van der Waals attractions, the hydrophobic-hydrophilic 
interactions, hydrogen bonding, and electrostatic interaction contribute the 
necessary enthalpy of formation.  In order for the association of the molecules to 
proceed there must be an energy gradient between their associated versus 
isolated states, and Israelachvili stated that self assembly will proceed as long as 
the interaction free energy per associated monomer 0Nµ , (where N is the number 
of associated monomers) is greater that the mean interaction free energy of the 
isolated monomers; 01
0 µµ <N .  This is true as long as 0Nµ  decreases with N, with 
0
Nµ  reaching a limiting value 168.  The energy gradient driven interactions of the 
molecules described underlie the HLB dependence of vesicle formation 
mentioned earlier as related to the shape and size of the hydrophilic head 
groups, and the lengths of the hydrophobic alkyl tails that dictate the HLB 
balance169. 
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4.2.1.1. Gel-Liquid Crystal Transition Temperature 
Formation of lamellar vesicles is dependent on not only the components 
themselves, but also on temperature.  The bilayer structures have different 
phases in which they exist.  The gel state is the most ordered, and the liquid 
crystal state is less ordered. Within the gel phase the alkyl tails of the 
amphiphiles are crystallized and can not diffuse.  In the liquid crystal state there 
is lateral diffusion of the bilayer components.  The liquid crystal phase of a 
system always exists above the gel phase. In order for niosomal vesicles to form 
the hydration must be set above the gel-liquid crystal transition temperature of 
the surfactant167,169.  The gel phase transition temperature of Span 60 is 57˚C, 
and therefore the hydration and extrusion temperatures are set to 60˚C167.   
4.2.2. Materials 
4.2.2.1.  Chemicals 
Niosome preparations and surfactant derivatization and treatments were 
made from sorbitan monostearate (Span 60), sorbitan monopalminate (Span 40), 
sorbitan monolaurate (Span 20), polyoxyethelene sorbitan monostearate (Tween 
61), cholesterol, and dicetyl phosphate (DCP), diisopropylethylamine (DIPEA), 
cyanuric chloride (CC), Triton-X 100, which all came from Sigma Chemical, St. 
Louis, MO. Surfactant properties are listed in Table 4.2 in Section 4.2.3.1. 
Fluorescent dyes, 5(6) carboxyfluorescein (CF) and 5(6) carboxyrhodamine (CR) 
were obtained from Biotium, Hayward, CA.  Phosphate buffered saline (PBS), 
and Sephadex G50, Histochoice tissue fixative, Hank’s Balanced Saline (HBS), 
Dulbecco’s Modified Eagle Medium (DMEM), Bovine serum albumin (BSA) and 
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goat serum were obtained from Fisher Scientific, Suwannee GA.   Collegenase P 
was obtained from Roche Applied Science, Indianapolis IN.  The Alexa  Fluor© 
488 protein fluorescent labeling kit came from Molecular Probes (A20181). 
4.2.2.2.  Vesicle Characterization Materials and Methods 
Particle analysis included light scattering, single particle optical sensing 
technology, optical microscopy, chromatography techniques and fluorescence 
measurements.   Fluorescence changes were measured to evaluate 
encapsulation by the vesicles and leakage over time.  The mean particle size and 
distribution of formed vesicles were determined using an Accusizer 780A optical 
particle analyzer from Particle Sizing Systems.  The algorithm behind the PSS 
technology combines single-particle light scattering and light extinction 
technologies.   Light scattering is used for particles less than 1 µm in diameter, 
with a lower limit of 0.5 µm, and light extinction is used for particle greater than 
1.0 µm.  Small volumes (0.005 - 0.1 ml, depending on concentration) of niosome 
suspensions are added to the diluting chamber and diluted and cycled through 
the through the sensor until the concentration of particles is such that they pass 
through individually, eliminating ‘coincidence’ of particles.  As the particles pass 
through a uniformly illuminated ‘optical particle sensor’ they obscure part of the 
sensor signal which produces an output pulse from a 35mW infrared diode.  The 
pulses represent these discrete particles whose magnitude corresponds to a 
particle diameter. Figure 4.2 shows a schematic diagram of the auto-dilutor 
system.   The accumulation of the pulses, interpreted by a signal processor, 
produces a particle size and concentration distribution plot (PSD).  Figure 4.3 
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shows a PSD plot of a polystyrene standard containing a mixture of particles with 
three different diameters, 0.7, 1.0, and 5 µm. The known sizes and 
concentrations of the standards allowed for calibration and verification of the 
instrument.   
 
Figure 4.2 Autodilution Scheme of Particle Sizing System. (PSS User manual) 
 
The vesicle suspensions were also characterized by observing the 
changes of their chromatography elution profiles details of which are described in 
the GEC purification below.  Essentially, the constituents of a vesicle suspension 
are separated by size as they elute through a packed bed matrix, and those 
constituents can be measured using UV absorbance or fluorescence intensity.  
By comparing changes in elution chromatograms the relative stability of the 
formed vesicles can be monitored. 
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Figure 4.3 Particle Size Distribution Plot of a Mix of Three Sizes of Polystyrene 
Latex Standards. 
 
Fluorescent dyes were used to study entrapment and retention in the 
niosomes because of the sensitivity and precision of fluorescent measurements.  
We were able to observe incremental changes as small as tenths of nano-moles 
of dyes in suspension.  The sensitivity of carboxyfluorescein dye to changes in 
fluorescence intensity with exposure to light was tested by exposing varied 
concentrations to as much as five day’s exposure to ambient light.  The results 
shown in Figure 4.4 indicate the dye’s resistance to decay despite exposure, 
reassuring us about any potential confounding effects of short term light 
exposure on signal changes.  Nonetheless, dye solutions were always stored 
away from light in 4˚C.    
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Figure 4.4 Stability of CF. The Decay of Varied Concentration of 
Carboxyfluorescein. 
  
 At low concentrations fluorescence intensity is proportional to dye 
concentration so encapsulation of dye can be calibrated by use of a standard 
curve, as shown in Figure 4.5.  At higher concentrations the relationship is not 
linear and measured intensity will decrease with increased concentration due to 
self quenching as shown in Figure 4.6.  Entrapment of dye by niosomes was 
measured by first disrupting the suspended niosomes with Triton X 100, a non-
fluorescing detergent, and then measuring the fluorescence intensity of the dye 
released by the vesicles into the suspending buffer solution70.  Light and 
fluorescence microscopy were also used to verify vesicle formation and 
disruption. 
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Figure 4.5 Calibration Curve of CF.  Carboxyfluorescein Molar Concentration vs. 
Fluorescence Intensity 
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Figure 4.6 Calibration Curve with a  Wide Range of Concentrations. 
Fluorescence Intensity with Respect to a Wide Range of Concentrations of 
Carboxyfluorescein Dye. 
 
4.2.2.3. Vesicle Purification Materials and Methods 
Niosome literature describes several methods of separating formed 
vesicles from un-encapsulated hydrating solutions and unformed lipids33.  Among 
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them are gel exclusion chromatography, dialysis, centrifugation, and 
ultracentrifugation.  Gel exclusion chromatography was chosen as an appropriate 
bench top method for this research.  Gel exclusion chromatography (GEC) is 
also referred to as size exclusion chromatography, and provides relatively rapid 
separation of formed vesicles from unformed lipids and unencapsulated dye (or 
drug).  Dialysis is time consuming and only eliminates the free dye and not the 
unformed lipids.  Centrifugation provides only partial separation of unformed 
lipids, created vesicle disruption, and has limited utility depending on vesicle 
density.  Ultracentrifugation was expensive and largely unavailable for our routine 
experimentation.   
4.2.2.3.1. Gel Exclusion Chromatography 
The theory behind GEC is straightforward.  Gel filtration media is packed 
into a column to form a packed bed.  The medium is a porous matrix of spherical 
particles, such as Sephadex G50, that are chemically and physically stable and 
non reactive.  Micrographs of hydrated Sephadex G50 beads at two 
magnifications are shown in Figure 4.7.  The packed bed is equilibrated  by 
flushing with a buffer solution (the mobile phase) such as phosphate buffered 
saline (PBS).  The liquid inside the matrix is referred to as the stationary phase. 
The void volume refers to the volume of the column not taken up by the matrix.  
Once a suspended sample is added to the gel matrix, buffer and sample move 
through the column.  Larger particles do not enter the pores of the gel matrix; 
they move through the column at the same rate as the buffer, and elute within the 
first column volume.  Particles small enough to be caught up in the gel matrix 
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pores elute later. The separation process takes place as one total column volume 
of buffer passes through the gel filtration medium.  Gel filtration is an isocratic 
chromatography technique, meaning that separation is achieved without the use 
of any kind of gradient. 
 
Figure 4.7  Sephadex G50 Hydrated Beads.  Left: 100x magnification, right: 
200x. 
 
According to the theory the particles or molecules will be separated 
according to the Stokes radius of the particle.  The equation for the Stokes radius 
is asM α=  where M is molecular weight, a is the Stokes radius, and s is the 
sedimentation coefficient, 
)1(
6 0
ρυ
πηα −=
N
,  where η0 is the viscosity of the solvent, 
υ is the partial specific volume of the particle, ρ is the density of the solvent, and 
N is Avogadro’s number.  Vesicle size can be calculated using the relationship 
between the volumes of the system; 
0
0
VV
VVk
t
e
d −
−=  where V0 is the void volume, Ve 
is the elution volume, Vi is the pore volume, and Vt is the total volume, kd is then 
the volume fraction of the stationary phase that is available to an eluting 
species170. 
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With GEC, hydrated samples were not only separated and purified, but 
also the sample’s stability and entrapment over time could be evaluated by 
studying the elution profile of the purified samples as they changed over time.  
The plot in Figure 4.8 shows an overlay of two elution profiles, or 
chromatograms, of two niosome suspensions of differing encapsulated PBS 
concentrations.  The abscissa is volume eluted and the ordinate represents the 
UV absorbance (fluorescence is also measured) of the eluting volume.  The first 
peak is the signal from the niosomes which are eluted in the void volume, and 
the second from the unencapsulated dye.   As a suspension of vesicles 
deteriorates over time, the first peak decreases and the dye released increases 
the second peak.  Theoretically, a newly purified stable suspension would have 
no second peak.   From the lack of a first peak signal in the 0.1M we discerned 
that vesicles were not viable at the higher salt concentration due to the osmotic 
gradient with the eluting buffer.   
 
Figure 4.8 Chromatogram of Span 60 Niosomes of Varied PBS Concentrations. 
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4.2.2.3.2. Fluorescence Intensity 
Fluorescent dyes are used as drug models commonly in research 
because of the high sensitivity of fluorescence spectroscopy, which can be as 
much as two orders of magnitude more sensitive than absorbance 
spectroscopy82.  Fluorescence spectroscopy uses changes in vibrational energy 
levels of the molecule or substance being measured to assess levels of 
fluorescence.  The sample is excited by exposing it to a known quantity of 
energy.  By absorbing the energy in the form of a photon of light at a particular 
wavelength the substance changes from a ground electronic state (low energy) 
to a high frequency state (higher energy).  Collisions between highly vibrating 
molecules cause loss and emission of energy as they drop back down from the 
excited high energy state to ground state and emit photons18,25.  Instrumental 
analysis of the energy absorbed and emitted at particular filter wavelengths 
provides fluorescence intensity values that can be used to interpret sample 
concentrations when compared to a standard curve (e.g. Figure 4.5.)  Initial 
fluorescence measurements were taken with a single measurement fluorescence 
spectrophotometer, and later measurements were taken using a fluorescent plate 
reader which allows for multiple readings to be taken at once.   Figure 4.9 shows 
the effect on vesicle disruption and subsequent release of dye from the vesicles 
on the concentration of dye in the measuring container (cuvette or plate well).   
The vessel on the left shows the dye concentration consistent within and outside 
the formed vesicles after hydration, while the middle shows the vesicles 
suspended in PBS with dye contained within them, and finally, the right vessel 
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indicates the release of the dye from the vesicles into the suspending PBS.  The 
dye released from the disrupted vesicles creates the change in signal of the 
fluorescence (FL) intensity.  
 
Figure 4.9 Release of Dye from Niosomes. 
 
4.2.2.3.3. UV Absorbance 
 
UV absorbance of materials is commonly used to measure concentration 
in solutions of proteins and nucleic acids.  The theory is straightforward; 
materials which absorb ultraviolet light (wavelengths from 200-400 nm in the near 
UV range171) have properties which obey the Beer-Lambert Law.  The law is 
expressed in different formulas shown below.  The transmittance of light (T) 
through the material is a ratio of the intensity of the incident light (I0) and the 
intensity of the light after passing through it (I1). 
lcA
I
I
T α−− === 1010
1
0 , where 
1
0
10log I
I
A =  and λ
πα k4=  so that 
lcA α=  
A is absorbance at a particular wavelength  
l is the path length in cm 
c is concentration in M 
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k is the extinction coefficient for the material 
λ is the wavelength of the light 
So for a material with a known extinction coefficient, at a particular wavelength, 
and a known path length, molar absorbance is proportional to 
concentration148,172,173. 
4.2.2.3.4. Ultrasound 
Energy can be added to order or to disrupt a system; in our niosome 
development experiments we used ultrasound for both of those purposes.  
Sound is the phenomenon we experience perceiving the propagation of pressure 
waves through air or water.  Mechanical vibrations create vibrating pressure 
waves transferring energy from the source to the pressure waves and to anything 
the waves contact.  Audible (or acoustic) sound frequencies range from 20 Hz to 
20KHz.  Ultrasound waves are above 20KHz and outside the range of human 
hearing141.  Exposure of a biological membrane to ultrasound causes 
sonoporation which is the temporary, non-destructive perforation of the cell 
membrane.  This transient state enhances permeability of therapeutic agents into 
cells and tissues115.   Similarly, the bilayer membrane structure of a self 
assembly vesicle exhibits a temporary permeability with exposure to acoustic 
forces174.  Our suspensions of formed niosomes were exposed to ultrasound in a 
bath sonicator to reduce lamellarity and size which is a common practice in 
vesicle synthesis175.  Experiments were conducted exposing different 
formulations of niosomes to diagnostic US frequencies to test the potential of US 
mediated drug release in vivo.   Intensity levels of US exposure vary for different 
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medical applications.  Power levels greater than 10 W/cm2 are used in surgical 
applications; therapeutic US ranges from 0.5-3 W/cm2,  and diagnostic US ranges 
from 0.1m W/cm2 to 0.5 W/cm2, 176.   
4.2.2.4. Equipment 
Table 4.1.  Equipment for Vesicle Development and Synthesis. 
Equipment Manufacturer Model 
Mass balance Denver Instrument 
Company 
A-250 
Rotary evaporator 
 
Buchi Laboratory, 
Switzerland 
Vaccuum Controller V-800 
Buchi-Rotavapor R-200 
Buchi-Heating Bath B-490 
Buchi VacR V-500 
 
Bath sonicator 
Laboratory Supplies CO., 
INC 
Model G1125PIG 
 
Particle sizing Particle Sizing Systems Accusizer 780ATM 
 
Fluorescence 
spectrophotometer 
Perkin Elmer LS-3B 
Fluorescence Plate 
Reader 
Biotek Flx800 
UV Microscope 
 
Lecia Type 090-135.002 
Inverted Fluorescence 
Microscope 
 
Olympus IX71 
Chromatography  column GE Healthcare 
(Amersham Biosciences) 
Superdex HiLoad XK 16/60 
Chromatography system GE Healthcare 
(Amersham Biosciences) 
ÄKTAprime 
Vortex Mixer Fisher Scientific Touch Mixer 231 
pH meter   
Echocardiography 
machine 
 
Acuson Aspen 
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4.2.3. Methods 
4.2.3.1.  Vesicle Synthesis 
4.2.3.1.1. Thin Film Hydration Techniques 
Traditional thin film hydration techniques were first described in the 
1960s6.  In niosome synthesis this method involves dissolving surfactants, 
cholesterol and, often, an electrostatic stabilizer (such as dicetyl phosphate) in a 
non polar solvent, such as chloroform, and then evaporating the solvent and 
forming a thin film of the dried chemicals on a vessel.  Once all solvent is 
removed, usually by employing a vacuum or nitrogen gas, the addition of an 
aqueous solution hydrates the thin film.  The hydrophobic/hydrophilic interactions 
of the amphiphilic molecules when exposed to the aqueous environment cause 
the self-assembly of lipid bilayer vesicles.  As the hydrophobic tails orient 
themselves together, they shield themselves from exposure to the water 
molecules, and the hydrophilic head groups line up together inwardly and 
outwardly exposed to the aqueous solution.  Figure 4.1 (left) earlier in the text 
shows a drawing of the orientation of the amphiphiles.  
Initially several different formulations were investigated.  While different 
sorbitan ester surfactants were assessed, a consistent ratio of surfactant to 
cholesterol to dicetyl phosphate was used throughout.  The stability of vesicles 
made using an equimolar ratio of surfactant to cholesterol with the addition of 
13% dicetyl phosphate had already been well described177,178.  A stable vesicle is 
defined as one which maintains a consistent size and retains a constant level of 
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encapsulant178. The first ‘generation’ of niosomes had lipid concentrations 
approximately 10 mM.  The concentration refers to the total lipid concentration in 
the niosome suspension after GEC.  It is calculated from the initial concentration 
of lipids used to make thin films and taking into account the dilution of the 
suspensions during GEC, and the process loss of vesicle as measured by 
particle counts. As a general rule the dilution from post hydration to post GEC is 
10x and the retention of formed vesicles is approximately 75%. 
The lipids were dissolved in chloroform and aliquoted into 50 ml round 
bottomed flasks.  Early films were created by blowing a constant stream of 
nitrogen gas at 5L/min. Later it was determined that residual chloroform could be 
further reduced using a vacuum and so the vacuum pump of the rotary 
evaporator was employed.  Once the films dried they were hydrated by adding 
either 0.01 M PBS, 5.0 mM CF, or 1.0-2.0 mM CR rotating for 1-2 hours in a 
60ºC water bath.  At regular intervals during hydration, the solutions were 
agitated on a vortex mixer.  Once complete, the solution was sonicated for 5-30 
minutes in a bath sonicator at 80 KHz and 80 watts.  Residual chloroform was 
measured by mass balance.  After 24 hours, the chloroform remaining was 
measured to be less than 0.35% of original solvent by mass before hydration.  
Table 4.2 shows the structures and descriptions of the surfactants investigated in 
our research.   The sorbitan monoesters are a family of alkyl esters of identical 
head groups and varying alkyl chain length. Polyoxyethylene (PEO) sorbitan 
monostearate (Tween 61) has the same structure as sorbitan monostearate, as 
the names suggest, but includes multiple PEO polymer chains on its head group.  
  53
The sorbitan monoester (Span) family was investigated because of its well 
documented facility to form vesicles and its biocompatibility; they are widely used 
in food, pharmaceutical and cosmetic industries93. 
Table 4.2 Surfactant Structures and Properties. 
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4.2.3.1.2. GEC Purification 
Once the hydration process is completed, 2 ml of 60˚C sample is injected 
into the sample loop of the chromatography system. A preprogrammed elution 
method is loaded from a PC.  The sample is injected by the system into the 
column from the sample loop through the injection port as 0.01M PBS is added 
continuously at 1.0 ml/min.  As the elution progresses, the system provides 
information about temperature, pressure, conductivity, and UV absorbance at 
280 nm.  The elution method is split into phases where the eluted materials are 
either captured or sent to waste; in the first phase the sample is introduced to the 
column.  Then the system resets the baseline UV reading to 0.  For the first third 
of the void volume the eluted material is discarded, after which the eluted 
material containing the separated niosomes is captured in 2 ml fractions.  Finally, 
once the void volume has passed through the column, the eluted material is 
again sent to waste, and the free dye is flushed from the column.   The maximum 
total volume of the XK 16/60 column is 124 ml.  In order to flush completely after 
a separation, the buffer is run for 2 total column volumes or 240 ml, although the 
bed packing volume is usually about 100 ml, plus or minus 3-5%.   
4.2.3.1.3. UV Absorbance 
The Akta prime system incorporated a UV sensor and automatically 
generated chromatograms for each separation or assessment elution that was 
run.  Although UV is not as sensitive to changes in fluorescent signals as 
fluorescence microscopy is, the curves provided useful run-by-run comparisons 
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of different formulations.  Unfortunately, the results did not prove as easily 
quantifiable as those of the fluorescence reading because both the niosomes and 
the fluorescent dye contained within them contributed to the signal at the 
niosome elution peak as seen in Figure 4.10.   The absorbance of niosomes at 
280 nm which contain no absorbing solution can be explained by the presence of 
double bonds and ring groups in the surfactants.  
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Figure 4.10 Intrinsic UV Absorbance of Niosomes.  Tw-CC-CF represents a 
niosome encapsulating CF dye, and Tw-CC-PBS represents a niosome 
encapsulating PBS.  The Tw-CC-CF curve has a second peak due to the 
absorbance of free dye. PBS does not absorb UV at 280 nm. 
4.2.3.1.4. Niosomes of Differing Surfactant Components 
  Niosomes made from Span 20, Span 40, Span 60, or Tween 61 as the 
surfactant component in 1:1:0.105 molar ratio with cholesterol and DCP were 
made as described encapsulating a 5mM solution of CF.  Table 4.3 shows the 
masses of lipid components used.  The encapsulation of the dye was measured 
by disrupting the vesicles with Triton X 100 in a de-ionized water (DI) solution.  
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Concentrations of entrapped dye were found by comparing the disrupted 
niosome fluorescence intensity to a standard curve.  Standard curves were 
created for each type of dye and new dye solution.  Particle sized distributions 
were run for each of the formulations.   
 
Table 4.3  Low Concentration Example of Vesicle Components.  
 
Surfactant mass(g) Mass (g) Total mols 
Sp20 SP40 Sp60 TW61 cholesterol DCP  
   0.148 0.0437 0.00635 2.37E-04 
  0.01  0.088 0.016 2.80E-04 
 0.094   0.088 0.016 4.90E-04 
0.081    0.088 0.016 4.91E-04 
 
4.2.3.1.5. Increased Lipid Concentrations 
In order to increase the dye entrapment capacity of the niosomes, the lipid 
concentrations were increased 7.5-10 fold, maintaining the original molar ratios 
of the components.  The GEC methods had to be adapted to the more 
concentrated hydrated solution.    
4.2.3.2.   Development of Tween 61-Span 60 Niosome 
In order to conjugate a targeting moiety to a niosome, a linking agent had 
to be conceived of that would either be attached or inserted into the niosomes 
after they are formed, or to be incorporated within the membrane during 
formation.  The latter approach would not require an additional process step or 
potentially affect vesicle stability.  The surfactant Tween 61 shown in the right 
side of Figure 4.12 (also seen in Table 4.2) is nearly identical in structure to Span 
60 except for the additional incorporation of polyethylene branches on the 
hydrophilic head group.  The polyethylene oxide (PEO) groups on the polar head 
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of Tween 61 surfactant potentially could be exploited as a linker for antibody 
conjugation. This linkage is analogous to antibody coupling on the distal end of 
PEG groups added to immunoliposomes 90,179.  
4.2.3.2.1. Tween-Span Mixed Formulations 
Based on the results of the stability studies blends of the surfactant 
component of the vesicles were examined. A combination of Span 60 and Tween 
61 was selected with the aim of retaining the desirable qualities of Span 60 
stability and retention, while maintaining the option to use the PEO polymer 
groups from the Tween 61 on the membrane surface for antibody attachment.  
We looked at combinations of small amounts of Tween 61 (0-10%) incorporated 
with Span 60 while maintaining the 1:1:0.1 molar ratio of surfactant to cholesterol 
to dicetyl phosphate. Table 4.4 shows masses of components used to make films 
of the varied combinations of surfactants.  For each formulation the retention of 
dye over time of the vesicles was compared to the solely Span 60 surfactant 
composition. 
Table 4.4 Masses of Vesicle Components for Varied Tween 61 Surfactant 
Percentages Ratios per Film. 
 
% Tween Tween 61 (g) Span 60 (g) Cholesterol (g) DCP(g) 
1.00% 0.00089 0.08826 0.10132 0.00752
3.25% 0.0028 0.08417 0.10333 0.00767
5.50% 0.00467 0.08027 0.10525 0.00781
7.75% 0.00643 0.07655 0.10707 0.00795
10.00% 0.00811 0.07300 0.10882 0.00808
  
  58
4.2.3.3.  Functionalization of Tween 61 with Cyanuric Chloride 
Tween 61 was functionalized prior to niosome synthesis by activation of 
the hydroxyl groups on the ends of the PEO chains.  In the presence of 
diisopropyl ethyl amine (DIPEA), Tween 61 and cyanuric chloride were incubated 
in a nitrogen environment.  The overall mechanism is shown in Figure 4.11.  The 
cyanuric chloride undergoes nucleophilic substitution binding to the terminal 
hydroxyl group of a PEO chain on the Tween 61 molecule. The molar ratio of 
Tween:CC:DIPEA was 1:0.8:2 90,180 and a 0.2 g/ml solution was made by 
combining 1g Tween 61, 0.124 g CC, 0.274 ml DIPEA, and 5 ml chloroform.  The 
Tween 61 and chloroform were combined in a round bottom flask. Cyanuric 
chloride was added and the DIPEA was withdrawn from a sealed flask using a 
long sharp metal syringe tip and added directly into the mixture.  The flask was 
rotated in a nitrogen environment for 36 hours.   The excess solution was stored 
and remained stable at -4ºC for several months.  The resulting functionalized 
Tween-CC solution was added to the surfactants and lipids in chloroform prior to 
forming a thin film.   
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Figure 4.11 Tween 61 Cyanuric Chloride Linking Mechanism. 
 
4.2.3.4.   Attachment and Verification of Antibody Conjugation 
The GEC purified niosome solutions were adjusted to pH 8.8 by titrating 1 
µl at a time of 1 M sodium hydroxide drop-wise while monitoring the pH.  IgG 
monoclonal antibodies (either fluorescently tagged Alexa-488 (AF)-IgGs or anti 
CD44 IM7) were incubated with the niosomes at a concentration of and gently 
shaken for 16 hours in the dark.  At pH 8.8 the antibody binds to the cyanuric 
chloride linker distal to the vesicle surface shown in Figure 4.12.  Linking of 
antibodies to either of the available chloride groups has equivalent potential 
energy, however linking a subsequent antibody to the second available chloride 
group would require much greater energy of activation, and is not favored when 
other linkers on other molecules are available105.  After antibody conjugation the 
immunoniosome (IN) solution pH is restored to 7.4 using 0.1 M PBS.  
Concentration of antibodies incubated was 5 µg protein /ml niosomes which is 
equivalent to 2.78 µg protein/ µmol lipid. Concentration of total lipids in the post 
GEC niosome solution is 1.8 mM, found by calculation from the original hydration 
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concentration of 0.0144 M accounting for the 6 times dilution factor and particle 
retention efficiency during GEC.   Viable binding groups of Tween-CC linkage are 
52% of the Tween component by calculation.  This value is based on the reaction 
molar ratio (1:0.8 of Tween:CC) and a published binding efficiency (65%) of the 
reaction of CC with 1.2-Dipalmitoyl-sn-glycero-3-phosphoethanolamine 
polyethylene glycol (DPPE-PEG)24.  The overall molar percentage of Tween in 
the total lipid concentration of the niosomes was 4.76%, making the Tween-CC 
linker 2.47% of total lipids, or 0.045 µmol Tween-CC/ml niosomes.  This provides 
2.68 * 1016 binding sites/ml niosomes.  Antibody incubation of 5 µg antibodies/ml 
of niosomes relates to a ratio of greater than 1300:1 Tween-CC binding sites to 
antibodies.   
In order to verify the efficacy of the linker chemistry and establish the 
ability to bind antibodies to the surface of the vesicles, antibodies were 
fluorescently tagged and incubated with non fluorescing niosomes for 
conjugation.  Fluorescent tagging of antibodies was done as described in the 
protocol from a commercially available kit from Molecular Probes. 
 
Figure 4.12 Antibody Conjugation. 
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4.2.3.5. Synovial Lining Cell Culture Methods 
 
Primary cell cultures of bovine synoviocytes were used in niosome 
incubation experiments.  These cells were provided grown and already fixed by a 
collaborator’s laboratory.  The following description of the synoviocyte primary 
culture comes from the resulting publication70.  The synovial membranes were 
harvested from the metacarpal phalangeal joints of 3 month old bovines.  After 
washing with phosphate buffered saline (PBS) the tissues were dispersed in 
0.1% collagenase P in 4% bovine serum albumin (BSA).  Isolated cells were 
washed with PBS suspended in Dulbecco’s DMEM containing 10% fetal calf 
serum at a concentration of 105 cells per ml.  The cells were plated in Labtek 8 
well micro-slides.  Cells were allowed to attach overnight.  The media was 
removed, and the cells washed with PBS and fixed for 2 hours in Histochoice.  A 
subset of fixed cells was immuno-stained with IM7 using standard 
immunohistochemical techniques. 
4.2.3.6. Immunoniosome Synovial Lining Cell Incubation Methods 
The fixed cell layers were pre-incubated in 0.01 M PBS with 2% goat 
serum with or without soluble IM7 antibody for 1 hour at room temperature prior 
to incubation with immunoniosomes.  Cells were rinsed with PBS and incubated 
for 1 hour at 37 ºC with fluorescent niosomes with or without antibody 
conjugation.  The cells were well rinsed to remove unbound niosomes and 
examined by fluorescent microscopy. Imaging of cells, cell nuclei, and INs was 
done with an Olympus 1X71 inverted fluorescent microscope fitted with DAPI and 
FITC (fluorescein isothiocyanate) filters allowing imaging of the green fluorescent 
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niosomes and the blue stained cell nuclei.  For a given image, a phase contrast 
picture was captured, and then the light and filters were changed to fluorescent 
mode to image the cell nuclei using the DAPI filter, and the FITC filter to image 
the fluorescent niosomes bound to the cells.  These images were captured and 
combined using DP-BWR image analysis software to overlay them.   
4.2.3.7. Proof of Concept Cell Binding 
To establish proof-of-concept cell binding, bovine synovial membrane 
lining (SL) cells were plated at 1x 103 cells/mm2 on glass multi-well slides and 
maintained in DMEM with 20% fetal bovine serum, until cells reached near 90% 
confluence.  The cell layers were washed and fixed for 24 hours in Histochoice 
fixative and rewashed Hanks Buffered Saline (HBS). The fixed cell layers were 
pre-incubated in PBS with 2% goat serum with or without soluble IM7 antibody 
for 1 hour at room temperature to prevent non specific binding.  Niosomes used 
in SL cell studies encapsulated 5(6) carboxyrhodamine 110 (CR), a photo-
bleaching resistant fluorescent dye. (Photobleaching is a loss of fluorescence 
intensity due to exposure to intense light.) Cells were rinsed and incubated for 1 
hour at 37 ºC with fluorescent niosomes or fluorescent niosomes derivatized with 
IM7 (purified IgG).  The cells were well rinsed to remove unbound niosomes and 
were examined by fluorescent microscopy.  
4.2.3.8. Statistical Methods 
Statistical differences in experimental values were calculated using 
standard error of the mean (SEM) of at least three repeated measures. The 
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formula for SEM is the ratio of the standard deviation of a data set divided by the 
square root of the number of repeated measures, n.  The standard deviation of a 
set of measured values is defined as the square root of the variance.  The 
variance is the summed deviations of the measured values from the mean of 
those values.  If xi is an observation among n observations and x  is the mean of 
all the observations (the sum of all measured values divided by the number of 
values measured) then the variance is:  
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The standard error of the mean is 
n
DevStSEM .= .  The SEM is represented 
graphically as y-axis error bars in the graphs in this document.  P-values are 
used as another statistical method included in some of the reported data.  In 
hypothesis testing resulting data are evaluated as being different than the mean 
of the measured values within a range of values.  A p-value is defined as the 
probability of a measure to be different than the mean of the measured values.  If 
a p-value of <0.001 is reported then there is less than 0.1% chance that there is 
no difference in the means of the measured value versus the comparison value, 
usually a control 181. 
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4.2.4. Experimental Designs  
4.2.4.1. Vesicle Formulation Assessment 
4.2.4.1.1. Sorbitan Ester Formulations 
Entrapment efficiency and membrane permeability of varied formulations 
of niosomes were evaluated.  Size reduction through sonication over time was 
assessed in each formulation.  Dye encapsulation capacity was assessed in 
each formulation.  Additionally the effect of sonication on vesicle size and count 
was evaluated in the different Span compositions.  The ability to accurately 
evaluate the entrapment of dye by niosomes depends on the ability to completely 
disrupt them.   
4.2.4.1.2. Tween-Span US Exposure Stability Study 
 Based on the results of the studies done on the different surfactant 
candidates, niosome made from either Tween or Span 60 as the surfactant 
component were evaluated for stability.   The different vesicle formulations were 
exposed to diagnostic ultrasound at 0, 5, 10 minutes using a transducer and an 
Accuson Aspen echocardiography machine.  Machine settings were kept 
constant throughout the experiment with the frequency set to 3.5 MHz, the 
dynamic range set to 70dB, and the initial gain set to 10 dB.  During the 
experiment the mechanical index of the instrument was varied.  Mechanical index 
(MI) is the ratio of the acoustic pressure over the square root of frequency.  
Therefore max MI corresponds to a maximum acoustic pressure at a given 
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frequency.   The formula is  
f
PMI =   where P is pressure in MPa, and f is 
frequency in MHz.  The spatial peak temporal average was 46 mW/cm2, and the 
total absolute power was 65 mW. Fluorescence readings of the niosomes and 
suspending fluid were obtained at 5 minute increments over 15 minutes of 
ultrasound exposure.  All vesicle characterization measurements were repeated 
three times at each 5 minute time increment. 
4.2.4.2. Polyoxyethylene Sorbitan Monostearate-Cyanuric Chloride 
Linker Chemistry 
 
  The Tween-CC linkers were prepared as described and tested by first 
attaching the fluorescently tagged IgG antibodies to non fluorescing niosomes 
and assessing the vesicle morphology and fluorescence of the resulting 
suspension, by GEC elution of the vesicle suspension.  To further verify the 
antibody binding to the niosomes, the post GEC purified AF-immunoniosomes 
were examined with an Olympus 1X71 inverted fluorescent microscope.  
Approximately 50 µl of immunoniosome suspension was pipetted onto a glass 
microscope slide and viewed at 10 and 40x using a FITC filter to verify the 
presence of fluorescent spherical particles.   Fluorescent images where captured 
using the Olympus DP-BSW software. 
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4.3. Results  
4.3.1. Sorbitan Ester Vesicle Formulations 
4.3.1.1. Results of the Varied Sorbitan Ester Formulations 
The varied formulations were evaluated for entrapment by fluorescent 
measurements and particle sizing.   The entrapment of dye by each formulation 
is shown in Figure 4.13.   The Tween 61 niosome shows the greatest 
encapsulation of dye, followed by Span 60.  Entrapment decreases with 
decreasing alkyl chain length.   Figures 4.14 show that Span 60 forms the 
greatest number of vesicles after hydration and retains the greatest amount of 
dye after GEC.   
 
Figure 4.13 Encapsulation of CF by Surfactant Type. 
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Figure 4.14 Formation of Niosomes after Hydration by Surfactant Type. 
 
In order to reduce vesicle size and lamellar number (number of bilayers) 
bath sonication over a range of times was tested in the Span 20 and Span 40 
niosomes after hydration and before GEC.  The data in Figure 4.15 show that 
vesicle size (number weight mean) decreases and vesicle count increases over 
sonication time to an asymptotic value.  The effect of sonication on the different 
surfactants is not identical however.  The concentration of particles greater than 
0.5 µm (the detection limit of particle size analyzer) of the Span 20 vesicles 
increases and reaches an asymptotic limit with sonication time while the 
concentration of the Span 40 particles increase to a greater degree and 
fluctuated more greatly.  With both surfactants the mean particle diameter 
decreases with sonication then levels out.  This is to be expected since 
sonication of vesicles reduces the number of bilayers in the vesicles and disrupts 
aggregates182 and is directly seen in the micrograph shown in Figure 4.16 which 
shows a light microscopy image of a PBS containing niosome sample on a 
hemocytometer slide before and after sonication which was used to reduce and 
unify particle size and lamellarity 183. 
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Figure 4.17 shows the effect on sonication over the entire vesicle size 
distribution. The curves show the particle size distribution of the unsonicated 
versus sonicated vesicles of Span 60 niosomes. The size distribution clearly 
shifts downward after sonication.  Based on the results of the Span 20 and Span 
40 niosomes it is assumed that a portion of the population of the Span 60 
niosomes that are not seen in the post sonication distribution have dropped 
below the detection limit of the PSS. 
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Figure 4.15 The Effect of Sonication Time on Particle Size and Counts. 
 
 
Figure 4.16 Sonication Effects. The Effect of Sonication on Vesicle Size 
Distribution in Span 60 Niosomes. 
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Figure 4.17 PSD Sonication Effects. The graph shows the shift in Particle Size 
Distribution in a bath sonicated Span 60 nisome sample.  The blue curve is the 
size distribution of the sample before sonication, and the red curve represent the 
distribution after sonication. 
 
4.3.1.2. Results of Ultrasound Exposure on Niosomes  
Ultrasound exposure experiments were conducted on niosomes whose 
surfactant component was either Tween 61 or Span 60, based on the results of 
the earlier sorbitan ester experiments, establishing the two as the candidate 
surfactants.  Vesicle suspensions of the different formulations were monitored by 
particle size distribution and fluorescence intensity measurements.  The graphs 
shown in Figure 4.18 represent the particle size distributions (PSD) of the control 
and experimental samples over the duration of the experiment.  On the left the 
curves represent the PSDs of the Span 60 niosomes before (blue) and after (red) 
US exposure.  The right side of Figure 4.18 shows the same thing for the Tween 
61 niosomes.  It is clear by the closeness of the curves in each that the disruptive 
effect of US on the formed particles was minimal.  The particle counts are 
expressed in numbers per ml of sample. 
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Figure 4.18 PSDs with Respect to US Exposure.  Left: Span 60 niosomes; right; 
Tween 61 niosomes.  For each blue is prior to US exposure, and red is after. 
 
In Figure 4.19 the effect of US exposure time is seen to be significantly 
greater in the Tween 61 niosomes than the Span 60 niosomes.  Figure 4.20 
indicates that release of dye is shown to increase with increased mechanical 
index in Tween 61 niosomes, whereas the stability of the vesicles in the Span 60 
with MI as shown in Figure 4.21.  Taken all together, the stability of the Span 60 
niosome and its ability to retain encapsulated materials is demonstrated to be 
greater than that of the Tween 61.  However, for controlled rapid release a 
Tween 61 vesicle may be desirable. 
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Figure 4.19 The Effect of US Exposure Time on Release of CF.  Error bars 
represent SEM of n>=3. 
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Figure 4.20 The Effect of MI on Released CF in a Tween 61 Niosome.  Error bars 
represent SEM of n>=3. 
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Figure 4.21 The Effect of MI on Particle Retention in the Span 60 Niosomes.  
Error bars represent SEM of n>=3. 
 
4.3.2. Results of Surfactant Blending 
Since the formulation of niosomes with Tween 61 as the sole surfactant 
component were seen to be less stable than the Span 60 niosomes both 
statically, and when stressed, the effect of the inclusion of a range of small molar 
percentages of Tween 61 in a Span 60 niosome on vesicle entrapment capacity 
and membrane stability was evaluated.  This was measured by retention of 
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entrapped dye over time at 4ºC in a PBS suspension.  Although Tween 61 
niosomes are reported to have a greater entrapment capacity 184 (which was 
confirmed by the data shown in Figure 4.13),  the observation was that niosomes 
whose surfactant component was entirely composed of Tween 61 lost three 
times more encapsulated dye relative to niosome formulations whose surfactant 
component was purely Span 60 under static conditions holding cholesterol and 
DCP molar ratios constant as shown in the tabulated values in the right side of 
Figure 4.22.   On the left side of the figure the data indicate that the inclusion of 
up to 10% by mole of Tween 61 had no significant effect on the retention of dye 
over the time examined.  Statistical differences were judged by evaluating the 
overlap of standard error of the mean graphically. Also, in order to increase the 
entrapment capacity of the vesicles, and therefore increase potential drug 
entrapment, the overall mass of lipids used was increased.  The results of the 
increase can be seen in the overlay chromatogram shown in Figure 4.23. 
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Figure 4.22 The Retention of CF in Tween 61-Span 60 Niosomes. Left: graphical 
depiction of the inclusion of 1-10% Tween.  Right:  Overall retention of dye in 
various formulations in 15 or more days. 
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Figure 4.23 Increased UV signal with Increased Lipid Concentration in Tw-CC-
CF Niosomes. 
 
 
4.3.3. Results of Linking Chemistry Development 
The verification of the linking chemistry was tested in two ways; first was 
the assessment of the elution of PBS containing niosomes conjugated to 
Alexafluor tagged antibodies.  After incubation with the antibodies the niosomes 
were purified using GEC which should have resulted in a suspension of non 
fluorescing niosomes conjugated to fluorescent antibodies.  That purified 
suspension was eluted through a GEC column and measured by UV absorbance 
at a wavelength of 280 nm.  Figure 4.24 shows a signal in the niosome elution 
volume.  There is also a very slight signal in the antibody elution volume (before 
120 ml) which show a few free AF antibodies; the protein and the bound dye 
would both contribute to the signal at that wavelength. 
This indicates that there are negligible numbers of free antibodies in the 
solution and demonstrates successful attachment of Alexa Fluor tagged IgGs to 
PBS containing niosomes.   
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Secondly, the niosome suspension was imaged using fluorescence 
microscopy as seen in Figure 4.25.  Further confirmation of the conjugation of AF 
antibodies was evident when fluorescent spheres were evident under a 
fluorescent microscope using a FITC filter.   The presence of distinct and discrete 
spherical fluorescent particles confirms the conjugation of the fluorescent 
antibodies to the non fluorescing niosomes and the efficacy of the linker to attach 
the antibodies to the surface of the niosome membrane. The discrete fluorescent 
spheres appear to be of the same size and relative size distribution of niosomes.  
These two independent measures indicate successful antibody conjugation of the 
AF antibodies to non fluorescing niosomes. 
 
Figure 4.24 Elution of IN with Fluorescent Antibodies. 
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Figure 4.25 Fluorescent micrograph of IN with Fluorescent Antibodies. 
 
The effect of the Tween-CC linker on the 10% Tween 61 niosome was 
evaluated over 22 days.  Figure 4.26 shows an overlay of four separate elutions 
of the same sample of post-GEC 10%Tween 61 niosomes.  Due to slight 
differences in column packing and suspension injection the chromatograms do 
not line up perfectly, but do indicate very little variation in the suspension over 
time.  
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Figure 4.26 Stability of the 10%Tw-CC-CR Post GEC Niosome. 
 
4.3.4. Binding of Immunoniosomes to Synovial Lining Cells 
The binding of the immunoniosomes to the target antigen in a fixed cell 
model was confirmed as follows. The fluorescent and light micrographs shown in 
Figure 4.27 demonstrate the specificity and selectivity of immunoniosome binding 
to target antigens.  The upper micrograph figures of cells (A, C, and E) 
correspond exactly to the fluorescent micrographs below them (B, D, and F).   
Parts A and B of Figure 4.27 correspond to the cells incubated with IM7 tagged 
niosomes and show binding of the immuno-niosomes evident by the bright 
spherical shapes attached at cell processes and cell membranes.  Whereas the 
cells pre-incubated with free IM7, shown in C and D, do not show the small 
spherical attachments due to blocking of the targeted binding sites.  This 
demonstrates the targeting selectivity of antibody antigen binding.  In parts E and 
F, cells have been incubated with unconjugated niosomes.  Additionally, the 
absence of binding in the cells incubated with untagged niosomes, parts E and F, 
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demonstrates the specificity.  In all of the fluorescence images some 
autofluorescence of cells is evident, but clearly distinct from the brighter point-like 
images of the fluorescent niosomes. In the left hand side of Figure 4.28, IHC 
staining techniques show the CD44 expression at the cell processes and at the 
cell membranes as indicated by the red arrows.  Correspondingly, binding of 
green fluorescent INs in the right hand side of Figure 4.28 is seen at cell 
processes and membranes.   
 
 
Figure 4.27 Experimental and Control Images of Synovial Lining Cells.  The 
upper slides (A), (C), and (E) show contrast micrographs and the lower slides 
(B), (D), and (F) are the corresponding fluorescent micrographs of those above 
them captured using a FITC filter. (A) and (B) show SL cells incubated with IM7-
tagged niosomes containing 1 mM CR dye. (C) and (D) are SL cells pre-
incubated with free IM7.  (E) and (F) are cells incubated with untargeted 
niosomes (no IM7). 
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Figure 4.28 Synovial Lining Cells.  Left: IHC stained for CD 44 with nuclear 
counterstaining.  Arrows indicate CD44 expressed on cell processes. (40 x 
magnification Olympus BH 2) 
 
4.4. Discussion 
The results of the experiments to this point confirm the capacity to develop 
monoclonal antibody conjugated niosomes targeted to specific cell receptors. 
The investigation of members of sorbitan ester family as the candidate surfactant 
in our vesicle revealed that Span 60 had the best combination of entrapment 
capacity, stability and retention versus the others studied.  However, since the 
polyoxyethylene polymers on the Tween 61 head group extend distal to the 
surface of the formed niosome they would provide ideal linking moieties for 
antibody conjugation.  Blending the surfactants in order to retain the desired 
properties of each surfactant was conceived and the results showed that the 
inclusion of as much as 10% of Tween 61 within a niosome composed of Span 
60 in the surfactant component maintained the desirable stability and retention 
properties of the ‘purely’ Span 60 niosome.  Sorbitan monostearate based 
niosomes can be functionalized through inclusion of a cyanuric chloride 
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derivatized polyoxyethylene monostearate to conjugate monoclonal IgG 
antibodies to the vesicle surfaces without requiring derivatization of the antibody.   
The coupling of IgG antibodies to formed and purified vesicles was 
verified.  The resulting ‘immunoniosome’ was shown to bind to target antigens in 
fixed cells.  In the fixed SL cell model targeting shows high selectivity and 
specificity demonstrated by the lack of IN binding to the target antigen when 
blocked with free antibodies specific to the antigen, and also the inability of 
untargeted (non antibody conjugated) niosomes to bind to cells.  The results of 
the fixed cell SL binding studies demonstrated that further investigations were 
warranted to investigate binding and then uptake by inflamed endothelial cells in 
vitro and in vivo.   The implications for therapeutic treatment of inflammatory 
diseases is significant not only in the capacity to target chemical therapy to 
affected tissues but also to block receptors of inflammatory pathways and to 
interrupt the perpetuating effect of the process 178.  Also, since the attachment of 
antibodies is independent of the type and generic to any IgG antibody, the 
system’s therapeutic targeting is flexible and may include more than one 
targeting vector if desired.  
In order to pursue live cell uptake experiments the size and particle 
distribution of INs would have to be addressed.  Size reduction protocols using 
extrusion, and monitored by sub-micron particle sizing,  would modify and verify 
vesicles of size conducive to cellular uptake177.   Additionally, measurement of 
optimal antibody coating density would need to be pursued.  By using activated 
fixed aortic endothelial cells (an appropriate model for vascular inflammatory 
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drug uptake studies) optimizations of the drug targeting system could be 
conducted prior to pursuing live cell uptake studies.  In liposome applications, as 
few as tens of antibodies or antibody fragments 185 conjugated per vesicle have 
shown binding and cellular uptake, necessitating the optimization of our immuno-
conjugation.   
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5. Fixed Endothelial Cell and Immunoniosome Binding Studies 
5.1. Background 
5.1.1. Endothelial Cells Antibody-Targeted Drug Delivery 
 
Endothelial cells are a type of epithelial cell; they are single-layer simple 
squamous epithelial cells which line blood vessels and are therefore the 
mediating layer between the blood stream and the tissue that they line.  Varying 
targeting drug delivery strategies have been studied using activated endothelial 
cells expressing adhesion molecules.  Different targeting schemes have been 
reviewed and/or studied including cardiovascular liposome targeting, 
nanomedicine, pulmonary targeting of liposomes with antioxidants and anti-
thrombotics,  and enzymatic therapeutics, also using polymeric nanocarriers.  
Vesicular or nanocarrier cardiovascular targeting strategies frequently include an 
endothelial cell model with a target adhesion molecule and the corresponding 
antigen vector.  In the studies described in this section 10%Tween-CC niosomes 
conjugated with an anti-CD44 antibody were targeted to bovine aortic endothelial 
cells (BAECs). 
The aim was to verify and quantify binding of the INs to activated BAECS 
under differing experimental variables such as incubation time, concentration of 
lipid and antibody coating.  Throughout these BAEC fixed cell binding 
experiments the niosome abbreviation IN refers to the formulation defined in Part 
4, the blended surfactant niosome with the Tween 61-cyanuric chloride linker, 
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containing the photobleaching resistant dye, carboxyrhodamine (CR), conjugated 
to the anti-CD44 antibody, IM7. 
5.2. Materials and Methods 
5.2.1. Materials and Chemicals 
 
Included in this list are the materials and chemicals new to this phase of 
the project that were not included in Section 4.2.2.1.   Cambrex endothelial cell 
basal media (EBM), bovine calf serum, penicillin-streptomycin, 0.05% (w/v) 
Trypsin-EDTA solution,  99% HEPES sodium salt,  and 100% ethanol all came 
from Fisher Scientific, as did all the pipettes, flasks, filters, syringes, and 
centrifuge tubes. The secondary antibodies used for IHC came from Sigma 
Chemical as did the Tris buffer, and sodium acetate. Cryo-preserved endothelial 
cells (BAEC) came from Clonetics, Inc. The IHC ABC staining kit (Cat# PK 7200) 
came from Vector labs, as did the diamino benzidine (DAB) substrate kit 
(SK4100), the diamidino-2-phenylindole (DAPI) nuclear mounting stain, and the 
hard set mounting media.  The potassium ferricyanide and uranyl acetate were a 
kind gift from Ed Haller from the Pathology Department of USF Health.  Osmium 
tetroxide and gelatin came from USF Health Core facilities. 
5.2.2. Methods 
5.2.2.1. Endothelial Cell Culture 
Endothelial cells were grown using classical sterile techniques in 25cm2 
sized cell culture flasks in endothelial basal media supplemented with 10% fetal 
calf serum, 1% penicillin-streptomycin and 1% non essential amino acids.  Cryo-
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preserved cells were started on flasks that had been coated with collagen to 
encourage adhesion.  Cell growth media was changed every 2-3 days.  The cells 
were cultured to a confluent monolayer and then sub-cultured into 8 well micro-
slides for incubation with INs and subsequent imaging.  Cells were sub-cultured 
by releasing their adherence from flasks with the enzyme trypsin, which is a 
serine protease of the pancreas which breaks down peptide bonds of the 
carboxyl groups of amino acids arginine and lysine.  The commercially available, 
purified form of trypsin is used commonly in cell culture to release cells from 
culture vessel surfaces.   
To release the cells from the flasks, first the growth media was removed 
by pipette, and then the cells were rinsed several times with 37˚C 0.01 M PBS to 
eliminate the anti-trypsin agents present in the endothelial media.  Next 2 ml of 
0.05% trypsin was added to the flask and incubated at 37˚C for 5-10 minutes.  
Release of cells from the surface was monitored using a phase contrast 
microscope.  Once the cells were released, the vessel wall was washed further 
with PBS, and the suspended cells were centrifuged for 3-4 minutes at 3000 rpm.  
The trypsin and PBS were removed by pipette from the resulting pellet of cells 
which were re-suspended in growth media and 400 µl aliquots were added to the 
individual wells of the micro-slides.   
The cells grew to near confluence in 1-2 days.  A day prior to incubation 
with INs, fresh media supplemented with 7 ng/ml TNF-α  (an inflammatory 
cytokine whose role in adhesion molecule expression is described in Section 2.3) 
was added to the culture to activate the cells and induce the expression of 
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adhesion molecule CD44.  Prior to incubation with INs the cells were fixed 
overnight with either Histochoice, for IHC staining, or with paraformadehyde, for 
fluorescence imaging.   
5.2.2.1.1. Gelatin Coating Procedure 
Coating of culture vessels with either collagen, gelatin or fibronectin helps 
encourage primary or cryo-preserved endothelial cells to proliferate in initial 
culturing.   A 2% by weight solution of solid gelatin was prepared in pyrogen free 
deionized (DI) water for flask coating.   The DI was heated to 80°C and the 
gelatin was dissolved in the water.  The dissolved gelatin and water were kept at 
the increased temperature for 10 minutes and then the solution was cooled to 
about 30˚C and filtered with a 0.22 µm syringe filter.  If the solution is allowed to 
cool too much then filtration becomes very difficult.  Then 1.5-2.0 ml of the 
solution was added to 25 cm2 culture flasks and incubated at 37˚C for 4 hours or 
longer. The excess solution was drawn off with a pipette and discarded while 
working under the sterile hood.  Unused gelatin solution can be stored at 4˚C for 
later use. 
5.2.2.2. Cell Fixation 
Fixation of cells stabilizes the structure and allows solvents to penetrate 
the plasma membrane.  Paraformaldehyde (PF), which does not fix by cross 
linking, has been identified as being the best preservative of cell structures.  
Because PF does not induce autofluorescence it is also a preferred fixative in 
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fluorescent microscopy applications.  Typically concentrations of 2-4% in buffer 
solution are reported for cell fixation.   
5.2.2.3. Immunohistochemical Staining 
Immunohistochemistry (IHC) is used to demonstrate the presence and 
location of antigens in cells or tissues.  There are several factors which 
determine how well the antigen will be detected, chief among them the density 
and dispersity of the antigens presented on the cells. The fixative type can have 
an effect on antibody-antigen binding if the cells structure is greatly changed in 
the fixation process.  Detection is also impaired due to the antigen signal versus 
non specific background binding.  This can be offset by using a blocking buffer, 
usually a non specific protein or serum of the antibody host.   The specificity of 
the antibody used is also important.  Monoclonal antibodies give the most 
specific binding and lowest background, especially when used after a binding 
buffer treatment.  
A subset of the experimental cells which had been TNF-α activated but 
not incubated with INs underwent IHC staining to verify the expression of the 
target antigen, CD44.   The commercially available kit from Vector Labs that was 
used employs an immunoperoxidase procedure with avidin-biotin binding.  
Avadin is a 68 kDa glycoprotein that has a very high affinity (1015/M) to bind to 
the smaller biotin molecule.  This affinity makes the binding essentially 
irreversible, and is 106 times greater than any antibody-antigen association. The 
kit is purchased specific to the cell type (e.g. mouse IgG) and primary antibody 
employed, and the primary antibody is specific to the target antigen to be 
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detected.  The general idea is that the primary antibody will adhere to the antigen 
that you wish to identify, and a secondary biotinylated antibody will adhere to the 
primary antibody.  The biotin groups on the secondary antibody provide binding 
sites for the avidin biotinylated enzyme complex containing horseradish 
peroxidase.   Cell nuclei were counterstained with diaminobenzidine (DAB) which 
provided an orientation of the expressed antigen relative to the rest of the cell.  
The staining procedure was carried out according to the instructions of the 
manufacturer. 
5.2.3. Incubation Experiments 
5.2.3.1. Design of Experiments  
The aim of the experiments was to assess the ability to bind the 
10%Tween-CC-CR niosome conjugated to IM7 with activated endothelial cells, 
and to examine the effect of experimental and design variables on binding.  
Variables examined, shown in Table 5.1, were incubation time, lipid 
concentration, and antibody coating density.   Each variable was given an 
individual eight well microslide.  Whenever PBS is mentioned the concentration 
was 0.01M unless otherwise indicated. 
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Table 5.1 Experimental Variables of BAEC-IN Binding Experiments. 
Concentration of IgG 
 (ug/ml) 
Lipid Conc. 
(mM) 
Incubation 
Time (hours) 
5.00 1.0125 mM 4 
0.50 5.0625 mM 2 
0.05 10.125 mM 1  
Control niosomes (non INs) 10.125 mM  
Control Abs  (pre IM7 post IN) 10.125 mM  
 
 
After incubation the cells were imaged with fluorescence microscopy to 
ascertain niosome binding relative to cell binding density by measuring the 
fluorescence intensity of the green bound niosomes and the blue DAPI stained 
cell nuclei.  A custom made MatlabTM analysis program described in Section 
5.2.4.3 allowed for the analysis of the fluorescent images and quantify the 
fluorescence intensity of binding relative to cell density.  The first set of 
experiments were done at an antibody concentration of 5.0 µg/ml antibody, and 
then the other antibody densities were examined with optimal variables found in 
the time and lipid concentration studies. 
In order to verify binding independent of the fluorescent techniques a 
subset of IN incubated BAECs were separately fixed and coated for imaging by 
scanning electron microscopy (SEM).   
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5.2.4. Description of Methods 
5.2.4.1. Incubation of Niosomes with Endothelial Cells 
Cells grown in 8 well micro-slides were fixed with 4% paraformaldehyde 
diluted in 0.01 M PBS at 4˚C overnight. Prior to incubation the fixative was rinsed 
from cells three times with PBS.  The cells were pre-incubated with 2% goat 
serum in PBS for 1 hour at 37˚C to prevent non specific protein interactions and 
then were rinsed three times with PBS.  The niosomes were added to the cells 
and incubated for the designated time.  After the IN-cell incubation the cells were 
rinsed three times with PBS and a drop of DAPI nuclear stain was added to each 
well.  After staining, the wells were removed from the slide and the mounting 
media was added drop-wise to the slide and a cover slip was placed over the 
cells and was left to dry before imaging. 
5.2.4.2. Fluorescent Microscopy Imaging of Incubated Cells 
Fluorescent and phase contrast imaging of cells, cell nuclei, and INs was 
done as described in Section 4.3.2.6.    Each treatment variable was imaged 
multiple times (3-5) in multiple wells (2-4) at 20x and 40x magnification.   
5.2.4.3. Image Analysis 
Overlays of fluorescent and phase contrast images were created as 
described in Section 4.2.3.6 in order to visualize binding. In order to quantify 
binding the images were analyzed using a customized image analysis Matlab™ 
(Mathworks) program.  Example output and compiled data from the program is 
included in Appendix D.  Essentially a graphic user interface was developed in 
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which the user first is prompted to import the fluorescent image of the nuclei as 
shown in Figure 5.1 left.  The image includes a scale bar, and the program uses 
it for calibration.  The right side of Figure 5.1 demonstrates the next step as the 
user is prompted to crop the image (if desired), before setting a threshold value 
of image intensity.  Setting the threshold allows the user to compensate for 
variability in image clarity and intensity and can be an iterative process with the 
desired outcome being the identification of the individual nuclei and the removal 
of background noise, as shown by the image in Figure 5.2.  Once the threshold is 
established, the nuclei are individually identified and counted, shown in the right 
side of Figure 5.2, by running Process 1.  Process 1 measures the area of each 
identified nuclei and creates minimum, maximum, and average values for the 
group, and then, using those values, it evaluates whether each one is a single or 
greater count (Figure 5.3) and then sums the group. 
 
 
Figure 5.1 Matlab Program Importing and Cropping. Left: Importing of the 
fluorescent nuclei image. Right: The original image is cropped for analysis. 
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Figure 5.2 Matlab Program Image Sorting.  Left: Setting the threshold in process 
1. Right: The identified objects are sorted and counted. 
 
 
 
 
Figure 5.3 Matlab Program Image Analysis. 
 
The fluorescent image of the niosomes which correspond to the same field 
as the previously imported nuclei image was imported (Figure 5.4 left).  The 
same process of setting a threshold was repeated. Process 2 sorts the niosome 
images.  Once the overall process was finished the program has calculated the 
number of cells, the total area of cell nuclei and the cell density, the niosome 
count, and created an overlay image of the two processed fluorescent images as 
seen in Figure 5.4 right.  The discrete counting of niosomes was amended to 
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calculating fluorescent area of the niosomes instead, reasons for which will be 
discussed in greater detail in the results section, Section 5.3.1.   
 
Figure 5.4 Matlab Program Fluorescent Nuclei and IN Overlay. Left: Importing 
the IN fluorescent images.  Right: Overlay of processed images 
5.2.4.4. Scanning Electron Microscopy  
Scanning electron microscopy was used to verify the binding of niosomes 
to cells independent of the fluorescent measures, and to assess the patterns of 
surface binding of niosomes to endothelial cells.  The cells were grown on square 
glass cover slips to allow for fixation and metal coating prior to SEM imaging.  
Before incubation with INs, the BAECs were rinsed with 37˚ C PBS several times 
to remove serum proteins, and then were fixed with 2.5% glutaraldehyde in PBS 
overnight at 4˚C.  The fixed cells were rinsed three times with PBS (cells may be 
stored at 4˚C in PBS at this point, if required).  Cells were then incubated with 
niosomes at 37˚C for the designated times and rinsed with PBS three times 
again afterwards.  A 1.5% potassium ferricyanide-1% osmium tetroxide solution 
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was prepared under a fume hood in DI and added to the cells to incubate in the 
dark for 1 hour1.   
Once the osmium fixation step was completed, the cells were rinsed three 
times with a 0.1 M sodium acetate buffer.  The lipids of the niosome membranes 
were fixed with the addition of a 1.5% uranyl acetate solution in 0.1 M Tris buffer 
for an hour.  Before the dehydration began, the fixative was rinsed three times 
with sodium acetate buffer.  Dehydration was done in a graded series for 5 
minutes per treatment starting with 30% ethanol, then 70%, 95%, and 100% 
twice.  Once the cells were dehydrated, they were substituted with a 1:1 
preparation of hexamethyldisilazane (HMDS) and 100% ethanol for five minutes 
followed by two five minute treatments of pure HMDS. The coverslips of fixed 
cells and niosomes were dried under the fume hood.  After this fixation process 
they were mounted on stubs and sputter coated by Ed Haller in the USF Health 
core facilities lab.  The SEM imaging was done with Betty Loorman of the 
Biological Electron Microscope Facility of the Biology Department at USF on a 
JOEL JSM 35 scanning electron microscope.  
 
  
                                                 
1 Extreme care must be taken working with these strong fixatives which 
can rapidly fix mucous membranes at low concentrations, and all contact with 
liquid and fumes must be avoided.  Dispose of chemicals in a dedicated OsO4 
container.  
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5.3. Results  
5.3.1. Endothelial Cell-Immunoniosome Images 
5.3.1.1. Fluorescent Micrographs 
Figure 5.5 shows the IHC stained BAECs with nuclear counterstain after 
activation with TNF-α.  White arrows indicate expressed CD44 on cell surfaces 
and processes.  Correspondingly, the two images in Figure 5.6 shows the green 
fluorescent niosomes attached to the cell processes and surfaces at different 
magnifications.  Both images represent INs conjugated to 5µg/ml IM7 antibodies 
and incubated for 2 hours prior to imaging.     
 
Figure 5.5 Immunohistochemical stain for CD44. 
 
 
 
Figure 5.6 Fluorescent and Contrast Overlay of BAECs and INs. Left: 40x 
magnification. Right 20x. 
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5.3.1.2. Scanning Electron Micrograph Images 
The left side of the SEM image shown in Figure 5.7 shows fixed cells 
incubated with INs, and the right side is a control of the same group of cells that 
were not incubated with INs.  The vesicles seen on the cell surface of the left 
image are spherical and appear to be approximately the same size as the post 
GEC niosomes.  The comparison was made by matching the vesicles to the 1 
µm white line above the 10 µm scale line as shown. 
 
Figure 5.7 Scanning Electron Micrographs of BAECs. Left: INs bound to cell 
surfaces. Right: Control. 
 
The graph in the left side of Figure 5.8 shows the effect of lipid 
concentration on relative binding density at different incubation times.  The graph 
in the right side of Figure 5.8 displays the same data relative to incubation time at 
the different lipid concentrations, and the control data shown there reflect the 
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incubation of non targeted niosomes (without conjugated antibodies) at the 
maximum lipid concentration.  
Figure 5.9 shows the affect of antibody concentration on the relative 
binding of INs to fixed BAECs.  In all graphs the error bars represent the 
standard error of the mean with n>=3. 
 
Figure 5.8 Binding Density with Respect to Time and Concentration.  Left: 
Binding density with respect to lipid concentration at different incubation times.  
Right: Binding with respect to time at different lipid concentrations as compared 
to controls. All p<0.01 as compared to controls. 
 
Figure 5.9 Binding Density with Respect to Antibody Concentration.   Graph 
shows relative binding density at 1 and 2 hour incubation times. 
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5.4. Discussion 
The aim of the experiments was to establish definitively that the drug 
targeting system would bind to fixed endothelial cells at the target antigen.  The 
IHC staining of Figure 5.5 indicates that CD44 was expressed on the fixed bovine 
endothelial cells at the cell processes and surface.  The two fluorescent 
micrograph-overlay images shown in Figure 5.6 indicate binding of the vesicles in 
those regions.  Furthermore, examination of the SEM images in Figure 5.7 shows 
that vesicles of the right size and shape were observed bound to cell surfaces 
and that similarly shaped features were not observed in the control image.  The 
binding of the vesicles to cell surfaces is observed in both cases to be non-
homogeneous, and the accumulation of multiple vesicles concentrated in small 
areas as compared to relatively sparse binding in other areas led us to believe 
that discrete counting of bound INs by fluorescent measures would be 
inaccurate.  The original MatlabTM routine created a ratio of discrete counts of cell 
nuclei to discrete counts of niosomes.  Once the SEM data revealed that 
niosomes may be bound closely together in groups making individual counting 
unlikely, the analysis was reconfigured to measure fluorescence intensity by area 
of binding and the data are shown to reflect binding area relative to controls.   
  The graph in Figure 5.8 left shows that the binding of INs at 1hour 
incubation time is independent of concentration of lipids.  The binding intensity at 
1 hour corresponded exactly to what was observed in the synovial lining studies.  
At increased incubation times the binding increased at the 5 mM lipid 
concentration, but little increased binding was observed in either an increase in 
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incubation time or in an increase in lipid concentration.  The graph of Figure 5.8 
right shows the same data with the controls included to clarify the effect of time 
on binding density with respect to each of the lipid concentrations.  The control 
data at each incubation time represent non-immunoniosomes incubated at the 
maximum lipid concentration. 
Immunoniosome binding relative to different coatings of antibody 
concentrations is shown in Figure 5.9.  With increasing antibody concentrations, 
increased relative binding was observed, although at the lower antibody 
concentrations there appeared to be no variation in binding at 4 hours.  Binding 
of INs at 1 hour was not studied based on the previous data.  Additional testing of 
binding relative to concentrations of antibodies between 1-5 µg/ml may yield an 
optimum point.   
 In conclusion, the results shown indicate that INs bind to activated fixed 
endothelial cells specifically and in a non homogeneous pattern.  The binding 
relative to time and lipid concentration increased to a limiting value but antibody 
concentration did not for the concentrations studied.   For the treatments studied, 
5 mM at 2 hours appears to be optimum in binding density while conserving 
material.  Further studies will be conducted to investigate uptake up by live 
endothelial cells in vitro to prepare for in vivo animal studies.   Section 6 
describes the uptake of IM7 conjugated immunoniosomes in live cells. 
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6. Live Endothelial Cell Uptake Studies 
6.1. Background  
6.1.1. Live Endothelial Cells in Targeted Drug Delivery  
Live endothelial cells have been used as a cell model for testing drug 
targeting efficacy for many applications including immunoliposomes targeting 
inflammation and for delivering anti-thrombolytics, and echogenic 
immunoliposomes for imaging and targeting.  The cells have been used in flow 
experiments for tumor targeting, using antibody fragments, and to address 
targeting of quiescent versus proliferating cells.  Uptake of antibody targeted drug 
delivery vesicles is highly dependent on the target antigen, as previously 
described (Section 2.3).  In order to further investigate the IM7 conjugated 
immunoniosome as an effective treatment against inflammation the uptake of the 
vesicles into cells needed to be verified using live cells.  Additionally, since 
accumulation, permeability, and uptake of vesicle by cells has been well 
established as being size dependent the size of the vesicles would need to be 
reduced.  A study involving liposomes suggests that the preferential size for 
uptake by atherosclerotic lesions is 200 nm.  Size reduction of niosomes has 
been reviewed115 and includes probe sonication, extrusion through polycarbonate 
filters, micro-fluidization, and high pressure homogenization.  Extrusion gave the 
best size control while maintaining comparable levels of encapsulation.   
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Microscopic methods used for investigating IN uptake by activated BAECs 
were confocal microscopy and transmission electron microscopy (TEM).  With 
confocal microscopy fluorescent images are captured in multiple x-y planes in a z 
direction.  The result provides three-dimensional information about cellular 
uptake of a fluorescent vesicle.  TEM provides very high magnification and 
resolution because the energy source from which the image is formed is a beam 
of electrons rather than light, which has a resulting wavelength (in a vacuum and 
at a small angle) 3 orders of magnitude lower than that of light. 
6.1.2. Dynamic Light Scattering 
Dynamic Light Scattering (DLS), also referred to as photon correlation 
spectroscopy, is used widely to measure the size and distribution of dispersed 
particles by measuring the changes in laser light projected through the particles.   
The random movement of small particles in a suspension is called Brownian 
motion, and is caused as particles collide with molecules from their surroundings 
and diffuse randomly.  When polychromatic light hits small suspended particles, 
the light is scattered in many directions; this is referred to as Raleigh scattering.  
However, when monochromatic light is shined into a solution of particles 
undergoing Brownian motion, the light hitting the moving particles undergoes a 
Doppler shift when changing wavelength, which can be measured.   The change 
in wavelength is related to the size of the particle that the light hit.   
Particles undergoing Brownian motion travel at different speeds related to 
their size; smaller particles move faster than larger ones.  This relationship is 
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defined by the Stokes-Einstein equation.  First, the Einstein relation describes 
diffusion of particles: 
TkD Bpµ= ; where D is the diffusion constant, µp is the mobility of the 
particles, kB is Boltzmann’s constant (a physical constant which relates energy 
and temperature;1.38 x 10 -23 J/K) , and T is the temperature in K.  Under 
conditions of low Reynolds number (the ratio of inertial to viscous forces) the 
mobility is related inversely to the drag coefficient, γ, where under Stokes Law, 
spherical particles of a radius r: 
rπηγ 6= ; η is the viscosity of the media in which the particle is 
dispersed.  Therefore taken together, the Stokes-Einstein equation becomes 
r
TkD Bπη6=   Diffusion coefficient units are in m2/s .  The hydrodynamic 
radius is then found by: 
D
Tkr BH πη6= .   
Through these relations, given viscosity and absorption of suspending 
media, and the temperature of system, the DLS system algorithms measure 
particle size and/or molecular weight of a suspension through the use of a digital 
correlator. The correlator measures how closely two signals are over a period of 
time.  Correlation is a statistical technique for reducing noise and finding a real 
signal within it; it measures the degree by which a signal is not random when it 
would appear to be.   The second order equation is: 
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6.1.3. Monoclonal Antibody Fragments 
  Another important consideration in effective targeted drug delivery is the 
persistence of the system within the bloodstream. Vesicle encapsulation of drugs 
has been shown to increase circulation time, improve bio-distribution, and 
prolong therapeutic plasma levels in vivo versus free drug administrations.  If the 
drug delivery vesicle or targeting vector provokes an immune response within the 
body and subsequent rapid clearance from the blood stream there may not be 
sufficient time or payload of drug delivered to be efficacious. Concern about the 
rapid and increasing clearance of immunoliposomes in vivo with subsequent 
intravenous injections was solved when antibody fragments were substituted for 
whole antibodies.   
While antibodies have been discussed in earlier sections, a description of 
the physical structure was not given in detail.  An antibody is a glycoprotein of 
molecular weight 150 kDa which is made up of two general types of polypeptide 
chains, two heavy chains and two light chains.  The light chains are about 25 kDa 
each, and each heavy chain is about 50 kDa. There are five subcategorizes of 
antibodies, IgA, IgE, IgD, IgM, and IgG. These differ by their heavy chains types 
and structural makeup.   The chains are held together by a series of disulfide 
bonds.  Figure 6.1 shows the general structure of an antibody with respect to the 
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different chains.  An IgG, which is the subgroup of interest for this research, is 
composed of either of two types of light chains, κ or λ, and the γ1 heavy chains, 
which designate the subgroup.  
The antigen binding (variable) region is indicated at the top of Figure 6.1, 
and is specific to the exact antigen to which the antibody binds.  The regions 
below are conserved, and consistent by antibody type.  The area between them 
is referred to as the hinge region.  Overall above the hinge is referred to as the 
F(ab’)2, and below the Fc region.  The immune response to the 
immunoliposomes was provoked by the Fc region of the antibody and was 
negated when Fab fragments were used.  As Figure 6.1 indicates, fragmentation 
of antibodies can include a single or a coupled Fab antigen binding group, in fact 
many more configurations and combinations have been studied and engineered 
for use in biopharmaceuticals, biosensors and diagnostics. 
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Figure 6.1 IgG Antibody Structure. (Source: Invitrogen) 
 
Fragmentation of antibodies is done using proteolysis reactions 
(degradation of protein by enzymes) using enzymes such as papain, or pepsin or 
ficin, and then subsequent purification steps are taken to separate Fc segments 
and non-fragmented whole antibodies from the desired Fab or F(ab’)2 fragments. 
6.2. Materials and Methods 
6.2.1. Materials and Chemicals 
Included in this list are the materials, chemicals, and equipment new to 
this phase of the project that were not included in the previous sections.   
Polycarbonate filters and polystyrene latex particle standards where obtained 
from Sigma Chemical.   The antibody fragmentation kit (Immunopure ® IgG1 Fab 
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and F(ab’)2 44880) was purchased from Pierce Biotechnology.  Propidium iodide 
nuclear stain (H-1300) was obtained from Vector Labs.  The gold particles were a 
gift from Ed Haller, USF Health Pathology.  Embed media and components for 
TEM (and assistance) were provided, kindly, by Dr Karl Muffly.  
Table 6.1 Equipment for Uptake Studies. 
Equipment Manufacturer Model 
Lipid Extruder and 
Assembly 
Northern Lipids Thermobarrel 10 ml 
Water bath Fisher Isotemp Open-Bath 
Circulator 
Submicron Dynamic Light 
Scattering Instrument 
Malvern Nano-S 
Confocal Microscope Leica SP3 
 
6.2.2. Methods 
6.2.2.1. Extrusion of Niosomes 
Prior to extrusion the niosomes were prepared through the hydration step 
and then frozen overnight.  Freezing and thawing the vesicle preparations 
prompts hydration of the lipids and equal distribution of encapsulated materials. 
The niosomes were extruded using a bench top stainless steel 10 ml 
Thermobarrel LipexTM Extruder.  Figure 6.2 shows the extruder and indicates the 
functional parts.  In order to set up the extrusion process the extruder must be 
disassembled so that the filter package can be put in place.  Two polycarbonate 
filters were stacked on top of a mesh disk and a support disk within the cavity of 
the filter support base and secured under an o-ring.  A drop or two of de-ionized 
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(DI) water was added between each filter while stacking to ensure good seating.  
The correct alignment of the filters is crucial to the extrusion process; poor 
alignment increases extrusion time and may necessitate changing filters before 
the extrusion sequence is complete. The barrel of the extruder was replaced and 
secured with wing nuts.   
 
Figure 6.2  Extruder Assembly. (Source: Northern Lipids Extruder Handbook) 
 
 
The vesicle suspension was pushed through the polycarbonate filters 
using high pressure nitrogen gas (N2) supplied through high pressure lines.  The 
direct pressure into the system from the N2 tank was controlled through a valve 
on the delivery tubing which is coupled to the gas inlet. 
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Figure 6.3  Nitrogen Delivery to Extruder. (Adapted from Northern Lipids Extruder 
Handbook.) 
 
The water jacket of the extruder was supplied 60˚C DI water by a heated 
water bath which was circulated by a peristaltic pump.  Once the circulating water 
equilibrated the extruder temperature, the filter assembly was conditioned by 
expressing 8-10 ml of heated PBS through it.  The pressure of the PBS delivery 
was relatively low; setting the pressure to 200 psig, and rapidly opening and 
closing the valve was sufficient to expel the liquid.  
Once the filters are conditioned, the heated niosome suspension was 
pipetted into the sample inlet.  Control of the niosome suspension temperature is 
important because extrusion must be done above the gel-to-liquid crystalline 
phase transition temperature of the surfactant component (or in the case of 
phospholipids, the component with the saturated alkyl tail) as described in 
Section 4.2.1.1.    The temperature of the sample added to the inlet was allowed 
to equilibrate for a moment before starting the extrusion (this is repeated at each 
successive step). The valve was opened to allow the pressure to push the 
niosome suspension through the filters. The extruded sample was expressed 
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from the outlet tube once the extrusion process was underway.  If sample was 
not expressed within a few seconds, the pressure was increased until the 
solution began to flow from the tube.  The maximum pressure set by the 
manufacturer was 800 psig.   Once the extruded sample was captured, the 
system pressure was vented by opening the pressure relief valve, and the 
sample was returned to the inlet.  This process was repeated ten times and loss 
from the process was usually less than 10%.  After extrusion, the niosome 
sample was ready for the GEC process.   
6.2.2.2. Dynamic Light Scattering Measurements 
 
Dynamic light scattering was used to measure the size of the extruded 
and purified vesicle suspensions using a Malvern Instruments Nanosizer S.  
Since the PSS particle analyzer (Section 4.2) had a lower detection limit of 0.5 
µm diameter particles, the new instrument was required to monitor the size and 
stability of the extruded vesicles.  The Malvern system provides size, molecular 
weight, and dispersity data using dynamic light scattering measurements with 
autocorrelation function.  The data results in a poly dispersity index which is a 
measure of the width of the particle size distribution peak of the sample.  The 
instrument allowed measurements of post GEC particles suspended in PBS.  
Operating parameters were programmed for measuring samples specifically in a 
standard operating procedure (SOP) in the instrument software (DTS).  The 
material properties, refractive index and UV absorbance of the material to be 
measured and the dispersant are input.  Refractive index was measured on a 
refractometer, and the UV absorbance of the niosome suspension at red laser 
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wavelength (633 nm) was measured using a UV spectrophotometer.  These 
values are used to allow the conversion of the intensity distribution to a volume or 
number distribution. 
Outputs from individual measurements include intensity and volume 
particle size distributions, cumulants and distribution fit curves, intensity and 
volume statistics, and the correlation data.  Calibration of the system was done 
with polystyrene latex standards.  Figure 6.4 shows the intensity PSD of a 60 nm 
and 220 nm mixture of polystyrene latex particle standards, and the Figure 6.5 
shows the correlation function curve.  The PSS system (as described in Section 
4.2.2.2) provided actual counts of particles, due to the single particle sensing 
measurement algorithm, whereas the Malvern instrument provides a distribution 
relative to a measured population-the area under the curve of the size distribution 
of the Nanosizer data is always 100%, and the area under the curve of the PSS 
size distribution is the number of particles measured and counted by the 
instrument.  Due to the difference in the underlying physics of these particle 
characterization tools, their data did not align well.  Despite claims to the contrary 
by the manufacturer, dispersions of vesicles between 700-1000 nm did not 
measure accurately or repeatedly in the Malvern instrument, at any dilution.  This 
would probably be due to the size limitation of Brownian motion. 
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Figure 6.4 Particle Size Distribution of 60 nm and 220 nm Standards. 
 
 
Figure 6.5 Correlation Function Curve of the Standards. 
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6.2.2.3. Antibody Fragmentation 
Antibodies were fragmented using a commercially available kit from Pierce 
according to the manufacturer’s instructions.  While the components of the 
columns and buffers are proprietary, essentially the process is the pH dependent 
digestion of the hinge proteins of the antibody by the thiol protease enzyme ficin 
(MW 25 kDa) in the presence of the amino acid cysteine.  At a concentration of 1 
mM cysteine, ficin will produce F(ab’)2 fragments, and at a concentration of 10 
mM cysteine, ficin will produce Fab fragments.  The digestion reaction takes 
place in a column and the resulting fragments are eluted out in different fractions 
using different buffers.  The UV absorption of the fractions was measured and a 
balance of proteins found that the initial yield was 70%.  The protein 
concentrations were measured using extinction coefficients of εFab= 7.5 x 104, 
and εIgG= 22.1 x 104 using Beers Law (see Section 4.2). 
6.2.2.4. Endothelial Cell Culture and Fixation Techniques 
Cells were cultured and activated as previously described in section 5.2.   
For confocal studies the cells were grown on 8 well micro-slides, for TEM the 
cells were grown on cover slips to allow for embedding into the resin.  Prior to 
incubation with live cells, the INs were filtered for sterility using a 0.2 µm syringe 
filter to eliminate possible contaminants.  
For the TEM studies a dilute solution of 15 nm spherical gold particles was 
encapsulated in 10% Tw-CC niosomes which were extruded, purified with GEC, 
and conjugated to IM7 antibodies in the usual manner.  The gold particles were 
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used in the niosomes to provide a strong signal during the TEM imaging.  Prior to 
IN incubation, the cells were well rinsed with warmed PBS. 
6.2.2.5. Fixation Techniques for Confocal Microscopy 
Fluorescent IN suspensions were diluted 1:1 in serum free endothelial media 
(to avoid unwanted protein interactions) and incubated with live bovine aortic 
endothelial cells (BAECs) at 37˚C for varied times.  After incubation the vesicle-
media mixture was discarded and the cells were rinsed three times with room 
temperature PBS and then were fixed with 1% paraformaldehyde in PBS for 15 
minutes.  After fixation, the cells were PBS rinsed again and incubated with 0.1% 
Triton X 100 solution for three minutes, to encourage membrane permeability for 
the nuclear stain, propidium iodide, which was left to penetrate for 30 minutes.  
Once the staining was complete, the cells were rinsed again, and the wells were 
removed.  A few drops of hard setting mounting solution were added to each 
slide and a glass coverslip was placed over the cells and allowed to harden 
overnight. 
6.2.2.6. Fixation Techniques for Transmission Electron Microscopy 
 
Incubation of cells with INs with the gold containing INs was done as 
described for the confocal studies.  Once the incubation was complete the cells 
were rinsed three times with room temperature PBS.  Cells were fixed with a 
2.5% solution of glutaraldehyde for 15 minutes at room temperature. Fixation of 
cells for TEM was similar to that of the SEM procedure.  A 1.5% potassium 
ferricyanide/1% osmium tetroxide solution in DI water was added to the rinsed 
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cells and left to fix for an hour in the dark.   The cells were rinsed three times for 
10 minutes each in 0.1M sodium acetate buffer.  The lipid membranes were 
stabilized by fixing in a 1.5% solution of uranyl acetate in a 0.1 Tris buffer, pH 6.3 
for 30 minutes and then were rinsed three times with DI water.  
Once the final fixation step was complete the cells went through a series 
of dehydration steps.  A series of ethanol in water was added as follows for 5 
minutes each, 30%, 70%, 95%, and 100% ethanol for 15 minutes.  After the 
alcohol series, the cells were cleared with 100% propylene oxide for 15 minute, 
and then a mixture of 100% propylene oxide mixed 1:1 with the embedding 
media. The embedding media was mixed together per the instructions from the 
EMS Technical Data Sheet for Araldite 502/EMBED-812 Embedding media as 
follows: Embed-812 -13.75 g, Araldite 502 -8.5 g, DDSA -27.5 g, DMP-30-0.9 g.  
The cells were embedded in the 1:1 mixture and allowed to dry overnight, and 
then was capsulated in pure embedding media.  The embedded cells were 
sectioned with a diamond knife and fixed onto copper grids stained with 8% 
uranyl acetate and lead citrate.  
6.2.3. Confocal Microscopy 
The confocal images were captured with a Leica SP2 using 40x oil 
objectives with FITC and rhodamine filters. The argon laser (blue light for green 
labels) provided wavelengths 458-514 nm, and the helium neon laser (red light 
for far red labels) provided light at a wavelength of 633 nm.  The Leica confocal 
software (LCS) was used for imaging and for post-image capture processing. 
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Once the fluorescently stained cell nuclei images were visually confirmed 
and focused by viewing through the microscope eyepiece, the image capture 
software was set up.  The two photomultiplier (PMT) gains and offsets were set 
for clarity and reduction of background noise, where possible.  Figure 6.6 shows 
the image acquisition screen where the settings are adjusted in the software.  
Table 6.2 shows the PMT gain and offset and z position settings for the 
samples examined. 
 
Figure 6.6  Leica Confocal Software Image Acquisition Window. 
 
Table 6.2 Confocal Settings. 
 
PMT 1  PMT 2 Z/Y Position Sample 
Gain  Offset Gain Offset (microns) 
Control 632 -11% 616 -7% -42 
20min-dim 520 -15% 464 -4% -49 
20min-brt 549 -14% 568 -14% -28 
1hour-run1 862.3 -5.10% 847 -3.60% -29 
1hour-run2 862.3 -5.10% 847 -3.60% -29 
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Once the settings are established the image capture stack has to be defined 
prior to going into scan mode.  Figure 6.7 shows the schematic for setting the z/y 
position in the LCS software.  By scrolling through the image using the z position 
the bottom and top positions were set to mark the start and end of the captured 
stack.   
 
Figure 6.7  Spatial Setting for Scan Mode Imaging. 
 
6.3. Experimental Designs 
Extrusion experiments were evaluated by taking aliquots of sample at each 
extrusion pass.  These samples were examined for size and entrapment of dye 
by GEC elution and DLS.  The GEC elution profiles were created by fluorescent 
measurements of sequentially eluted fractions.  Particle size distribution was 
measured by DLS to see the effect of extrusion passes on vesicle formation and 
dispersity. 
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For the confocal uptake studies with whole antibodies conjugated to 
fluorescent immuniosomes incubation times examined were 20 mins, 1 hour, 2 
hours, and a control of 2 hours at 4˚C to check for non specific binding.  Confocal 
images of INs conjugated to IM7 Fab fragments were measured at 1 hour.  TEM 
incubation time was 1 hour.  All antibody or fragment coating was at a done at 
concentrations of 5 µg/ml.  
6.4. Results  
6.4.1. Extrusion Results 
In Figure 6.8 the fluorescence chromatograms show the GEC elution of each 
sample.  The first peak represents the fluorescent signal from the niosomes 
(partially quenched due to concentration) and the second peak represents the 
unencapsulated free dye.  Figure 6.9 shows the particle size distribution of the 
niosome fractions captured during GEC.  
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Figure 6.8  Elution of Extrusions 0-10 for a 10% TW-CC-CF Hydration Sample. 
 
 
Figure 6.9 Dynamic Light Scattering Data of Extruded Samples. 
 
The cell nuclei are stained red in the confocal images, and the INs are green.  
All images shown are at the maximum area of cell nuclei. Figure 6.10 shows the 
20 min incubation.  The z value represents the depth within the stack that the 
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image represents.  Figure 6.11 shows the 1 hour incubation, and Figure 6.12 is 
the 2 hour incubation.  The control cells are shown in Figure 6.13. These figures 
represent incubations with whole antibody bound INs.   The LCS software 
provided a post imaging function called slice that allowed for a cross section of x-
z or y-z plane to be viewed. The narrow images shown in Figure 6.14 are 
individual cross sections for each incubation slide already shown.  The final 
confocal image is seen in Figure 6.15 representing the incubation of BAECs with 
fragment conjugated immunoniosomes.  
 
 
Figure 6.10  Confocal BAECs 20 Minute Incubation. Image at -7.001 mm (Range 
of stack: 0,-12.537 mm) 
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Figure 6.11 Confocal BAECs I Hour Incubation.  Image at -11.56 mm (Range of 
stack: 0,-20.00 mm) 
 
 
 
 
Figure 6.12 Confocal BAECs 2 Hour Incubation.   Image at -11.07 mm (Range of 
stack: 0, 20.03 mm) 
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Figure 6.13  Confocal BAECs Control.  Incubation at 4° C for 2 hrs.  Image at 
4.88 mm (Range of stack: 11.07,0 mm) 
 
 
 
Figure 6.14  Confocal Cross Sections. 
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Figure 6.15 Fab-IN BAEC Confocal Image. 
 
6.4.2. TEM  
Figure 6.16 shows the TEM image a single endothelial cell captured from the 
incubation of INs containing gold particles with BAECs.  The arrows indicate the 
niosomes bound to the surface of the endothelial cell.  
 
Figure 6.16  TEM of Au-INs. 
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6.5. Conclusions 
 
The extrusion studies indicated that eight passes through the system is 
preferable for these vesicles versus the suggested ten passes used in the 
synthesis of liposomes. Each successive extrusion pass up until the eight 
showed an increase in the formed niosome signal of Figure 6.8, and 
correspondingly showed a taller and sharper peak in the dynamic light scattering 
data of Figure 6.9.  In each data set, reduction of niosome formation and peak 
was seen in the tenth pass sample. 
The confocal images suggest uptake of immunoniosomes by live endothelial 
cells.   Penetration of IM7-niosomes continues between 20 min and 1 hour, but 
does not appear to increase appreciatively thereafter.  The cross section images 
raise the possibility that INs are attaching to the junctions between the cells, 
although there are niosomes visible in some images near nuclei.  Controls show 
no binding at 4˚C. Absolute verification of location of the vesicles either within or 
on the surface of the cell remains to be done.  Membrane staining was attempted 
to clarify the imaging, but since the nature of the vesicle membrane is analogous 
to that of a cell membrane, cross staining did not allow for the desired distinction 
of IN position using that technique.  An independent measure is needed to 
confirm uptake such as radio labeling of vesicle components or encapsulated 
material. 
The IN-Fab incubation showed very sparse binding.  This may be due to 
disruption of the antigen couple of the fragment dissociating when exposed to the 
binding pH.  Using the F(ab’)2 fragments instead of the single Fab’s may provide 
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binding closer to that of the whole antibodies and should better preserve the 
antigen binding sites.  As it stands although the potential for fragment use is 
demonstrated, the fragment binding requires optimization.   
The TEM image shows adhesion to the surface of cell by the gold INs, none 
were observed within the cell, however a very small sample of cells were 
identified in the media, and an improvement of the cell embedding technique may 
allow for clearer data.  
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7. Conclusions and Contributions 
7.1. Introduction  
The research that this document represents created a new drug delivery 
system with a novel linking chemistry targeted to treat a very significant 
pathological condition, atherosclerosis.  The long term goal of this research was 
to create, test, and optimize a drug delivery carrier with a targeting vector that 
could be used to treat the vulnerable plaque of atherosclerosis and test it 
experimentally in vivo in an atherosclerotic animal model.   
The fixed cell binding results of this research strongly demonstrate and ability 
of the immunoniosome to bind to a target antigen and to do so selectively and 
specifically.  The uptake results do not definitively demonstrate the exact fate of 
the IM7 conjugated niosomes when bound to inflammatory endothelial cells.   
There has been sufficient demonstration within the body of liposome literature to 
establish that the correct antigen-antibody couple will enable the uptake of 
antibody bearing vesicles into the endothelium through endocytosis.  Further 
studies evaluating uptake of immunoniosomes by endothelial cells will need to be 
pursued.   
Regardless of uptake, the binding of niosomes bearing drug payload has the 
potential for therapeutic effect by virtue of localization and antigen binding site 
blocking.  If a drug bearing particle is localized to a pathological site, in situ drug 
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release will provide higher concentration of drug at the desired location than a 
systemic delivery would.  Also, a critical factor in the progression of inflammatory 
diseases, and the build up of atherosclerotic plaque, is the destructive 
proliferation of inflammatory cells at the sites of chronic inflammation.  By 
blocking the binding of inflammatory cells and the cell uptake sites, their 
accumulation within the tissues would be mitigated.   Whether the targeted 
vesicles are taken up by the cells through endocytosis, or remain on the surface 
of the inflammatory site, the potential for treatment remains. 
The immunoniosome system was evaluated in this research for use in 
targeting inflammatory processes; it would not necessarily be limited to that 
application.  The system is capable of encapsulating a solution of either 
hydrophilic or hydrophobic drug, and of binding to any IgG and, except where 
limited by size or surface hindrances, any protein.  With these capacities, many 
different applications of the system are possible and remain to be pursued.  The 
creation of the Tween 61-cyanuric chloride linker provides a highly reactive 
binding moiety which can undergo nucleophilic substitution reactions easily and 
without prior derivatization of the binding species.  The potential of the system to 
be used for other applications is significant. 
7.2. Contributions  
The contributions of this research to the field of targeted drug delivery include 
the synthesis and characterization of a novel formulation of an antibody targeted 
non ionic surfactant vesicle drug carrier.  There is no information in the literature 
describing niosomes composed of a blend of surfactants as a tool to 
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simultaneously maintain required physical properties while creating linking 
moieties.  The creation of an antibody linker by the functionalization of a 
polyoxyethylene sorbitan monostearate molecule is novel, as is the creation of 
the polyoxyethylene sorbitan monostearate-cyanuric chloride linker molecule.  
There is no reported use of non ionic surfactant vesicles designed for active 
targeting with monoclonal antibodies.   
7.3.  Future Work 
Future work in the vesicle characterization of this research includes the 
further investigation of uptake of INs by activated endothelial cells, and a 
refinement of the antibody fragment binding process.   Entrapment of an HMG 
CoA reductase inhibitor drug, atorvastatin, will be pursued prior to the onset of 
the in vivo animal study.  The protocol for the study has already been developed 
and granted approval by the USF IACUC and the US Army Medical Research 
and Material Command Animal Care and use Review Office.  Table 7.1 outlines 
the experimental design of the research.   
The atherosclerotic animal model that will be used in the experiments is a 
knock out mouse which lacks the ligand apolipoprotein E (apoE) which promotes 
lipoprotein clearance.  The apoE- deficient mice are bred using homologous 
recombination in embryonic stem cells to be susceptible to developing 
atherosclerosis.   
The animals will be fed a high fat diet to encourage the formation and 
progression of atherosclerotic lesions and plaque.  After the 8-10 week feeding 
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period, the treatment phase lasts 6 weeks.  Treatments of experimental groups 
are outlined in Table 7.1.  
Table 7.1 Future Work: In Vivo Atherosclerotic Mouse Study 
Treatment Group  
(n=6 for all)  Treatment  
Test low 1. Surfactant vesicle coated with 
antibody fragments and containing 
drug  atorvastatin (test substance-low 
drug concentration) 
Test high 2. Surfactant vesicle coated with 
antibody fragments and containing 
atorvastatin (test substance-high drug 
concentration) 
Control targeted non drug 3. Surfactant vesicle coated with 
antibody fragments and containing 
buffered saline solution 
Control non targeted with 
drug 
4. Surfactant vesicle without antibody 
containing atorvastatin   
Control free drug low 5. Free drug atorvastatin low 
concentration (control) 
Control free drug high 6. Free drug atorvastatin high 
concentration (control) 
Control injection 
7. Buffered saline (control) 
 
Treatments will be administered by tail vein injection, and weekly blood 
samples will be taken by submandibular bleeding to assess blood cholesterol, 
triglycerides, and atherosclerotic markers (e.g. C-reactive protein).  Weekly body 
weight will also be measured.    
At the end of the treatment period, the mouse aortas will be evaluated for 
differences in plaque progression, the bio-distribution of the atorvastatin drug in 
the animal’s organs will be assessed, and the lipid blood levels will be studied.  
The expectation from this study is that the targeted drug treatment group will 
show a reduction of plaque progression relative to the free drug groups and 
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controls.  Additionally the study may demonstrate the extrahepatic effects of the 
statin on the build up of plaques, since statin treatment does not affect the 
production of cholesterol in the liver in the mouse model. 
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Appendix A.  Particle Sizing Systems Data and Software Output  
 
The images below are Particle Sizing Systems Accusizer software output 
from a 3 size polystyrene latex standard for size and count calibration of 
instrument.  The axes scales can be set, and the y axis can display units of 
number of particles counted (# Part.) or numbers of particles counted per ml of 
sample injected for analysis (# Part./ml as shown).  For a given injection volume 
the cumulative number of counts can be found in the volume fraction calculation 
menu in the display menu.  To obtain the number of particles per ml divide the 
calculated number of particles listed in the volume fraction calculation by sample 
volume injected.  For example in the sample below 0.025 ml was injected.  The 
calculated # is 147011.  The total number per ml is 5.88 x 106 particles per ml. 
 
 
Figure A.1 Particle Size Distribution of Standards 
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Figure A.2 Sample Number Calculation 
 
: 
Table A.1 Data Exported From PSD ASCII File 
Particle Sizing Systems, Inc.   
Santa Barbara, Calif., 
USA 
  
Model 780 AccuSizer   
Caption: standard  MML 0.7, 1. 5 um peaks 25 uL 
injection 
  
File Name =   
3_24_03.003 
  
Sensor Model:   LE400-0.5 
SUM  
S/N:  8910 Cal.  File:   0008910s.sns 
Elapsed Time of Data 
Collection =   
60 Sec.   
Background File =  NONE   
Total # Part. Sized 
(>=Thres. 0.52 um ) =  
101593   
Calculated Total No. of 
Particles in Sample =  
150625   
Dilution Factor =  1.48   
Fluid Volume Sampled 
=  
60 ml  No. of 
Channel
s =  
512   
NUM-WT Mean =  0.91 um  Mode = 0.73 um  Median 
=  
0.73
VOL-WT Mean =  7.93 um  Mode = 5.34 um  Median 
=  
5.32
Summary of Detailed Distribution, Weightings   
Diameter # Part. Cum 
Num  
Num % Vol % Cum 
Num % 
Vol Num % 
(microns) Sized  >=Diam. >=Diam. >=Diam. 
0.52418 288 10159
3
0.283 0.007 100 100 
0.5313 328 10130
5
0.323 0.009 99.717 99.993 
0.53851 312 10097
7
0.307 0.009 99.394 99.984 
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0.55324 400 10031
3
0.394 0.012 98.74 99.965 
0.56076 368 99913 0.362 0.012 98.346 99.953 
0.56837 389 99545 0.383 0.013 97.984 99.941 
0.57609 818 99156 0.805 0.028 97.601 99.928 
0.58392 799 98338 0.786 0.028 96.796 99.901 
0.59185 715 97539 0.704 0.026 96.01 99.872 
0.59989 643 96824 0.633 0.025 95.306 99.846 
0.60804 631 96181 0.621 0.025 94.673 99.821 
0.6163 265 95550 0.261 0.011 94.052 99.796 
0.62467 571 95285 0.562 0.025 93.791 99.784 
0.63315 285 94714 0.281 0.013 93.229 99.76 
0.64175 701 94429 0.69 0.033 92.948 99.747 
0.65047 1084 93728 1.067 0.053 92.258 99.714 
0.65931 709 92644 0.698 0.036 91.191 99.66 
0.66826 1647 91935 1.621 0.088 90.493 99.624 
0.67734 2336 90288 2.299 0.13 88.872 99.536 
0.68654 1655 87952 1.629 0.096 86.573 99.407 
0.69586 5436 86297 5.351 0.327 84.944 99.311 
0.70532 7096 80861 6.985 0.445 79.593 98.984 
0.7149 3987 73765 3.924 0.26 72.608 98.539 
0.72461 8772 69778 8.634 0.596 68.684 98.279 
0.73445 9730 61006 9.577 0.688 60.049 97.683 
0.74443 8951 51276 8.811 0.659 50.472 96.995 
0.75454 3857 42325 3.797 0.296 41.661 96.336 
0.76479 6126 38468 6.03 0.489 37.865 96.04 
0.77517 4295 32342 4.228 0.357 31.835 95.55 
0.7857 2792 28047 2.748 0.242 27.607 95.193 
0.79638 1624 25255 1.599 0.146 24.859 94.951 
0.80719 509 23631 0.501 0.048 23.26 94.805 
0.81816 680 23122 0.669 0.066 22.759 94.757 
0.82927 447 22442 0.44 0.046 22.09 94.691 
0.84054 331 21995 0.326 0.035 21.65 94.645 
0.85195 250 21664 0.246 0.028 21.324 94.61 
0.86352 202 21414 0.199 0.023 21.078 94.582 
0.87525 181 21212 0.178 0.022 20.879 94.559 
0.88714 225 21031 0.221 0.028 20.701 94.538 
0.89919 180 20806 0.177 0.023 20.48 94.51 
0.91141 181 20626 0.178 0.024 20.303 94.486 
0.92379 354 20445 0.348 0.05 20.124 94.462 
0.93633 267 20091 0.263 0.039 19.776 94.412 
0.94905 197 19824 0.194 0.03 19.513 94.373 
0.96194 190 19627 0.187 0.03 19.319 94.343 
0.97501 196 19437 0.193 0.032 19.132 94.312 
0.98825 313 19241 0.308 0.054 18.939 94.28 
1.00168 254 18928 0.25 0.046 18.631 94.226 
1.01528 794 18674 0.782 0.148 18.381 94.18 
1.02907 784 17880 0.772 0.153 17.6 94.032 
1.04305 1684 17096 1.658 0.341 16.828 93.88 
1.05722 2565 15412 2.525 0.541 15.17 93.538 
1.07158 2938 12847 2.892 0.646 12.646 92.997 
1.08614 2610 9909 2.569 0.597 9.754 92.352 
1.10089 1310 7299 1.289 0.312 7.185 91.754 
1.11584 1259 5989 1.239 0.312 5.895 91.442 
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1.131 670 4730 0.659 0.173 4.656 91.13 
1.14636 328 4060 0.323 0.088 3.996 90.957 
1.16193 134 3732 0.132 0.038 3.673 90.869 
1.17772 106 3598 0.104 0.031 3.542 90.831 
1.19371 60 3492 0.059 0.018 3.437 90.8 
1.20993 47 3432 0.046 0.015 3.378 90.782 
1.22636 31 3385 0.031 0.01 3.332 90.767 
1.24302 39 3354 0.038 0.013 3.301 90.757 
1.2599 37 3315 0.036 0.013 3.263 90.744 
1.27702 22 3278 0.022 0.008 3.227 90.73 
1.29436 17 3256 0.017 0.007 3.205 90.722 
1.31194 34 3239 0.033 0.014 3.188 90.716 
1.32976 32 3205 0.031 0.013 3.155 90.702 
1.34783 19 3173 0.019 0.008 3.123 90.688 
1.36613 28 3154 0.028 0.013 3.105 90.68 
1.38469 23 3126 0.023 0.011 3.077 90.667 
1.4035 14 3103 0.014 0.007 3.054 90.656 
1.42256 22 3089 0.022 0.011 3.041 90.65 
1.44189 13 3067 0.013 0.007 3.019 90.638 
1.46147 13 3054 0.013 0.007 3.006 90.631 
1.48132 14 3041 0.014 0.008 2.993 90.624 
1.50144 10 3027 0.01 0.006 2.98 90.616 
1.52184 15 3017 0.015 0.009 2.97 90.61 
1.54251 8 3002 0.008 0.005 2.955 90.6 
1.56346 11 2994 0.011 0.008 2.947 90.595 
1.5847 14 2983 0.014 0.01 2.936 90.588 
1.60622 16 2969 0.016 0.012 2.922 90.578 
1.62804 6 2953 0.006 0.005 2.907 90.566 
1.65015 7 2947 0.007 0.006 2.901 90.561 
1.67257 10 2940 0.01 0.008 2.894 90.556 
1.69529 14 2930 0.014 0.012 2.884 90.547 
1.71832 6 2916 0.006 0.005 2.87 90.535 
1.74166 9 2910 0.009 0.008 2.864 90.53 
1.76531 9 2901 0.009 0.009 2.855 90.521 
1.78929 13 2892 0.013 0.013 2.847 90.512 
1.81359 8 2879 0.008 0.009 2.834 90.499 
1.83823 3 2871 0.003 0.003 2.826 90.491 
1.8632 5 2868 0.005 0.006 2.823 90.487 
1.88851 7 2863 0.007 0.008 2.818 90.481 
1.91416 6 2856 0.006 0.008 2.811 90.473 
1.94016 3 2850 0.003 0.004 2.805 90.465 
1.96651 10 2847 0.01 0.014 2.802 90.462 
1.99322 5 2837 0.005 0.007 2.793 90.448 
2.0203 1 2832 0.001 0.001 2.788 90.441 
2.04774 3 2831 0.003 0.005 2.787 90.439 
2.07555 3 2828 0.003 0.005 2.784 90.435 
2.10375 3 2825 0.003 0.005 2.781 90.43 
2.13232 3 2822 0.003 0.005 2.778 90.425 
2.16129 3 2819 0.003 0.005 2.775 90.42 
2.19064 3 2816 0.003 0.006 2.772 90.414 
2.2204 9 2813 0.009 0.018 2.769 90.409 
2.25056 4 2804 0.004 0.008 2.76 90.391 
2.28113 4 2800 0.004 0.008 2.756 90.383 
2.31211 4 2796 0.004 0.009 2.752 90.375 
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2.34352 3 2792 0.003 0.007 2.748 90.366 
2.37535 4 2789 0.004 0.01 2.745 90.359 
2.40762 1 2785 0.001 0.002 2.741 90.349 
2.44032 3 2784 0.003 0.008 2.74 90.347 
2.47347 4 2781 0.004 0.011 2.737 90.339 
2.50706 3 2777 0.003 0.008 2.733 90.328 
2.54112 2 2774 0.002 0.006 2.73 90.32 
2.57563 2 2772 0.002 0.006 2.729 90.314 
2.61062 3 2770 0.003 0.01 2.727 90.308 
2.64608 3 2767 0.003 0.01 2.724 90.298 
2.68202 0 2764 0 0 2.721 90.288 
2.71845 3 2764 0.003 0.011 2.721 90.288 
2.75538 2 2761 0.002 0.007 2.718 90.278 
2.7928 2 2759 0.002 0.008 2.716 90.27 
2.83074 0 2757 0 0 2.714 90.262 
2.86919 4 2757 0.004 0.017 2.714 90.262 
2.90816 1 2753 0.001 0.004 2.71 90.245 
2.94766 3 2752 0.003 0.014 2.709 90.241 
2.9877 3 2749 0.003 0.014 2.706 90.227 
3.02828 5 2746 0.005 0.025 2.703 90.213 
3.06942 1 2741 0.001 0.005 2.698 90.188 
3.11111 3 2740 0.003 0.016 2.697 90.183 
3.15337 0 2737 0 0 2.694 90.167 
3.1962 2 2737 0.002 0.012 2.694 90.167 
3.23961 1 2735 0.001 0.006 2.692 90.155 
3.28362 1 2734 0.001 0.006 2.691 90.149 
3.32822 0 2733 0 0 2.69 90.143 
3.37343 3 2733 0.003 0.021 2.69 90.143 
3.41925 0 2730 0 0 2.687 90.122 
3.46569 0 2730 0 0 2.687 90.122 
3.51277 0 2730 0 0 2.687 90.122 
3.56048 0 2730 0 0 2.687 90.122 
3.60885 1 2730 0.001 0.008 2.687 90.122 
3.65787 2 2729 0.002 0.017 2.686 90.114 
3.70755 0 2727 0 0 2.684 90.097 
3.75791 1 2727 0.001 0.009 2.684 90.097 
3.80896 1 2726 0.001 0.01 2.683 90.087 
3.86069 3 2725 0.003 0.031 2.682 90.077 
3.91313 0 2722 0 0 2.679 90.046 
3.96629 2 2722 0.002 0.022 2.679 90.046 
4.02016 5 2720 0.005 0.058 2.677 90.024 
4.07477 3 2715 0.003 0.036 2.672 89.966 
4.13012 2 2712 0.002 0.025 2.669 89.93 
4.18622 2 2710 0.002 0.026 2.667 89.905 
4.24308 1 2708 0.001 0.014 2.666 89.878 
4.30071 4 2707 0.004 0.057 2.665 89.865 
4.35913 2 2703 0.002 0.03 2.661 89.808 
4.41834 6 2701 0.006 0.092 2.659 89.778 
4.47835 1 2695 0.001 0.016 2.653 89.686 
4.53918 6 2694 0.006 0.1 2.652 89.67 
4.60084 6 2688 0.006 0.104 2.646 89.57 
4.66333 4 2682 0.004 0.072 2.64 89.465 
4.72668 8 2678 0.008 0.151 2.636 89.393 
4.79088 26 2670 0.026 0.511 2.628 89.242 
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4.85595 25 2644 0.025 0.511 2.603 88.732 
4.92191 21 2619 0.021 0.447 2.578 88.22 
4.98877 39 2598 0.038 0.865 2.557 87.773 
5.05653 58 2559 0.057 1.339 2.519 86.909 
5.12522 104 2501 0.102 2.5 2.462 85.57 
5.19483 222 2397 0.219 5.557 2.359 83.07 
5.26539 468 2175 0.461 12.199 2.141 77.512 
5.33691 772 1707 0.76 20.955 1.68 65.313 
5.40941 567 935 0.558 16.026 0.92 44.359 
5.48288 206 368 0.203 6.063 0.362 28.333 
5.55736 47 162 0.046 1.44 0.159 22.27 
5.63284 19 115 0.019 0.606 0.113 20.83 
5.70936 9 96 0.009 0.299 0.094 20.223 
5.78691 8 87 0.008 0.277 0.086 19.924 
5.86551 2 79 0.002 0.072 0.078 19.647 
5.94518 7 77 0.007 0.263 0.076 19.575 
6.02594 4 70 0.004 0.156 0.069 19.313 
6.10779 3 66 0.003 0.122 0.065 19.156 
6.19075 2 63 0.002 0.085 0.062 19.034 
6.27484 8 61 0.008 0.353 0.06 18.95 
6.36007 1 53 0.001 0.046 0.052 18.597 
6.44646 2 52 0.002 0.096 0.051 18.551 
6.53403 3 50 0.003 0.149 0.049 18.455 
6.62278 6 47 0.006 0.311 0.046 18.306 
6.71274 3 41 0.003 0.162 0.04 17.994 
6.80392 0 38 0 0 0.037 17.832 
6.89634 1 38 0.001 0.059 0.037 17.832 
6.99001 1 37 0.001 0.061 0.036 17.774 
7.08496 0 36 0 0 0.035 17.713 
7.18119 1 36 0.001 0.066 0.035 17.713 
7.27873 0 35 0 0 0.034 17.647 
7.3776 0 35 0 0 0.034 17.647 
7.47781 2 35 0.002 0.149 0.034 17.647 
7.57939 3 33 0.003 0.233 0.032 17.497 
7.68234 4 30 0.004 0.324 0.03 17.264 
7.78669 2 26 0.002 0.169 0.026 16.94 
7.89246 4 24 0.004 0.351 0.024 16.772 
7.99966 0 20 0 0 0.02 16.42 
8.10832 0 20 0 0 0.02 16.42 
8.21846 0 20 0 0 0.02 16.42 
8.33009 0 20 0 0 0.02 16.42 
8.44324 0 20 0 0 0.02 16.42 
8.55792 1 20 0.001 0.112 0.02 16.42 
8.67417 0 19 0 0 0.019 16.309 
8.79199 0 19 0 0 0.019 16.309 
8.91141 0 19 0 0 0.019 16.309 
9.03246 0 19 0 0 0.019 16.309 
9.15515 2 19 0.002 0.274 0.019 16.309 
9.2795 1 17 0.001 0.143 0.017 16.034 
9.40555 0 16 0 0 0.016 15.892 
9.5333 0 16 0 0 0.016 15.892 
9.6628 1 16 0.001 0.161 0.016 15.892 
9.79405 1 15 0.001 0.168 0.015 15.731 
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9.92708 0 14 0 0 0.014 15.563 
10.06192 0 14 0 0 0.014 15.563 
10.19859 0 14 0 0 0.014 15.563 
10.33712 0 14 0 0 0.014 15.563 
10.47753 1 14 0.001 0.205 0.014 15.563 
10.61985 0 13 0 0 0.013 15.358 
10.7641 0 13 0 0 0.013 15.358 
10.91031 1 13 0.001 0.232 0.013 15.358 
11.05851 0 12 0 0 0.012 15.126 
11.20872 0 12 0 0 0.012 15.126 
11.36097 1 12 0.001 0.262 0.012 15.126 
11.51528 0 11 0 0 0.011 14.864 
11.6717 0 11 0 0 0.011 14.864 
11.83024 0 11 0 0 0.011 14.864 
11.99093 0 11 0 0 0.011 14.864 
12.1538 0 11 0 0 0.011 14.864 
12.31889 1 11 0.001 0.334 0.011 14.864 
12.48622 0 10 0 0 0.01 14.53 
12.65582 0 10 0 0 0.01 14.53 
12.82773 0 10 0 0 0.01 14.53 
13.00197 0 10 0 0 0.01 14.53 
13.17857 1 10 0.001 0.409 0.01 14.53 
13.35758 1 9 0.001 0.426 0.009 14.121 
13.53902 0 8 0 0 0.008 13.696 
13.72292 0 8 0 0 0.008 13.696 
13.90932 0 8 0 0 0.008 13.696 
14.09825 0 8 0 0 0.008 13.696 
14.28975 1 8 0.001 0.521 0.008 13.696 
14.48385 0 7 0 0 0.007 13.175 
14.68059 0 7 0 0 0.007 13.175 
14.87999 0 7 0 0 0.007 13.175 
15.08211 0 7 0 0 0.007 13.175 
15.28697 0 7 0 0 0.007 13.175 
15.49462 0 7 0 0 0.007 13.175 
15.70508 0 7 0 0 0.007 13.175 
15.91841 1 7 0.001 0.72 0.007 13.175 
16.13463 1 6 0.001 0.75 0.006 12.454 
16.35379 0 5 0 0 0.005 11.704 
16.57593 0 5 0 0 0.005 11.704 
16.80108 0 5 0 0 0.005 11.704 
17.02929 0 5 0 0 0.005 11.704 
17.2606 0 5 0 0 0.005 11.704 
17.49505 0 5 0 0 0.005 11.704 
17.73269 0 5 0 0 0.005 11.704 
17.97356 1 5 0.001 1.037 0.005 11.704 
18.21769 0 4 0 0 0.004 10.668 
18.46515 1 4 0.001 1.124 0.004 10.668 
18.71596 0 3 0 0 0.003 9.543 
18.97018 1 3 0.001 1.219 0.003 9.543 
19.22786 0 2 0 0 0.002 8.324 
19.48903 0 2 0 0 0.002 8.324 
19.75375 1 2 0.001 1.376 0.002 8.324 
20.02207 0 1 0 0 0.001 6.948 
20.29403 0 1 0 0 0.001 6.948 
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20.56969 0 1 0 0 0.001 6.948 
20.84909 0 1 0 0 0.001 6.948 
21.13229 0 1 0 0 0.001 6.948 
21.41933 0 1 0 0 0.001 6.948 
21.71027 0 1 0 0 0.001 6.948 
22.00517 0 1 0 0 0.001 6.948 
22.30407 0 1 0 0 0.001 6.948 
22.60702 0 1 0 0 0.001 6.948 
22.9141 0 1 0 0 0.001 6.948 
23.22534 0 1 0 0 0.001 6.948 
23.54082 0 1 0 0 0.001 6.948 
23.86058 0 1 0 0 0.001 6.948 
24.18468 0 1 0 0 0.001 6.948 
24.51318 0 1 0 0 0.001 6.948 
24.84615 0 1 0 0 0.001 6.948 
25.18363 0 1 0 0 0.001 6.948 
25.52571 0 1 0 0 0.001 6.948 
25.87242 0 1 0 0 0.001 6.948 
26.22385 0 1 0 0 0.001 6.948 
26.58006 0 1 0 0 0.001 6.948 
26.9411 0 1 0 0 0.001 6.948 
27.30704 0 1 0 0 0.001 6.948 
27.67796 0 1 0 0 0.001 6.948 
28.05391 0 1 0 0 0.001 6.948 
28.43497 0 1 0 0 0.001 6.948 
28.82121 0 1 0 0 0.001 6.948 
29.21269 0 1 0 0 0.001 6.948 
29.60949 0 1 0 0 0.001 6.948 
30.01168 0 1 0 0 0.001 6.948 
30.41933 0 1 0 0 0.001 6.948 
30.83252 0 1 0 0 0.001 6.948 
31.25132 0 1 0 0 0.001 6.948 
31.67581 0 1 0 0 0.001 6.948 
32.10607 0 1 0 0 0.001 6.948 
32.54217 0 1 0 0 0.001 6.948 
32.9842 0 1 0 0 0.001 6.948 
33.43222 0 1 0 0 0.001 6.948 
33.88634 1 1 0.001 6.948 0.001 6.948 
34.34662 0 0 0 0 0 0 
34.81316 0 0 0 0 0 0 
35.28603 0 0 0 0 0 0 
35.76532 0 0 0 0 0 0 
36.25113 0 0 0 0 0 0 
36.74353 0 0 0 0 0 0 
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Generated reports for each sample run show user designated data, 
method, run and evaluation notes. 
 
Figure B.1  Akta Prime Elution Chromatogram Showing UV Absorbance and 
Conductivity 
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Figure B.2 Akta Prime Method Notes 
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Each programmed method run created an overlay of all experimental 
curves generated.  The data for each curve represented in the overlay can be 
individually exported as an ASCII file. 
   
 
 
 
Figure B.3 Akta Prime Chromatogram Showing All Measures 
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The BioTek Instruments fluorescent plate reader uses KC Junior software 
for creating an operating procedure and translating the intensity data into 
concentration data based on a designated calibration curve. 
Below are the steps for setting up a 96 well plate and the resulting data 
available for export to Microsoft Excel. 
 C.1 Defined Protocol 
 
Figure C.1 Fluorescent Plate Reader: Protocol Definition 
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Figure C.2 Fluorescent Plate Reader: Defined Plate Reader Geometry 
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Figure C.3 Fluorescent Plate Reader: Define Individual Well Measurement Types 
 
C.2 Stored Standard Curve Example 
 
Figure C.4 Fluorescent Plate Reader: Stored Standard Curve 
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Measured Intensity  
 
Figure C.5 Fluorescent Plate Reader: Fluorescence Intensity by Wells 
 
C.3  Data Exported to Excel 
 
Figure C.6 Fluorescent Plate Reader:  Intensity Data Exported to Microsoft Excel 
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Appendix D.  Matlab™ Image Analysis 
 
The Matlab program which produced this example output was constructed 
by John Elliott, M.S. ChE while working in the Chemical Engineering Department 
at USF in 2006-2007.  The overall process of the image analysis and the images 
produced was described in Section 5.2.4.3.  Below is the data output from the 
Matlab Command Window.   
These examples were run with 20x magnification images files from BAECs 
incubated with INs for 2 hours at 37˚C.   
 
Command Window Output  
caldata =  
 
6x1 struct array with fields: 
    Area 
    Centroid 
    BoundingBox 
 
 
X_Cal = 
 
    0.4669 
 
 
handles =  
 
          figure1: 153.0455 
      pushbutton7: 7.0457 
      pushbutton6: 6.0457 
         listbox1: 5.0457 
      pushbutton5: 4.0457 
      pushbutton4: 3.0457 
      pushbutton3: 2.0457 
      pushbutton2: 1.0457 
      pushbutton1: 0.0457 
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togglebutton1: 159.0455 
            axes3: 154.0455 
           output: 153.0455 
         filename: 'W1_20x_D1.tif' 
        root_file: 'C:\Program Files\MATLAB71\work\images\10-05-06\' 
           banner: [1024x1360x3 uint8] 
              Cal: 0.2180 
 
h = 
 
     1 
 
h = 
 
     2 
 
celldata =  
 
76x1 struct array with fields: 
    Area 
    Centroid 
    BoundingBox 
 
max_area = 
 
        1243 
 
cell_mean = 
 
  104.2558 
 
max_area2 = 
 
   476 
 
h = 
 
     3 
 
filename2 = 
 
W1_20x_F1a.tif 
 
root_file2 = 
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C:\Program Files\MATLAB71\work\images\10-05-06\ 
 
filename2 = 
 
W1_20x_F1.tif 
 
root_file2 = 
 
C:\Program Files\MATLAB71\work\images\10-05-06\ 
 
h = 
 
     4 
 
celldata22 =  
 
1699x1 struct array with fields: 
    Area 
    Centroid 
    BoundingBox 
 
handles =  
 
          figure1: 153.0455 
      pushbutton7: 7.0457 
      pushbutton6: 6.0457 
         listbox1: 5.0457 
      pushbutton5: 4.0457 
      pushbutton4: 3.0457 
      pushbutton3: 2.0457 
      pushbutton2: 1.0457 
      pushbutton1: 0.0457 
    togglebutton1: 159.0455 
            axes3: 154.0455 
           output: 153.0455 
         filename: 'W1_20x_D1.tif' 
        root_file: 'C:\Program Files\MATLAB71\work\images\10-05-06\' 
           banner: [1024x1360x3 uint8] 
              Cal: 0.2180 
              myX: [1 1360] 
              myY: [1 1024] 
            sub_A: [571x571x3 uint8] 
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 rect_userD: [10.0968 248.8353 570.2515 570.2515] 
            sub_B: [571x571 uint8] 
           sub_BB: [571x571 uint8] 
            sub_C: [571x571 logical] 
          labeled: [571x571 double] 
       numObjects: 76 
        RGB_label: [571x571x3 uint8] 
      numObjects2: 42 
          red_set: [5 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2 6 4 11 14] 
          ful_set: [5 0 0 0 0 1 13 29 14 7 4 1 0 0 0 0 0 0 0 2] 
          fatcell: [1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 2 1 1 1 1 1 1 2 2 1 1 2] 
               A2: [1024x1360x3 uint8] 
           sub_A2: [571x571x3 uint8] 
       RGB_label2: [571x571x3 uint8] 
      nio_ful_set: [1630 41 13 6 2 1 0 0 2 1 0 0 1 0 0 0 0 1 0 1] 
      nio_red_set: [1630 41 13 6 2 1 0 0 2 1 0 0 1 0 0 0 0 1 0 1] 
 
handles =  
 
           figure1: 153.0455 
       pushbutton7: 7.0457 
       pushbutton6: 6.0457 
          listbox1: 5.0457 
       pushbutton5: 4.0457 
       pushbutton4: 3.0457 
       pushbutton3: 2.0457 
       pushbutton2: 1.0457 
       pushbutton1: 0.0457 
     togglebutton1: 159.0455 
             axes3: 154.0455 
            output: 153.0455 
          filename: 'W1_20x_D1.tif' 
         root_file: 'C:\Program Files\MATLAB71\work\images\10-05-06\' 
            banner: [1024x1360x3 uint8] 
               Cal: 0.2180 
               myX: [1 1360] 
               myY: [1 1024] 
             sub_A: [571x571x3 uint8] 
        rect_userD: [10.0968 248.8353 570.2515 570.2515] 
             sub_B: [571x571 uint8] 
            sub_BB: [571x571 uint8] 
             sub_C: [571x571 logical] 
           labeled: [571x571 double] 
        numObjects: 76 
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 RGB_label: [571x571x3 uint8] 
       numObjects2: 42 
           red_set: [5 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2 6 4 11 14] 
           ful_set: [5 0 0 0 0 1 13 29 14 7 4 1 0 0 0 0 0 0 0 2] 
           fatcell: [1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 2 1 1 1 1 1 1 2 2 1 1 2] 
                A2: [1024x1360x3 uint8] 
            sub_A2: [571x571x3 uint8] 
        RGB_label2: [571x571x3 uint8] 
       nio_ful_set: [1630 41 13 6 2 1 0 0 2 1 0 0 1 0 0 0 0 1 0 1] 
       nio_red_set: [1630 41 13 6 2 1 0 0 2 1 0 0 1 0 0 0 0 1 0 1] 
          finalpic: [571x571x3 uint8] 
    cellTotalCount: 80 
 
handles =  
 
           figure1: 153.0455 
       pushbutton7: 7.0457 
       pushbutton6: 6.0457 
          listbox1: 5.0457 
       pushbutton5: 4.0457 
       pushbutton4: 3.0457 
       pushbutton3: 2.0457 
       pushbutton2: 1.0457 
       pushbutton1: 0.0457 
     togglebutton1: 159.0455 
             axes3: 154.0455 
            output: 153.0455 
          filename: 'W1_20x_D1.tif' 
         root_file: 'C:\Program Files\MATLAB71\work\images\10-05-06\' 
            banner: [1024x1360x3 uint8] 
               Cal: 0.2180 
               myX: [1 1360] 
               myY: [1 1024] 
             sub_A: [571x571x3 uint8] 
        rect_userD: [10.0968 248.8353 570.2515 570.2515] 
             sub_B: [571x571 uint8] 
            sub_BB: [571x571 uint8] 
             sub_C: [571x571 logical] 
           labeled: [571x571 double] 
        numObjects: 76 
         RGB_label: [571x571x3 uint8] 
       numObjects2: 42 
           red_set: [5 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2 6 4 11 14] 
           ful_set: [5 0 0 0 0 1 13 29 14 7 4 1 0 0 0 0 0 0 0 2] 
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 fatcell: [1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 2 1 1 1 1 1 1 2 2 1 1 2] 
                A2: [1024x1360x3 uint8] 
            sub_A2: [571x571x3 uint8] 
        RGB_label2: [571x571x3 uint8] 
       nio_ful_set: [1630 41 13 6 2 1 0 0 2 1 0 0 1 0 0 0 0 1 0 1] 
       nio_red_set: [1630 41 13 6 2 1 0 0 2 1 0 0 1 0 0 0 0 1 0 1] 
          finalpic: [571x571x3 uint8] 
    cellTotalCount: 80 
         totalArea: 7.0877e+004 
 
handles =  
 
           figure1: 153.0455 
       pushbutton7: 7.0457 
       pushbutton6: 6.0457 
          listbox1: 5.0457 
       pushbutton5: 4.0457 
       pushbutton4: 3.0457 
       pushbutton3: 2.0457 
       pushbutton2: 1.0457 
       pushbutton1: 0.0457 
     togglebutton1: 159.0455 
             axes3: 154.0455 
            output: 153.0455 
          filename: 'W1_20x_D1.tif' 
         root_file: 'C:\Program Files\MATLAB71\work\images\10-05-06\' 
            banner: [1024x1360x3 uint8] 
               Cal: 0.2180 
               myX: [1 1360] 
               myY: [1 1024] 
             sub_A: [571x571x3 uint8] 
        rect_userD: [10.0968 248.8353 570.2515 570.2515] 
             sub_B: [571x571 uint8] 
            sub_BB: [571x571 uint8] 
             sub_C: [571x571 logical] 
           labeled: [571x571 double] 
        numObjects: 76 
         RGB_label: [571x571x3 uint8] 
       numObjects2: 42 
           red_set: [5 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2 6 4 11 14] 
           ful_set: [5 0 0 0 0 1 13 29 14 7 4 1 0 0 0 0 0 0 0 2] 
           fatcell: [1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 2 1 1 1 1 1 1 2 2 1 1 2] 
                A2: [1024x1360x3 uint8] 
            sub_A2: [571x571x3 uint8] 
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   RGB_label2: [571x571x3 uint8] 
       nio_ful_set: [1630 41 13 6 2 1 0 0 2 1 0 0 1 0 0 0 0 1 0 1] 
       nio_red_set: [1630 41 13 6 2 1 0 0 2 1 0 0 1 0 0 0 0 1 0 1] 
          finalpic: [571x571x3 uint8] 
    cellTotalCount: 80 
         totalArea: 7.0877e+004 
      cell_density: 0.0011 
 
 
handles =  
 
           figure1: 153.0455 
       pushbutton7: 7.0457 
       pushbutton6: 6.0457 
          listbox1: 5.0457 
       pushbutton5: 4.0457 
       pushbutton4: 3.0457 
       pushbutton3: 2.0457 
       pushbutton2: 1.0457 
       pushbutton1: 0.0457 
     togglebutton1: 159.0455 
             axes3: 154.0455 
            output: 153.0455 
          filename: 'W1_20x_D1.tif' 
         root_file: 'C:\Program Files\MATLAB71\work\images\10-05-06\' 
            banner: [1024x1360x3 uint8] 
               Cal: 0.2180 
               myX: [1 1360] 
               myY: [1 1024] 
             sub_A: [571x571x3 uint8] 
        rect_userD: [10.0968 248.8353 570.2515 570.2515] 
             sub_B: [571x571 uint8] 
            sub_BB: [571x571 uint8] 
             sub_C: [571x571 logical] 
           labeled: [571x571 double] 
        numObjects: 76 
         RGB_label: [571x571x3 uint8] 
       numObjects2: 42 
           red_set: [5 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2 6 4 11 14] 
           ful_set: [5 0 0 0 0 1 13 29 14 7 4 1 0 0 0 0 0 0 0 2] 
           fatcell: [1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 2 1 1 1 1 1 1 2 2 1 1 2] 
                A2: [1024x1360x3 uint8] 
            sub_A2: [571x571x3 uint8] 
        RGB_label2: [571x571x3 uint8] 
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     nio_ful_set: [1630 41 13 6 2 1 0 0 2 1 0 0 1 0 0 0 0 1 0 1] 
       nio_red_set: [1630 41 13 6 2 1 0 0 2 1 0 0 1 0 0 0 0 1 0 1] 
          finalpic: [571x571x3 uint8] 
    cellTotalCount: 80 
         totalArea: 7.0877e+004 
      cell_density: 0.0011 
     nioTotalCount: 1699 
 
handles =  
 
           figure1: 153.0455 
       pushbutton7: 7.0457 
       pushbutton6: 6.0457 
          listbox1: 5.0457 
       pushbutton5: 4.0457 
       pushbutton4: 3.0457 
       pushbutton3: 2.0457 
       pushbutton2: 1.0457 
       pushbutton1: 0.0457 
     togglebutton1: 159.0455 
             axes3: 154.0455 
            output: 153.0455 
          filename: 'W1_20x_D1.tif' 
         root_file: 'C:\Program Files\MATLAB71\work\images\10-05-06\' 
            banner: [1024x1360x3 uint8] 
               Cal: 0.2180 
               myX: [1 1360] 
               myY: [1 1024] 
             sub_A: [571x571x3 uint8] 
        rect_userD: [10.0968 248.8353 570.2515 570.2515] 
             sub_B: [571x571 uint8] 
            sub_BB: [571x571 uint8] 
             sub_C: [571x571 logical] 
           labeled: [571x571 double] 
        numObjects: 76 
         RGB_label: [571x571x3 uint8] 
       numObjects2: 42 
           red_set: [5 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2 6 4 11 14] 
           ful_set: [5 0 0 0 0 1 13 29 14 7 4 1 0 0 0 0 0 0 0 2] 
           fatcell: [1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 2 1 1 1 1 1 1 2 2 1 1 2] 
                A2: [1024x1360x3 uint8] 
            sub_A2: [571x571x3 uint8] 
        RGB_label2: [571x571x3 uint8] 
       nio_ful_set: [1630 41 13 6 2 1 0 0 2 1 0 0 1 0 0 0 0 1 0 1] 
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   nio_red_set: [1630 41 13 6 2 1 0 0 2 1 0 0 1 0 0 0 0 1 0 1] 
          finalpic: [571x571x3 uint8] 
    cellTotalCount: 80 
         totalArea: 7.0877e+004 
      cell_density: 0.0011 
     nioTotalCount: 1699 
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The following is a text file generated by the Leica Confocal Software which 
details the operating parameters and the stacking instructions for combining the 
fluorescent images. 
Leica Microsystems Heidelberg GmbH  
This file is intended for read-only purposes changes here will not affect the 
images.  
Date:  Tuesday, June 19, 2007  
Time:  16:05  
 
File Version:  26000000  
  
EXPERIMENT INFORMATION  
Number of Images: 3  
Type:           Series with 'tif'-files   
  
DIMENSION DESCRIPTION #0  
Pixel Size in Byte:   1  
Resolution in Bit:    8  
Max Value:                  255.0000000000  
Min Value:            0.000000e+000  
Label:                I  
Number of Dimensions: 4  
Dimension_0:     120  
Logical Size:     512  
Physical Length:  1.365967e-004 m  
Physical Origin:  0.000000e+000 m  
Dimension_1:     121  
Logical Size:     512  
Physical Length:  1.365967e-004 m  
Physical Origin:  0.000000e+000 m  
Dimension_2:     6815843  
Logical Size:     2  
Physical Length:  0.000000e+000  
Physical Origin:  0.000000e+000  
Dimension_3:     122  
Logical Size:     1  
Physical Length:  0.000000e+000  
Physical Origin:  0.000000e+000  
Series Name: Series038  
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Description:   
  
HARDWARE PARAMETER #0  
AOTF (458)  49.328449  
AOTF (476)  0.000000  
AOTF (488)  50.671551  
AOTF (514)  0.000000  
AOTF (561)  50.012210  
AOTF (633)  0.000000  
AOTF (458)  0.000000  
AOTF (476)  0.000000  
AOTF (488)  0.000000  
AOTF (514)  0.000000  
AOTF (561)  0.000000  
AOTF (633)  0.000000  
PMT 1 Active Active  
PMT 1 (Offs.)  -21.600000  
PMT 1 (HV)  631.887456  
PMT 2 Active Active  
PMT 2 (Offs.)  -13.600000  
PMT 2 (HV)  616.060961  
PMT 3 Inactive Inactive  
PMT Trans Inactive Inactive  
Beam Expander Beam Exp 6 Beam Exp 6  
Excitation Beam Splitter FW DD 488/568 DD 488/568  
External Detection FW Mirror  Mirror   
Hardware Type No.  2.000000  
Scan Field Rotation  -0.038943  
Rotation Direction  1  
X Scan Actuator Active Active  
X Scan Actuator (Gain)  2.745308  
X Scan Actuator (Offs.)  0.000000  
Y Scan Actuator Active Active  
Y Scan Actuator (Gain)  2.745308  
Y Scan Actuator (Offs.)  0.000000  
Z Scan Actuator Inactive Inactive  
Z Scan Actuator (POS)  -0.000048  
Scan Speed  200.000000  
Phase  10.546875  
Y-Phase  0.122100  
SP Mirror 1 (left)  500.000000  
SP Mirror 1 (right)  550.000000  
SP Mirror 1 (stain) FITC FITC  
SP Mirror 2 (left)  570.000000  
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SP Mirror 2 (right)  700.000000  
SP Mirror 2 (stain) TRITC TRITC  
SP Mirror 3 (left)  750.000000  
SP Mirror 3 (right)  850.000000  
SP Mirror 3 (stain) None None  
Objective HCX PL APO CS  40.0x1.25 OIL UV HCX PL APO CS  
40.0x1.25 OIL UV  
Order number (Obj.)  506179  
Numerical aperture (Obj.)  1.250000  
  
SCANNER INFORMATION #0  
RoiScan  0  
IsSequential  0  
ChaserUVShutter  0  
ChaserVisibleShutter  0  
MPShutter  0  
UVShutter  0  
VisibleShutter  1  
ScanMode xyz Active  
Pinhole [m]  0.000081  
Pinhole [airy]  0.998666  
Size-Width [µm]  136.596680  
Size-Height [µm]  136.596680  
Size-Depth  0.000000  
StepSize [µm]  0.040703  
Voxel-Width [µm]  0.266790  
Voxel-Height [µm]  0.266790  
Voxel-Depth  0.000000  
Zoom  2.745308  
Scan-Direction  1  
Y-Scan-Direction  1  
SequentialMode  0  
Frame-Accumulation  1  
Frame-Average  1  
Line-Average 1  
Resolution  8  
Channels  2  
Format-Width  512  
Format-Height  512  
Sections  1  
  
TIME INFORMATION #0  
Stamped Dimension: 2  
Stamp_0:     2007:06:19,15:38:12:546  
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Stamp_1:     2007:06:19,15:38:12:546  
  
LUT DESCRIPTION #0  
LUT_0  
Name:                    Green  
Inverted (1=yes / 0=no): 0  
LUT_1  
Name:                    Red  
Inverted (1=yes / 0=no): 0  
  
SEQUENTIAL INFORMATION #0  
Sequence Count:  0  
  
SERIES INFORMATION #0  
Number of Series:  3  
  
IMAGES INFORMATION #0  
Number of Images:  2  
Image Width:       512  
Iamge Length:      512  
Bits per Sample:   8  
Samples per Pixel: 1  
  
*************************************** NEXT IMAGE *********************************  
DIMENSION DESCRIPTION #1  
Pixel Size in Byte:   1  
Resolution in Bit:    8  
Max Value:                  255.0000000000  
Min Value:            0.000000e+000  
Label:                I  
Number of Dimensions: 4  
Dimension_0:     120  
Logical Size:     512  
Physical Length:  1.365967e-004 m  
Physical Origin:  0.000000e+000 m  
Dimension_1:     121  
Logical Size:     512  
Physical Length:  1.365967e-004 m  
Physical Origin:  0.000000e+000 m  
Dimension_2:     6815843  
Logical Size:     2  
Physical Length:  0.000000e+000  
Physical Origin:  0.000000e+000  
Dimension_3:     122  
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Logical Size:     3  
Physical Length:  -3.256268e-007 m  
Physical Origin:  -3.661267e-005 m  
Series Name: Series045  
Description:   
  
HARDWARE PARAMETER #1  
AOTF (458)  49.328449  
AOTF (476)  0.000000  
AOTF (488)  50.671551  
AOTF (514)  0.000000  
AOTF (561)  50.012210  
AOTF (633)  0.000000  
AOTF (458)  0.000000  
AOTF (476)  0.000000  
AOTF (488)  0.000000  
AOTF (514)  0.000000  
AOTF (561)  0.000000  
AOTF (633)  0.000000  
PMT 1 Active Active  
PMT 1 (Offs.)  -21.600000  
PMT 1 (HV)  631.887456  
PMT 2 Active Active  
PMT 2 (Offs.)  -13.600000  
PMT 2 (HV)  616.060961  
PMT 3 Inactive Inactive  
PMT Trans Inactive Inactive  
Beam Expander Beam Exp 6 Beam Exp 6  
Excitation Beam Splitter FW DD 488/568 DD 488/568  
External Detection FW Mirror  Mirror   
Hardware Type No.  2.000000  
Scan Field Rotation  -0.038943  
Rotation Direction  1  
X Scan Actuator Active Active  
X Scan Actuator (Gain)  2.745308  
X Scan Actuator (Offs.)  0.000000  
Y Scan Actuator Active Active  
Y Scan Actuator (Gain)  2.745308  
Y Scan Actuator (Offs.)  0.000000  
Z Scan Actuator Inactive Inactive  
Z Scan Actuator (POS)  -0.000043  
Scan Speed  200.000000  
Phase  10.546875  
Y-Phase  0.122100  
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SP Mirror 1 (left)  500.000000  
SP Mirror 1 (right)  550.000000  
SP Mirror 1 (stain) FITC FITC  
SP Mirror 2 (left)  570.000000  
SP Mirror 2 (right)  700.000000  
SP Mirror 2 (stain) TRITC TRITC  
SP Mirror 3 (left)  750.000000  
SP Mirror 3 (right)  850.000000  
SP Mirror 3 (stain) None None  
Objective HCX PL APO CS  40.0x1.25 OIL UV HCX PL APO CS  
40.0x1.25 OIL UV  
Order number (Obj.)  506179  
Numerical aperture (Obj.)  1.250000  
  
SCANNER INFORMATION #1  
RoiScan  0  
IsSequential  0  
ChaserUVShutter  0  
ChaserVisibleShutter  0  
MPShutter  0  
UVShutter  0  
VisibleShutter  1  
ScanMode xyz Active  
Pinhole [m]  0.000081  
Pinhole [airy]  0.998666  
Size-Width [µm]  136.596680  
Size-Height [µm]  136.596680  
Size-Depth [µm]  0.325627  
StepSize [µm]  0.162813  
Voxel-Width [µm]  0.266790  
Voxel-Height [µm]  0.266790  
Voxel-Depth [µm]  0.162813  
Zoom  2.745308  
Scan-Direction  1  
Y-Scan-Direction  1  
SequentialMode  0  
Frame-Accumulation  1  
Frame-Average  1  
Line-Average 1  
Resolution  8  
Channels  2  
Format-Width  512  
Format-Height  512  
Sections  84  
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TIME INFORMATION #1  
Stamped Dimension: 2  
Stamp_0:     2007:06:19,15:45:23:593  
Stamp_1:     2007:06:19,15:45:23:593  
Stamp_2:     2007:06:19,15:45:26:843  
Stamp_3:     2007:06:19,15:45:26:843  
Stamp_4:     2007:06:19,15:45:30:93  
Stamp_5:     2007:06:19,15:45:30:93  
  
LUT DESCRIPTION #1  
LUT_0  
Name:                    Green  
Inverted (1=yes / 0=no): 0  
LUT_1  
Name:                    Red  
Inverted (1=yes / 0=no): 0  
  
SEQUENTIAL INFORMATION #1  
Sequence Count:  0  
  
IMAGES INFORMATION #1  
Number of Images:  6  
Image Width:       512  
Iamge Length:      512  
Bits per Sample:   8  
Samples per Pixel: 1  
  
*************************************** NEXT IMAGE *********************************  
DIMENSION DESCRIPTION #2  
Pixel Size in Byte:   1  
Resolution in Bit:    8  
Max Value:                  255.0000000000  
Min Value:            0.000000e+000  
Label:                I  
Number of Dimensions: 4  
Dimension_0:     120  
Logical Size:     512  
Physical Length:  1.372375e-004 m  
Physical Origin:  0.000000e+000 m  
Dimension_1:     121  
Logical Size:     512  
Physical Length:  1.372375e-004 m  
Physical Origin:  0.000000e+000 m  
Dimension_2:     6815843  
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Logical Size:     2  
Physical Length:  0.000000e+000  
Physical Origin:  0.000000e+000  
Dimension_3:     122  
Logical Size:     125  
Physical Length:  -2.018886e-005 m  
Physical Origin:  -3.815939e-005 m  
Series Name: Series049  
Description:   
  
HARDWARE PARAMETER #2  
AOTF (458)  49.328449  
AOTF (476)  0.000000  
AOTF (488)  50.671551  
AOTF (514)  0.000000  
AOTF (561)  50.012210  
AOTF (633)  0.000000  
AOTF (458)  0.000000  
AOTF (476)  0.000000  
AOTF (488)  0.000000  
AOTF (514)  0.000000  
AOTF (561)  0.000000  
AOTF (633)  0.000000  
PMT 1 Active Active  
PMT 1 (Offs.)  -21.600000  
PMT 1 (HV)  631.887456  
PMT 2 Active Active  
PMT 2 (Offs.)  -13.600000  
PMT 2 (HV)  616.060961  
PMT 3 Inactive Inactive  
PMT Trans Inactive Inactive  
Beam Expander Beam Exp 6 Beam Exp 6  
Excitation Beam Splitter FW DD 488/568 DD 488/568  
External Detection FW Mirror  Mirror   
Hardware Type No.  2.000000  
Scan Field Rotation  -0.038943  
Rotation Direction  1  
X Scan Actuator Active Active  
X Scan Actuator (Gain)  2.732488  
X Scan Actuator (Offs.)  0.000000  
Y Scan Actuator Active Active  
Y Scan Actuator (Gain)  2.732488  
Y Scan Actuator (Offs.)  0.000000  
Z Scan Actuator Inactive Inactive  
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Z Scan Actuator (POS)  -0.000048  
Scan Speed  200.000000  
Phase  10.546875  
Y-Phase  0.122100  
SP Mirror 1 (left)  500.000000  
SP Mirror 1 (right)  550.000000  
SP Mirror 1 (stain) FITC FITC  
SP Mirror 2 (left)  570.000000  
SP Mirror 2 (right)  700.000000  
SP Mirror 2 (stain) TRITC TRITC  
SP Mirror 3 (left)  750.000000  
SP Mirror 3 (right)  850.000000  
SP Mirror 3 (stain) None None  
Objective HCX PL APO CS  40.0x1.25 OIL UV HCX PL APO CS  
40.0x1.25 OIL UV  
Order number (Obj.)  506179  
Numerical aperture (Obj.)  1.250000  
  
SCANNER INFORMATION #2  
RoiScan  0  
IsSequential  0  
ChaserUVShutter  0  
ChaserVisibleShutter  0  
MPShutter  0  
UVShutter  0  
VisibleShutter  1  
ScanMode xyz Active  
Pinhole [m]  0.000081  
Pinhole [airy]  0.998666  
Size-Width [µm]  137.237549  
Size-Height [µm]  137.237549  
Size-Depth [µm]  -20.188864  
StepSize [µm]  0.162813  
Voxel-Width [µm]  0.268042  
Voxel-Height [µm]  0.268042  
Voxel-Depth [µm]  0.162813  
Zoom  2.732488  
Scan-Direction  1  
Y-Scan-Direction  1  
SequentialMode  0  
Frame-Accumulation  1  
Frame-Average  1  
Line-Average 1  
Resolution  8  
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Channels  2  
Format-Width  512  
Format-Height  512  
Sections  125  
  
TIME INFORMATION #2  
Stamped Dimension: 2  
Stamp_0:     2007:06:19,15:54:21:453  
Stamp_1:     2007:06:19,15:54:21:453  
Stamp_2:     2007:06:19,15:54:24:703  
Stamp_3:     2007:06:19,15:54:24:703  
Stamp_4:     2007:06:19,15:54:27:953  
Stamp_5:     2007:06:19,15:54:27:953  
Stamp_6:     2007:06:19,15:54:31:203  
Stamp_7:     2007:06:19,15:54:31:203  
Stamp_8:     2007:06:19,15:54:34:437  
Stamp_9:     2007:06:19,15:54:34:437  
Stamp_10:     2007:06:19,15:54:37:687  
Stamp_11:     2007:06:19,15:54:37:687  
Stamp_12:     2007:06:19,15:54:40:937  
Stamp_13:     2007:06:19,15:54:40:937  
Stamp_14:     2007:06:19,15:54:44:187  
Stamp_15:     2007:06:19,15:54:44:187  
Stamp_16:     2007:06:19,15:54:47:437  
Stamp_17:     2007:06:19,15:54:47:437  
Stamp_18:     2007:06:19,15:54:50:687  
Stamp_19:     2007:06:19,15:54:50:687  
Stamp_20:     2007:06:19,15:54:53:937  
Stamp_21:     2007:06:19,15:54:53:937  
Stamp_22:     2007:06:19,15:54:57:187  
Stamp_23:     2007:06:19,15:54:57:187  
Stamp_24:     2007:06:19,15:55:00:437  
Stamp_25:     2007:06:19,15:55:00:437  
Stamp_26:     2007:06:19,15:55:03:687  
Stamp_27:     2007:06:19,15:55:03:687  
Stamp_28:     2007:06:19,15:55:06:937  
Stamp_29:     2007:06:19,15:55:06:937  
Stamp_30:     2007:06:19,15:55:10:187  
Stamp_31:     2007:06:19,15:55:10:187  
Stamp_32:     2007:06:19,15:55:13:437  
Stamp_33:     2007:06:19,15:55:13:437  
Stamp_34:     2007:06:19,15:55:16:687  
Stamp_35:     2007:06:19,15:55:16:687  
Stamp_36:     2007:06:19,15:55:19:937  
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Stamp_37:     2007:06:19,15:55:19:937  
Stamp_38:     2007:06:19,15:55:23:187  
Stamp_39:     2007:06:19,15:55:23:187  
Stamp_40:     2007:06:19,15:55:26:437  
Stamp_41:     2007:06:19,15:55:26:437  
Stamp_42:     2007:06:19,15:55:29:687  
Stamp_43:     2007:06:19,15:55:29:687  
Stamp_44:     2007:06:19,15:55:32:937  
Stamp_45:     2007:06:19,15:55:32:937  
Stamp_46:     2007:06:19,15:55:36:187  
Stamp_47:     2007:06:19,15:55:36:187  
Stamp_48:     2007:06:19,15:55:39:437  
Stamp_49:     2007:06:19,15:55:39:437  
Stamp_50:     2007:06:19,15:55:42:687  
Stamp_51:     2007:06:19,15:55:42:687  
Stamp_52:     2007:06:19,15:55:45:937  
Stamp_53:     2007:06:19,15:55:45:937  
Stamp_54:     2007:06:19,15:55:49:187  
Stamp_55:     2007:06:19,15:55:49:187  
Stamp_56:     2007:06:19,15:55:52:437  
Stamp_57:     2007:06:19,15:55:52:437  
Stamp_58:     2007:06:19,15:55:55:687  
Stamp_59:     2007:06:19,15:55:55:687  
Stamp_60:     2007:06:19,15:55:58:937  
Stamp_61:     2007:06:19,15:55:58:937  
Stamp_62:     2007:06:19,15:56:02:187  
Stamp_63:     2007:06:19,15:56:02:187  
Stamp_64:     2007:06:19,15:56:05:437  
Stamp_65:     2007:06:19,15:56:05:437  
Stamp_66:     2007:06:19,15:56:08:687  
Stamp_67:     2007:06:19,15:56:08:687  
Stamp_68:     2007:06:19,15:56:11:937  
Stamp_69:     2007:06:19,15:56:11:937  
Stamp_70:     2007:06:19,15:56:15:187  
Stamp_71:     2007:06:19,15:56:15:187  
Stamp_72:     2007:06:19,15:56:18:437  
Stamp_73:     2007:06:19,15:56:18:437  
Stamp_74:     2007:06:19,15:56:21:687  
Stamp_75:     2007:06:19,15:56:21:687  
Stamp_76:     2007:06:19,15:56:24:937  
Stamp_77:     2007:06:19,15:56:24:937  
Stamp_78:     2007:06:19,15:56:28:187  
Stamp_79:     2007:06:19,15:56:28:187  
Stamp_80:     2007:06:19,15:56:31:437  
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Stamp_81:     2007:06:19,15:56:31:437  
Stamp_82:     2007:06:19,15:56:34:687  
Stamp_83:     2007:06:19,15:56:34:687  
Stamp_84:     2007:06:19,15:56:37:937  
Stamp_85:     2007:06:19,15:56:37:937  
Stamp_86:     2007:06:19,15:56:41:187  
Stamp_87:     2007:06:19,15:56:41:187  
Stamp_88:     2007:06:19,15:56:44:437  
Stamp_89:     2007:06:19,15:56:44:437  
Stamp_90:     2007:06:19,15:56:47:687  
Stamp_91:     2007:06:19,15:56:47:687  
Stamp_92:     2007:06:19,15:56:50:937  
Stamp_93:     2007:06:19,15:56:50:937  
Stamp_94:     2007:06:19,15:56:54:187  
Stamp_95:     2007:06:19,15:56:54:187  
Stamp_96:     2007:06:19,15:56:57:437  
Stamp_97:     2007:06:19,15:56:57:437  
Stamp_98:     2007:06:19,15:57:00:687  
Stamp_99:     2007:06:19,15:57:00:687  
Stamp_100:     2007:06:19,15:57:03:937  
Stamp_101:     2007:06:19,15:57:03:937  
Stamp_102:     2007:06:19,15:57:07:187  
Stamp_103:     2007:06:19,15:57:07:187  
Stamp_104:     2007:06:19,15:57:10:437  
Stamp_105:     2007:06:19,15:57:10:437  
Stamp_106:     2007:06:19,15:57:13:687  
Stamp_107:     2007:06:19,15:57:13:687  
Stamp_108:     2007:06:19,15:57:16:937  
Stamp_109:     2007:06:19,15:57:16:937  
Stamp_110:     2007:06:19,15:57:20:187  
Stamp_111:     2007:06:19,15:57:20:187  
Stamp_112:     2007:06:19,15:57:23:437  
Stamp_113:     2007:06:19,15:57:23:437  
Stamp_114:     2007:06:19,15:57:26:687  
Stamp_115:     2007:06:19,15:57:26:687  
Stamp_116:     2007:06:19,15:57:29:937  
Stamp_117:     2007:06:19,15:57:29:937  
Stamp_118:     2007:06:19,15:57:33:187  
Stamp_119:     2007:06:19,15:57:33:187  
Stamp_120:     2007:06:19,15:57:36:437  
Stamp_121:     2007:06:19,15:57:36:437  
Stamp_122:     2007:06:19,15:57:39:687  
Stamp_123:     2007:06:19,15:57:39:687  
Stamp_124:     2007:06:19,15:57:42:937  
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Stamp_125:     2007:06:19,15:57:42:937  
Stamp_126:     2007:06:19,15:57:46:187  
Stamp_127:     2007:06:19,15:57:46:187  
Stamp_128:     2007:06:19,15:57:49:437  
Stamp_129:     2007:06:19,15:57:49:437  
Stamp_130:     2007:06:19,15:57:52:687  
Stamp_131:     2007:06:19,15:57:52:687  
Stamp_132:     2007:06:19,15:57:55:921  
Stamp_133:     2007:06:19,15:57:55:921  
Stamp_134:     2007:06:19,15:57:59:171  
Stamp_135:     2007:06:19,15:57:59:171  
Stamp_136:     2007:06:19,15:58:02:421  
Stamp_137:     2007:06:19,15:58:02:421  
Stamp_138:     2007:06:19,15:58:05:671  
Stamp_139:     2007:06:19,15:58:05:671  
Stamp_140:     2007:06:19,15:58:08:921  
Stamp_141:     2007:06:19,15:58:08:921  
Stamp_142:     2007:06:19,15:58:12:171  
Stamp_143:     2007:06:19,15:58:12:171  
Stamp_144:     2007:06:19,15:58:15:421  
Stamp_145:     2007:06:19,15:58:15:421  
Stamp_146:     2007:06:19,15:58:18:671  
Stamp_147:     2007:06:19,15:58:18:671  
Stamp_148:     2007:06:19,15:58:21:921  
Stamp_149:     2007:06:19,15:58:21:921  
Stamp_150:     2007:06:19,15:58:25:171  
Stamp_151:     2007:06:19,15:58:25:171  
Stamp_152:     2007:06:19,15:58:28:421  
Stamp_153:     2007:06:19,15:58:28:421  
Stamp_154:     2007:06:19,15:58:31:671  
Stamp_155:     2007:06:19,15:58:31:671  
Stamp_156:     2007:06:19,15:58:34:921  
Stamp_157:     2007:06:19,15:58:34:921  
Stamp_158:     2007:06:19,15:58:38:171  
Stamp_159:     2007:06:19,15:58:38:171  
Stamp_160:     2007:06:19,15:58:41:421  
Stamp_161:     2007:06:19,15:58:41:421  
Stamp_162:     2007:06:19,15:58:44:671  
Stamp_163:     2007:06:19,15:58:44:671  
Stamp_164:     2007:06:19,15:58:47:921  
Stamp_165:     2007:06:19,15:58:47:921  
Stamp_166:     2007:06:19,15:58:51:171  
Stamp_167:     2007:06:19,15:58:51:171  
Stamp_168:     2007:06:19,15:58:54:421  
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Stamp_169:     2007:06:19,15:58:54:421  
Stamp_170:     2007:06:19,15:58:57:671  
Stamp_171:     2007:06:19,15:58:57:671  
Stamp_172:     2007:06:19,15:59:00:921  
Stamp_173:     2007:06:19,15:59:00:921  
Stamp_174:     2007:06:19,15:59:04:171  
Stamp_175:     2007:06:19,15:59:04:171  
Stamp_176:     2007:06:19,15:59:07:421  
Stamp_177:     2007:06:19,15:59:07:421  
Stamp_178:     2007:06:19,15:59:10:671  
Stamp_179:     2007:06:19,15:59:10:671  
Stamp_180:     2007:06:19,15:59:13:921  
Stamp_181:     2007:06:19,15:59:13:921  
Stamp_182:     2007:06:19,15:59:17:171  
Stamp_183:     2007:06:19,15:59:17:171  
Stamp_184:     2007:06:19,15:59:20:421  
Stamp_185:     2007:06:19,15:59:20:421  
Stamp_186:     2007:06:19,15:59:23:671  
Stamp_187:     2007:06:19,15:59:23:671  
Stamp_188:     2007:06:19,15:59:26:921  
Stamp_189:     2007:06:19,15:59:26:921  
Stamp_190:     2007:06:19,15:59:30:171  
Stamp_191:     2007:06:19,15:59:30:171  
Stamp_192:     2007:06:19,15:59:33:421  
Stamp_193:     2007:06:19,15:59:33:421  
Stamp_194:     2007:06:19,15:59:36:671  
Stamp_195:     2007:06:19,15:59:36:671  
Stamp_196:     2007:06:19,15:59:39:921  
Stamp_197:     2007:06:19,15:59:39:921  
Stamp_198:     2007:06:19,15:59:43:171  
Stamp_199:     2007:06:19,15:59:43:171  
Stamp_200:     2007:06:19,15:59:46:421  
Stamp_201:     2007:06:19,15:59:46:421  
Stamp_202:     2007:06:19,15:59:49:671  
Stamp_203:     2007:06:19,15:59:49:671  
Stamp_204:     2007:06:19,15:59:52:921  
Stamp_205:     2007:06:19,15:59:52:921  
Stamp_206:     2007:06:19,15:59:56:171  
Stamp_207:     2007:06:19,15:59:56:171  
Stamp_208:     2007:06:19,15:59:59:421  
Stamp_209:     2007:06:19,15:59:59:421  
Stamp_210:     2007:06:19,16:00:02:671  
Stamp_211:     2007:06:19,16:00:02:671  
Stamp_212:     2007:06:19,16:00:05:921  
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Stamp_213:     2007:06:19,16:00:05:921  
Stamp_214:     2007:06:19,16:00:09:171  
Stamp_215:     2007:06:19,16:00:09:171  
Stamp_216:     2007:06:19,16:00:12:421  
Stamp_217:     2007:06:19,16:00:12:421  
Stamp_218:     2007:06:19,16:00:15:671  
Stamp_219:     2007:06:19,16:00:15:671  
Stamp_220:     2007:06:19,16:00:18:921  
Stamp_221:     2007:06:19,16:00:18:921  
Stamp_222:     2007:06:19,16:00:22:171  
Stamp_223:     2007:06:19,16:00:22:171  
Stamp_224:     2007:06:19,16:00:25:421  
Stamp_225:     2007:06:19,16:00:25:421  
Stamp_226:     2007:06:19,16:00:28:671  
Stamp_227:     2007:06:19,16:00:28:671  
Stamp_228:     2007:06:19,16:00:31:921  
Stamp_229:     2007:06:19,16:00:31:921  
Stamp_230:     2007:06:19,16:00:35:171  
Stamp_231:     2007:06:19,16:00:35:171  
Stamp_232:     2007:06:19,16:00:38:421  
Stamp_233:     2007:06:19,16:00:38:421  
Stamp_234:     2007:06:19,16:00:41:671  
Stamp_235:     2007:06:19,16:00:41:671  
Stamp_236:     2007:06:19,16:00:44:921  
Stamp_237:     2007:06:19,16:00:44:921  
Stamp_238:     2007:06:19,16:00:48:171  
Stamp_239:     2007:06:19,16:00:48:171  
Stamp_240:     2007:06:19,16:00:51:421  
Stamp_241:     2007:06:19,16:00:51:421  
Stamp_242:     2007:06:19,16:00:54:671  
Stamp_243:     2007:06:19,16:00:54:671  
Stamp_244:     2007:06:19,16:00:57:921  
Stamp_245:     2007:06:19,16:00:57:921  
Stamp_246:     2007:06:19,16:01:01:171  
Stamp_247:     2007:06:19,16:01:01:171  
Stamp_248:     2007:06:19,16:01:04:421  
Stamp_249:     2007:06:19,16:01:04:421  
  
LUT DESCRIPTION #2  
LUT_0  
Name:                    Green  
Inverted (1=yes / 0=no): 0  
LUT_1  
Name:                    Red  
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Inverted (1=yes / 0=no): 0  
  
SEQUENTIAL INFORMATION #2  
Sequence Count:  0  
  
IMAGES INFORMATION #2  
Number of Images:  250  
Image Width:       512  
Iamge Length:      512  
Bits per Sample:   8  
Samples per Pixel: 1 
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